{
    "url": "https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231x10k.htm",
    "report_type": "10-K",
    "context": [
        {
            "id": 0,
            "context": "Item 1.\nBusiness\nCompany Overview We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases. Our initial focus is on the development of products, using our proprietary owned and in-licensed drug delivery technologies, that could help address rare genetic skin diseases, particularly those for which there are currently no approved treatments or cures. Our first lead product, QRX003, is a topical lotion under clinical development as a potential treatment for Netherton Syndrome (\u201cNS\u201d), a rare hereditary genetic disease. The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor and the product is formulated with the proprietary in-licensed Invisicare\u00ae technology, QRX003 is currently being tested in two ongoing clinical studies in the United States (\u201cU.S.\u201d) under an open Investigational New Drug (\u201cIND\u201d) application with the Food and Drug Administration (\u201cFDA\u201d). Both studies are actively recruiting patients in five clinical sites across the US. The opening of additional clinical sites in Europe and elsewhere is currently under evaluation. We also intend to pursue the development of QRX003 for additional rare diseases including, among others, Peeling Skin Syndrome, SAM Syndrome and Palmoplantar Keratoderma. Other development products in our pipeline include QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (\u201cRDEB\u201d). In addition, we entered into Research Agreements with the Queensland University of Technology (\u201cQUT\u201d), under which we have obtained an option for global licenses to QRX007 and QRX008 as potential treatments of NS and scleroderma respectively.",
            "type": "paragraph"
        },
        {
            "id": 1,
            "context": "We were incorporated under the laws of the State of Israel in 1986 under the name Montiger Ltd. Between 1986 and 2021, we underwent several name changes, including the name change to Cellect Biotechnology Ltd. (\u201cCellect\u201d). On October 28, 2021, Cellect completed the business combination with Quoin Pharmaceuticals, Inc., a Delaware corporation (\u201cQuoin Inc.\u201d), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2021 (the \u201cMerger Agreement\u201d), by and among Cellect, Quoin Inc. and CellMSC, Inc., a Delaware corporation and wholly-owned subsidiary of Cellect (\u201cMerger Sub\u201d), pursuant to which Merger Sub merged with and into Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the \u201cMerger\u201d). Immediately after completion of the Merger, Cellect changed its name to \u201cQuoin Pharmaceuticals, Ltd.\u201d In addition, on October 28, 2021, Cellect sold the entire share capital of its subsidiary, Cellect Biotherapeutics Ltd., which retained all of Cellect\u2019s then existing assets, to EnCellX Inc. (\u201cEnCellX\u201d), a newly formed U.S. privately held company.",
            "type": "paragraph"
        },
        {
            "id": 2,
            "context": "Netherton Syndrome NS is a rare autosomal recessive genetic disease caused by a mutation in the SPINK5 gene and has an incidence of approximately 1/200,000 births. The SPINK5 gene encodes a protein, called lympho-epithelial kazal type related inhibitor (\u201cLEKTI\u201d) that serves as a brake system on the activity of certain proteases (enzymes that digest proteins) in the skin called Kallikreins. The absence of the LEKTI protein, as a result of the genetic defect that causes NS, leads to unregulated protease activity in the skin by the Kallikreins, resulting in too few layers of the outer skin (stratum corneum), thereby leading to a highly defective and compromised skin barrier. As a result, patients with NS suffer from a variety of medical issues including regular, severe infections, skin cancer, chronic pruritis, asthma, and allergies among others.",
            "type": "paragraph"
        },
        {
            "id": 3,
            "context": "Newborns with NS have reddened skin (erythroderma) and sometimes a thick parchment-like covering of skin (collodion membrane). The skin is red and scaly all over. Hair shafts are fragile and break easily due to trichorrhexis or \u201cbamboo hair,\u201d resulting in short sparse hair. In older children and adults, the scaling may have a distinctive circular pattern (ichthyosis linearis circumflexa). Babies with NS may be born prematurely. Trouble gaining weight in infancy and childhood is common and can be severe. Infants may also have recurrent skin infections and septicemia. They may develop hypernatremia (elevated sodium levels in the blood) due to excessive loss of fluid from the skin surface. Because hairs may not be affected at birth, and then may be sparse in all babies in the first months of life, the characteristic hair defect that is diagnostic of NS may not be detected initially. Infants with NS may be misdiagnosed as having congenital ichthyosiform erythroderma, atopic dermatitis or psoriasis. Atopic dermatitis (red, itchy patches of skin) may be present, and a cradle cap-like scale and redness may appear on the face, scalp and eyebrows.",
            "type": "paragraph"
        },
        {
            "id": 4,
            "context": "There are currently no approved therapies to treat NS. In the absence of an approved therapeutic product, patients can only obtain minor symptomatic relief, generally by the regular use of emollients and moisturizing creams and lotions. Other topical agents must be used with caution because the highly compromised skin in NS patients may allow ingredients from some topically applied medications to be excessively absorbed into the bloodstream, which may pose a danger to the patient. Use of topical keratolytic agents, such as urea or lactic acid derivatives, may be limited by skin irritation and is generally reserved for older children or adults. Base line treatment may also include oral antihistamines, which can help to control the itchy, eczematous component, and topical or systemic antibiotics as",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "4 needed. Oral and topical steroids and systemic biologics may be beneficial in reducing inflammation and the eczematous component of the disease. However, the well-documented side effects of long-term steroid use need to be carefully considered. There is a critical need for a new and effective treatment for NS.Our Product CandidatesQRX003QRX003 is a topical lotion being developed for the treatment of NS. The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor whose mechanism of action is to target the kallikreins responsible for the process of skin shedding. Due to the genetic mutation of the SPINK5 gene, which results in the absence of the LEKTI protein, these kallikreins go unregulated and become hyperactive resulting in the uncontrolled desquamation that leads to the highly defective skin barrier in NS patients. When applied to the skin, QRX003 is designed to perform the function of the missing LEKTI protein and down regulate, but not completely stop, the activity of kallikreins, leading to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.While several other companies are pursuing the development of products to treat NS, we believe, to date we are the only company that is actively dosing subjects in NS clinical studies under an open IND with the FDA. QRX003 was developed using Invisicare\u00ae polymer delivery technology licensed from Skinvisible Pharmaceuticals, Inc. (\u201cSkinvisible\u201d). See \u201c\u2014Intellectual Property\u2014License Agreement with Skinvisible.\u201d The Invisicare\u00ae polymer delivery technology is an optimized topical delivery system that moisturizes the skin whilst simultaneously providing a protective barrier against allergens, toxins and other environmental agents.QRX004QRX004 contains two active ingredients as a potential treatment for RDEB. One active ingredient induces a read-through of nonsense mutations and leads to creation of robust and sustained type VII collagen, which is designed to improve wound closure, reduce blistering and stronger skin. This product is being developed using Invisicare\u00ae delivery technology in-licensed from Skinvisible. See \u201c\u2014Intellectual Property\u2014License Agreement with Skinvisible.\u201dQRX007 and QRX008In November 2021, we entered into the Research Agreement with QUT, pursuant to which we have an option for up to six months after the project completion to in-license the QRX007 product. QRX007 is a bi-functional protein designed to be highly selective and potent inhibitor of the KLK5 and KLK7 kallikreins as a potential treatment for NS. QRX007 is in pre-clinical testing for NS. In May 2022, we entered into another Research Agreement with QUT, pursuant to which we have an option for up to six months after the project completion to in-license a small molecule VLA-4 inhibitor, the QRX008 product. QRX008 is a potential treatment for scleroderma, a rare autoimmune disease for which there is currently no approved treatment, and it is under early-stage development by QUT.Regulatory Status of QRX003 for the Treatment of NSOn November 29, 2019, we submitted a pre-IND meeting request to the FDA regarding the proposed development of QRX003 as a potential treatment for NS. On January 30, 2020, we received feedback from the FDA, which we believe has provided us with a clear path forward for the development of QRX003 as a potential treatment for NS.With regard to the proposed clinical program, the agency confirmed that in the case of a rare disease, findings from a single Phase 3 trial along with supportive data could be used to establish efficacy. In response to our query, the agency stated that QRX003 may be a candidate for one or more expedited regulatory approval pathways.We submitted an IND in March 2022 to the FDA to initiate a clinical study of QRX003 in adult NS patients. We received a \u2018Study May Proceed\u2019 notification from the FDA on June 13, 2022, which cleared us to initiate clinical testing of QRX003 in NS patients. This study is fully up and running and five clinical sites in the U.S. have been opened and are actively recruiting and dosing patients. This study originally was designed as a randomized, double blinded assessment of two different doses of QRX003 versus a placebo vehicle in 18 adult NS patients. The test materials are applied once daily, over a twelve-week period, to pre-selected areas of the patient\u2019s body. Based on discussions with the FDA, a number of different clinical endpoints are being assessed in the study, including but not limited to, an Investigators Global Assessment (IGA), Patient\u2019s Global Assessment (PaGA) and Pruritis. In its communication allowing our 5",
            "type": "paragraph"
        },
        {
            "id": 6,
            "context": "study to proceed, the FDA provided further feedback on our development program providing guidance on this initial study that could better inform future studies.In November 2022, we submitted a protocol for our second clinical study in NS patients under our currently open IND and we were cleared by the FDA to initiate testing in NS patients in December 2022. This study originally was designed to be conducted in ten adult NS patients who are currently receiving, and will continue to do so throughout the study, off-label systemic therapy, primarily systemic biologic therapy. This is an open-label study with no placebo control and is being conducted at the same clinical sites as ongoing double-blinded study.On October 24, 2023, we released positive initial clinical results obtained from the first six evaluable subjects in our open-label study. Upon completion of dosing, five of the six patients reported that their pruritis or itch was either absent or negligible. In addition, according to the IGA assessment, three of the six subjects demonstrated positive improvement in skin appearance on completion of the study while the other three subjects demonstrated improvements in skin appearance at various points throughout the study, though not necessarily on completion of the study. In addition, all six subjects reported a favorable impression of QRX003 across a number of key metrics.As a result of this positive initial data and the absence of any safety concerns from both studies, on November 8, 2023 we submitted a number of protocol amendments to the FDA, under our open IND, with a view to optimizing both studies and potentially leading to even better clinical outcomes and a more rapid regulatory approval. These protocol amendments included eliminating the lower dose from the double-blinded study, modifying the dosing frequency from once-daily to twice-daily and increasing the number of subjects from 18 to 30. For the open-label study, the number of subjects was increased from 10 to 20 and dosing was modified from once-daily to twice-daily. On December 13, 2023, we announced that we were cleared by the FDA to implement these protocol amendments. We submitted a further protocol amendment to the FDA in February 2024 requesting approval to reduce the age of eligibility for enrollment into both of clinical to fourteen years and older from eighteen years and older. On March 4, 2024, we announced that clearance had been received to implement this protocol amendment also.In March 2022, we submitted a briefing document to the European Medicines Agency (\u201cEMA\u201d) seeking guidance regarding the clinical and regulatory development of QRX003 for the European Union (\u201cEU\u201d), to which we received comprehensive and constructive feedback. We also intend to apply for Orphan Drug status in the U.S. and Europe as well as Rare Pediatric Disease designation in the U.S. for QRX003.Commercial StrategyQRX003 has the potential to become the first approved treatment for NS to reach the market both in the U.S. and Europe and may therefore likely be used in a large proportion of patients. We currently anticipate that QRX003, if approved, would be applied once or twice daily over the patient\u2019s entire body. Because NS is a chronic disease and does not spontaneously resolve, we believe there is an opportunity for the product, should it be approved, for long-term chronic use.We intend to self-commercialize QRX003, and other rare disease products the company may develop, if approved, in both the U.S. and Europe. Because of the very low number of patients and the fact that diagnosis and treatment are generally provided by a relatively small number of board-certified dermatologists in major urban areas, this concentration of care will enable us to market QRX003 with a small, dedicated salesforce to target patients and caregivers in the U.S. Outside of the U.S., we have currently established nine separate marketing partnerships for QRX003 that cover 61 different countries including Australia, New Zealand, the Middle East, Central and Eastern Europe, Turkey, Canada, China, Taiwan, Hong Kong, Singapore and the major countries in Latin America.Once the commercial infrastructure has been established for QRX003 for NS, the subsequent approval and addition of new rare disease indications or products will not result in a significant increase in the size of that infrastructure. In particular, it is highly likely that physicians who treat patients with NS would also treat patients with Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Epidermolysis Bullosa, enabling our sales personnel to discuss several products, once approved, with each treating physician.A key element of our commercial strategy will be to add new products to our portfolio beyond those which we develop ourselves. This will be achieved through in-licensing, acquisition or the establishment of research partnerships with universities or other institutions. While it is intended that these products will treat rare and orphan diseases, we may widen our scope of interest beyond rare skin diseases as we believe this will not add significant incremental burden to an already established commercial infrastructure.6",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "| Patents | Trademarks |\n| U.S. Patent No. 7,674,471 (exp. March 10, 2024) and U.S. Patent No. 8,318,818 (exp. July 10, 2025) directed to Invisicare\u00ae technology licensed from Skinvisible. | U.S. Trademark Registration No. 6918421 for word mark \u201cRARE DISEASES ARE ONLY RARE IF YOU DON\u2019T LIVE WITH ONE\u201d filed by Quoin Pharmaceuticals, Inc. |\n| U.S.and PCT patent applications directed to adjunctive therapy for NS with QRX003 filed by Quoin Pharmaceuticals Inc. | U.S. Trademark Registration No. 7071539 for design and words \u201cQuoin Pharmaceuticals\u201d filed by Quoin Pharmaceuticals, Inc. |\n| \u200b | U.S. Trademark Application No. 98/184,357 for word mark \u201cQELTIQ\u201d filed by Quoin Pharmaceuticals, Inc. |",
            "type": "table"
        },
        {
            "id": 8,
            "context": "| \u25cf | preclinical laboratory tests, in vitro and in vivo preclinical studies and formulation and stability studies; |\n| \u25cf | the submission to the FDA of an application for human clinical testing, which is known as an IND application; |\n| \u25cf | adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug; |\n| \u25cf | the submission to the FDA of a new drug application (\u201cNDA\u201d) for a drug; and |\n| \u25cf | satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP (\u201ccGMP\u201d) requirements to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity; |\n| \u25cf | the approval by the FDA of an NDA. |",
            "type": "table"
        },
        {
            "id": 9,
            "context": "an institutional review board (\u201cIRB\u201d) must review and approve the clinical trial protocol and informed consent form required to be provided to each trial subject or his or her legal representative prior to a clinical trial commencing, and conduct on-going monitoring of the study until completed or termination to assure that appropriate steps are taken to protect the human subjects participating in the research.The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients. Imposition of a clinical hold may be full or partial. The IRB will also monitor the clinical trial until completed. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB\u2019s requirements, or may impose other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:Phase 1: In Phase 1 studies, the product candidate is initially introduced into healthy human volunteers and tested for safety, dosage and tolerability, absorption, distribution, metabolism and excretion and, effect on the body.Phase 2: Phase 2 studies are conducted in a limited patient population. These studies continue to evaluate safety while gathering preliminary data on effectiveness in patients with the targeted disease or condition.Phase 3: Phase 3 trials further evaluate efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the drug. In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) the single trial is supported by other confirmatory evidence.Post-approval studies, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These studies are used to gather additional information about a product\u2019s safety and/or efficacy in patients affected by the therapeutic indication.After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing and distribution of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product\u2019s pharmacology, chemistry, manufacture, and controls. The submission of most NDAs is subject to the payment of a substantial application user fee. Under an approved NDA, the applicant is also subject to an annual program fee. These fees typically increase annually. An NDA for a drug that has been designated as an orphan drug is not subject to an application fee, unless the NDA includes an indication for other than a rare disease or condition.Pursuant to the current Prescription Drug User Fee Act (\u201cPDUFA\u201d) goals, FDA\u2019s goal for acting on the submission of an NDA for a new molecular entity is ten months from the date the FDA files the NDA. The FDA conducts a preliminary review of an NDA within 60 days after submission to determine whether it is sufficiently complete to permit substantive review, before determining whether to file the NDA. This two-month preliminary review effectively extends the typical NDA review period to twelve months. In rare cases, the FDA may request additional information rather than file an NDA. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.The FDA may also refer applications for novel pharmaceutical products, as well as pharmaceutical products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee, typically a panel that includes clinicians, statisticians and other experts, for review, evaluation, and a recommendation as to whether the NDA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the pharmaceutical product is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the respective claimed indication.9",
            "type": "paragraph"
        },
        {
            "id": 10,
            "context": "Following the FDA\u2019s evaluation of an NDA, it will issue an approval letter or a complete response letter (\u201cCRL\u201d). An approval letter authorizes the sponsor to begin commercial marketing of the drug for specific indications. A CRL means that the review cycle of the application is complete and the application will not be approved in its present form. A CRL describes the specific deficiencies in the NDA identified by the FDA and may recommend actions that the applicant might take, including providing additional clinical data, such as an additional Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing, to resolve the deficiencies. If a CRL is issued, the sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the sponsor submits the recommended data and information, the FDA may decide that the NDA does not satisfy the criteria for approval.As condition to a product\u2019s regulatory approval, the FDA may require a sponsor to conduct Phase 4 studies designed to further assess the drug\u2019s safety and effectiveness after NDA approval, or may require other testing and surveillance programs to monitor the safety of the approved product. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy (\u201cREMS\u201d) to assure the safe use of the drug. A REMS could include medication guides, communication plans to healthcare professionals or other elements to assure safe use, such as provider certification or training, restricted distribution methods, and patient registries.There are a variety of regulations governing clinical trials and requirements for obtaining marketing approval for pharmaceutical products outside the United States. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries and regions must be obtained prior to the commencement of marketing the product in those countries. The approval process varies from one regulatory authority to another and the time may be longer or shorter than that required for FDA approval. In the EU, Canada and Australia, regulatory requirements and approval processes are similar, in principle, to those in the United States.Disclosure of Clinical Trial InformationSponsors of clinical trials of FDA-regulated products, including drugs and biologic products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.Pediatric InformationUnder the Pediatric Research Equity Act (\u201cPREA\u201d), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by the FDA to be substantially relevant to the growth or progression of a pediatric cancer.The Best Pharmaceuticals for Children Act (\u201cBPCA\u201d) provides a six-month extension of any patent or non-patent exclusivity for a drug if certain conditions are met. Conditions for exclusivity include the FDA\u2019s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.Expedited ProgramsThe FDA is required to facilitate the development, and expedite the review, of drug products that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.10",
            "type": "paragraph"
        },
        {
            "id": 11,
            "context": "Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.The FDA is also required to expedite the development and review of applications for approval of products that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the product candidate. The FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor\u2019s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.Orphan Drug DesignationPursuant to the Orphan Drug Act, the FDA may grant special status, or orphan designation, to a drug intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or there is no reasonable expectation that the sales of the product will offset the cost of developing and making the drug available in the United States. A request for orphan drug designation must be submitted before the NDA is submitted. Following the grant of orphan designation, the FDA will publicly disclose the identity of the therapeutic drug candidate and its potential orphan use. Orphan designation does not shorten the duration of the regulatory review and approval process.If a drug candidate with orphan designation subsequently receives the first FDA approval for the disease or condition for which it has orphan designation, the drug is entitled to a seven-year period of market exclusivity subject to certain exceptions (e.g., clinical superiority of a subsequent product). This means that the FDA may not approve another drug application authorizing another manufacturer to market the same drug for the same indication for seven years. This does not preclude competitors from receiving approval of the same product that has orphan exclusivity for a different indication or a different product for the same indication for which the orphan product has exclusivity. The orphan designation of a drug also provides the sponsor with certain financial incentives including tax credits and waiver of PDUFA fees.Rare Pediatric Disease Priority Review Voucher ProgramUnder the Rare Pediatric Disease Priority Review Voucher program, the FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease. The voucher entitles the sponsor to priority review of one subsequent marketing application.A voucher may be awarded only for an approved rare pediatric disease product application. A rare pediatric disease product application is an NDA for a product that treats or prevents a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years; in general, the disease must affect fewer than 200,000 such individuals in the U.S.; the NDA must be deemed eligible for priority review; the NDA must not seek approval for a different adult indication (i.e., for a different disease/condition); the product must not contain an active ingredient that has been previously approved by the FDA; and the NDA must rely on clinical data derived from studies examining a pediatric population such that the approved product can be adequately labeled for the pediatric population. Before NDA approval, the FDA may designate a product in development as a product for a rare pediatric disease, but such designation is not required to receive a voucher.To receive a rare pediatric disease priority review voucher, a sponsor must notify the FDA, upon submission of the NDA, of its intent to request a voucher. If the FDA determines that the NDA is a rare pediatric disease product application and grants priority review, and if the NDA is approved, the FDA will award the sponsor of the NDA a voucher upon approval of the NDA. The FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S. within 365 days of the product\u2019s approval.The voucher, which is transferable to another sponsor, may be submitted with a subsequent NDA or biologics license application (\u201cBLA\u201d) and entitles the holder to priority review of the accompanying NDA or BLA. The sponsor submitting the priority review voucher must notify the FDA of its intent to submit the voucher with the NDA or BLA at least 90 days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee. The FDA must take action on an NDA or BLA under priority review within six months of receipt of the NDA or BLA.11",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "The Rare Pediatric Disease Priority Review Voucher program was reauthorized in the Creating Hope Reauthorization Act in December 2020. After September 30, 2024, the FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers, unless the program is extended.Post-Marketing ObligationsAll approved drug products are subject to continuing regulation by the FDA, including record-keeping requirements, reporting of adverse experiences with the product, sampling and distribution requirements, notifying the FDA and gaining approval for certain manufacturing or labeling changes, complying with certain electronic records and signature requirements, submitting periodic reports to the FDA, maintaining and providing updated safety and efficacy information to the FDA, and complying with FDA promotion and advertising requirements. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action, criminal prosecution, or civil penalties.The FDA may require post-marketing studies or clinical trials to develop additional information regarding the safety of a product. These studies or trials may involve continued testing of a product and development of data, including clinical data, about the product\u2019s effects in various populations and any side-effects associated with long-term use. The FDA may require post-marketing studies or trials to investigate known serious risks or signals of serious risks or identify unexpected serious risks and may require periodic status reports if new safety information develops. Failure to conduct these studies in a timely manner may result in substantial civil fines.Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and to list their products with the FDA. The FDA periodically inspects manufacturing facilities in the United States and abroad in order to assure compliance with the applicable cGMP regulations and other requirements. Facilities also are subject to inspections by other federal, foreign, state or local agencies. In complying with the cGMP regulations, manufacturers must continue to assure that the product meets applicable specifications, regulations and other post-marketing requirements. Any third-party manufacturers must also maintain compliance with all applicable regulations and requirements. Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing or recall or seizure of product.Also, newly discovered or developed safety or efficacy data may require changes to a product\u2019s approved labeling, including the addition of new warnings and contraindications, additional pre-clinical or clinical studies, or even in some instances, revocation or withdrawal of the approval. Violations of regulatory requirements at any stage, including after approval, may result in various adverse consequences, including the FDA\u2019s withdrawal of an approved product from the market, other voluntary or FDA-initiated action that could delay or restrict further marketing, and the imposition of civil fines and criminal penalties against the NDA holder. In addition, later discovery of previously unknown problems may result in restrictions on the product or NDA holder, including withdrawal of the product from the market. Furthermore, new government requirements may be established that could delay or prevent regulatory approval of our products under development, or affect the conditions under which approved products are marketed.Data PrivacyWe are subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal information. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. Certain privacy and data protection laws, such as the Health Insurance Portability and Accountability Act (HIPAA) and the California Consumer Privacy Act (CCPA), may not apply to us directly at this time, but those laws may apply to the investigators, health care professionals, third party payors, and business partners with whom we have relationships and so may apply to our processing of personal information that we receive from or share with such third parties. We may also engage service providers, such as contract research organizations, to process personal information on our behalf. We cannot ensure that all our contractors, vendors, licensees, business partners or collaborators will comply with all applicable privacy and data protection laws and regulations. The failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.Commercial Product PricingIn the United States and some foreign jurisdictions, many of the markets in which we may do business in the future, the prices of pharmaceutical products are subject to direct price controls (by law) and to drug reimbursement programs with varying price control mechanisms.12",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class in certain cases. Cost reduction initiatives and other provisions of this and other more recent legislation could decrease the coverage and reimbursement that is provided for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act or other more recent legislation may result in a similar reduction in payments from private payors.Healthcare ReformHealthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. Recently, healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (\u201cIRA\u201d) in August 2022, which will, among other things, allow U.S. Department of Health and Human Services (\u201cHHS\u201d) to negotiate the selling price of certain drugs and biologics that the Centers for Medicare & Medicaid Services (\u201cCMS\u201d) reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in October 2023, the IRA will also penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is unclear to what extent additional statutory, regulatory, and administrative initiatives will be enacted and implemented.European Regulatory AuthoritiesIn the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of such products to consumers. The approach taken varies from member state to member state. Some jurisdictions operate positive and/or negative list systems under which products may be marketed only once a reimbursement price has been agreed. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products, as exemplified by the role of the National Institute for Health and Clinical Excellence in the United Kingdom, which evaluates the data supporting new medicines and passes reimbursement recommendations to the government. In addition, in some countries cross-border imports from low-priced markets (parallel imports) exert commercial pressure on pricing within a country.Environmental and Safety LawsWe do not use, handle, store, or dispose of hazardous materials and our operations do not produce hazardous waste. Accordingly, we are not subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials. Any waste generated is non-hazardous and is disposed of by third party contractors. Likewise, given that we have less than 10 employees, we are not subject to the recordkeeping requirements under the Occupational Safety and Health Administration (\u201cOSHA\u201d) although other OSHA regulations may apply. OSHA and/or the Environmental Protection Agency may promulgate regulations that may affect our research and development programs.We are also subject to various laws and regulations governing laboratory practices and the experimental use of animals.EmployeesAs of December 31, 2023, we had four full-time employees and no part-time employees. Our employees are not represented by any collective bargaining agreements, and we have never experienced an organized work stoppage.13",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "Enforceability of Civil LiabilitiesTo the extent any of our shareholders may seek to enforce a U.S. judgment in Israel against us or our executive officers and directors, or to assert U.S. securities law claims in Israel, shareholders may have difficulties enforcing such a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws, in Israel.We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our officers and directors.Moreover, among other reasons, including but not limited to fraud or absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.Available InformationWe are subject to the informational requirements of the Exchange Act. Prior to January 1, 2023, we qualified as a \u201cforeign private issuer\u201d as such term is defined in Rule 405 under the Securities Act. Effective January 1, 2023, we are obligated to file or furnish reports, proxy statements, and other information on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a foreign private issuer. You can read our SEC filings over the Internet at the SEC\u2019s website at www.sec.gov. Our filings with the SEC are also available free of charge on the investors section of our website at www.quoinpharma.com when such reports are available on the SEC\u2019s website. From time to time, we also use multiple social media channels to communicate with the public about Quoin and its products. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage you to review the information we post on such social media channels as our LinkedIn page (https://www.linkedin.com/company/quoin-pharmaceuticals/) and our Twitter account (@Quoinpharma). This list may be updated from time to time on our investor relations website.Information contained on or accessible through the websites and social media channels referred to above is not incorporated by reference in, or otherwise a part of, this Annual Report, and any references to these websites and social media channels are intended to be inactive textual references only.14",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "Item 1A. Risk Factors Investing in our securities involves a high degree of risk. You should carefully consider the risk factors discussed below as well as other information we include in this Annual Report, including our consolidated financial statements and the related notes and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations.\u201d If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the market price of our securities could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements as a result of certain factors including the risks described below and elsewhere in this Annual Report and our other SEC filings. For a summary of the risk factors included in this Item 1A and for further details on our forward-looking statements, see \u201cCautionary Note Regarding Forward-Looking Statements and Summary of Risk Factors\u201d on page 1.",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "Risks Related to Our Financial Position and Capital Requirements\nWe have a limited operating history that you can use to evaluate us, and the likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by a small developing company. Our wholly owned subsidiary, Quoin Inc., commenced operations in 2018. As such, we have a limited operating history and our operations are subject to all of the risks inherent in the establishment of a new business enterprise, including a lack of operating history. Since inception, our operations have been primarily limited to acquiring and licensing intellectual property rights, undertaking research and conducting preclinical and clinical studies for our initial programs and negotiating and executing the Merger and financings. We have not yet obtained regulatory approval for any product candidates. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate. The likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by a small developing company starting a new business enterprise and the highly competitive environment in which we will operate. Since we have a limited operating history, we cannot assure you that our business will be profitable or that we will ever generate sufficient revenues to meet our expenses and support our anticipated activities. In addition, there is no guarantee that any of our product candidates with ever receive approval from the U.S. Food and Drug Administration, or the \u201cFDA.\u201d We cannot be certain that our business strategy will be successful or that we will be solvent at any particular time. Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the early stages of the development of any company. If we fail to address any of these risks or difficulties adequately, our business will likely suffer. Because of the numerous risks and uncertainties associated with developing and commercializing our products, we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable and you may never receive a return on an investment in our securities. An investor in our securities must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of products in the medical and pharmaceutical industries. We may never successfully commercialize our products and our business may fail.",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "We have incurred significant losses since our inception and have limited cash available for our operations. To date, we have not commercialized any products and have not generated any revenue. We believe that we have sufficient cash for operating our business for at least the next twelve months from the date of filing this Form 10-K. However, the Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, unanticipated or higher than expected clinical trial costs and the ability to estimate such occurrences, if any, on the Company\u2019s cash, liquidity, additional financing requirements, and availability. Accordingly, we may need to raise additional funds during this period. We have devoted a majority of our financial resources to research and development, including our preclinical and ongoing clinical development activities. To date, we have funded our operations primarily through our founders\u2019 funding expenditures and the sale of equity and convertible securities.",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates or these candidates participate in Early Access or Named Patient programs, which we expect will take a number of years and is subject to significant uncertainty. Additional financing will be required to complete the research and development of our product candidates and our other operating requirements, which may not be available at acceptable terms, if at all. If we are unable to obtain additional funding when it becomes necessary, the development of our product candidates will be impacted and we would likely be forced to delay, reduce, or terminate some or all of our development programs, all of which could have a material adverse effect on our business, results of operations and financial condition.",
            "type": "paragraph"
        },
        {
            "id": 19,
            "context": "15\n\n| \u25cf | continue and/or initiate clinical development of our product candidates, including\u2014QRX003\u2014a topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare\u00ae technology, which is under clinical development as a potential treatment for Netherton Syndrome (\u201cNS\u201d); |\n| \u25cf | further enhance our internal control systems; |\n| \u25cf | initiate the development of additional product candidates for other rare disease indications; |\n| \u25cf | acquire or in-license other products and technologies and advance those product candidates into clinical trials; |\n| \u25cf | seek marketing approvals for our product candidates that successfully complete clinical trials; |\n| \u25cf | ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; |\n| \u25cf | maintain, expand and protect our intellectual property portfolio; |\n| \u25cf | hire additional clinical, regulatory, research, executive and administrative personnel; and |\n| \u25cf | create additional infrastructure to support our operations and our product development and planned future commercialization efforts. |\n| \u25cf | completing our research and preclinical development of product candidates; |\n| \u25cf | initiating and completing clinical trials for product candidates with favorable results; |\n| \u25cf | seeking, obtaining, and maintaining marketing approvals for product candidates that successfully complete clinical trials; |\n| \u25cf | establishing and maintaining supply and manufacturing relationships with third parties; |\n| \u25cf | launching and commercializing product candidates for which we may obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; |\n| \u25cf | maintaining, protecting and expanding our intellectual property portfolio; and |\n| \u25cf | attracting, hiring and retaining qualified personnel. |",
            "type": "table"
        },
        {
            "id": 20,
            "context": "| \u25cf | significantly delay, scale back or discontinue the development or commercialization of any future product candidates; |\n| \u25cf | seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or |\n| \u25cf | relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves. |\n| \u25cf | successfully implementing preclinical studies which may be predictive of clinical outcomes; |\n| \u25cf | successful enrollment in clinical trials and completion of those trials with favorable results; |\n| \u25cf | receipt of marketing approvals from applicable regulatory authorities; |",
            "type": "table"
        },
        {
            "id": 21,
            "context": "| \u25cf | obtaining and maintaining patent and trade secret protection for current and future product candidates; |\n| \u25cf | establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and |\n| \u25cf | successfully commercializing our products, if approved, including successfully establishing a sales force, marketing and distribution infrastructure, whether alone or in collaboration with others. |\n| \u25cf | our research methodology may be unsuccessful in identifying potential product candidates; or |\n| \u25cf | potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unsuitable for administration in patients in clinical trials, unlikely to receive marketing approval or unmarketable. |\n| \u25cf | delays in reaching an agreement with the FDA or other regulatory authorities on final trial design, including selection of dose and clinical outcome assessments and related efficacy endpoints |\n| \u25cf | delays in obtaining from the FDA, or comparable foreign regulatory authority, authorization to administer an investigational new drug product to humans through the submission or acceptance of an IND or similar foreign application; |\n| \u25cf | imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities; |\n| \u25cf | delays in reaching agreement on acceptable terms with prospective contract research organizations (\u201cCROs\u201d) and clinical trial sites; |\n| \u25cf | our inability to adhere to clinical trial requirements directly or with third parties such as CROs; |",
            "type": "table"
        },
        {
            "id": 22,
            "context": "| \u25cf | clinical trial site or CRO non-compliance with good clinical practices (\u201cGCPs\u201d), good laboratory practices, or other regulatory requirements; |\n| \u25cf | inability or failure of clinical trial sites to adhere to the clinical trial protocol; |\n| \u25cf | delays in obtaining required IRB approval at each clinical trial site, or an IRB reversing such approval resulting in the suspension or termination of a trial at that; |\n| \u25cf | delays in recruiting and retaining suitable patients to participate in a trial particularly for a rare disease such as NS; |\n| \u25cf | delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites; |\n| \u25cf | delays in having patients complete participation in a trial or return for post-treatment follow-up; |\n| \u25cf | delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression; |\n| \u25cf | clinical sites dropping out of a trial to the detriment of enrollment; |\n| \u25cf | time required to add new clinical sites; or |\n| \u25cf | delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials. |\n| \u25cf | be delayed in obtaining marketing approval for our future product candidates; |\n| \u25cf | not obtain marketing approval at all; |\n| \u25cf | obtain approval for indications or patient populations that are not as broad as originally intended or desired; |\n| \u25cf | obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; |\n| \u25cf | be subject to additional post-marketing testing requirements; or |\n| \u25cf | have the product removed from the market after obtaining marketing approval. |",
            "type": "table"
        },
        {
            "id": 23,
            "context": "| \u25cf | regulatory authorities may withdraw, suspend, or limit their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy; |\n| \u25cf | regulatory authorities may require the addition of labeling statements, such as black box warnings or contraindications; |\n| \u25cf | we may be required to change the way the product is administered or conduct additional clinical trials or post-marketing surveillance; |\n| \u25cf | we could be sued and held liable for harm caused to patients; or |\n| \u25cf | our reputation may suffer. |\n| \u25cf | regulatory authorities disagreeing with the design or implementation of our clinical trials; |\n| \u25cf | such authorities may disagree with our interpretation of data from preclinical studies or clinical trials; |\n| \u25cf | such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States; |\n| \u25cf | unfavorable or unclear results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval; |\n| \u25cf | serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; |\n| \u25cf | the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; |\n| \u25cf | we may be unable to demonstrate that a product candidate\u2019s clinical and other benefits outweigh its safety risks; |",
            "type": "table"
        },
        {
            "id": 24,
            "context": "| \u25cf | such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a New Drug Application (\u201cNDA\u201d) or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials; |\n| \u25cf | such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates; |\n| \u25cf | such authorities may find deficiencies in the manufacturing processes, testing systems or facilities of our third-party manufacturers with which we contract for clinical and commercial supplies; or |\n| \u25cf | regulations of such authorities may significantly change in a manner rendering our clinical data insufficient for approval. |\n| \u25cf | issue a warning or untitled letter asserting that we are in violation of the law; |\n| \u25cf | seek an injunction or impose civil or criminal penalties or monetary fines; |\n| \u25cf | suspend or withdraw regulatory approval; |\n| \u25cf | suspend any ongoing clinical trials; |\n| \u25cf | refuse to approve a pending NDA or supplements to an NDA submitted by us; |\n| \u25cf | seize product or require a product recall; or |\n| \u25cf | refuse to allow us to enter into supply contracts, including government contracts. |",
            "type": "table"
        },
        {
            "id": 25,
            "context": "We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing the drug for the type of disease or condition will be recovered from sales of the product in the United States.Orphan drug designation entitles a party to financial incentives, such as tax advantages and user fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in certain circumstances, such as a showing of clinical superiority (i.e., another product is safer, more effective or makes a major contribution to patient care) over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which the orphan product has exclusivity.We intend to apply for orphan drug designation in the United States for QRX003 for the treatment of NS. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for a product candidate in specific indications, we may not be the first to obtain regulatory approval of the product candidate for the orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for orphan designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan drug designation does not ensure that we will receive marketing exclusivity in a particular market, and we cannot assure you that any future application for orphan drug designation in any other geography or with respect to any other future product candidate will be granted. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.We may pursue Rare Pediatric Disease designation for QRX003 for the treatment of NS or other of our product candidates. There is no assurance that we will obtain such designation. Moreover, a Rare Pediatric Disease designation by the FDA does not guarantee that the NDA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that any of our product candidates will receive marketing approval.Under the Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying NDA for the treatment of a rare pediatric disease, the sponsor of such an application may be awarded a transferable rare pediatric disease priority review voucher that can be used to obtain priority review for a subsequent NDA or BLA. We intend to pursue Rare Pediatric Disease designation for QRX003 for the treatment of NS, but there is no assurance that we will receive such designation. On December 27, 2020, the Creating Hope Reauthorization Act extended the Rare Pediatric Disease Priority Review Voucher Program, and after September 30, 2024, the FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. There is no guarantee that any of our product candidates will be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program. Additionally, designation of a drug for a rare pediatric disease does not guarantee that an NDA will meet the other eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare Pediatric Disease designation does not lead to faster development or regulatory review of the product, or increase the likelihood that it will receive marketing approval.We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.As a result of our limited financial and human resources, we will have to make strategic decisions as to which product candidates to pursue and may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or other 22",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "| \u25cf | develop therapeutics that are superior to other products in the market; |\n| \u25cf | attract qualified scientific, product development and commercial personnel; |\n| \u25cf | obtain patent and/or other proprietary protection for our product candidates; |\n| \u25cf | obtain required regulatory approvals; and |\n| \u25cf | successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics. |",
            "type": "table"
        },
        {
            "id": 27,
            "context": "| \u25cf | demonstration of clinical safety and efficacy compared to other products; |\n| \u25cf | the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors; |\n| \u25cf | the prevalence and severity of any AEs; |\n| \u25cf | limitations or warnings contained in the FDA-approved label for such products; |\n| \u25cf | availability of alternative treatments; |\n| \u25cf | pricing and cost-effectiveness; |\n| \u25cf | the effectiveness of our, or any of our collaborators\u2019, sales and marketing strategies; |\n| \u25cf | our ability to obtain hospital or payor formulary approval; |\n| \u25cf | our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement; and |\n| \u25cf | the willingness of patients to pay out-of-pocket in the absence of third-party coverage. |",
            "type": "table"
        },
        {
            "id": 28,
            "context": "| \u25cf | different regulatory requirements for drug approvals in foreign countries; |\n| \u25cf | differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; |\n| \u25cf | reduced protection for intellectual property rights; |\n| \u25cf | unexpected changes in tariffs, trade barriers and regulatory requirements; |\n| \u25cf | economic weakness, including inflation, or political instability in particular foreign economies and markets; |\n| \u25cf | compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |\n| \u25cf | foreign taxes, including withholding of payroll taxes; |\n| \u25cf | foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; |\n| \u25cf | workforce uncertainty in countries where labor unrest is more common than in the United States; |\n| \u25cf | production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and |\n| \u25cf | business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. |",
            "type": "table"
        },
        {
            "id": 29,
            "context": "reduce the likelihood of reimbursement for our future products. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. For instance, government and private payors who reimburse patients or healthcare providers are increasingly seeking greater upfront discounts, additional rebates and other concessions to reduce prices for pharmaceutical products. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.Risks Related to Our Reliance on Third PartiesWe rely on third parties to conduct some aspects of our compound formulation, research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing.We do not expect to independently conduct all aspects of our drug development activities, compound formulation research or preclinical studies of product candidates. We currently rely and expect to continue to rely on third parties to conduct some or all aspects of our preclinical studies and formulation development.Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities.If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.We rely, or will rely, on third-party manufacturers to produce the supply of our preclinical product, clinical product candidates and commercial supplies of any approved product candidates.Reliance on third-party manufacturers entails risks, including risks that we would not be subject to if we manufactured the product candidates ourselves.Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If the FDA determines that our third-party manufacturers are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may not approve an NDA until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance. Moreover, our failure, or the failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, our third-party manufacturers are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although we do not have day-to-day control over the operations of our third-party manufacturers, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.26",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "| \u25cf | the inability to meet any product specifications and quality requirements consistently; |\n| \u25cf | a delay or inability to procure or expand sufficient manufacturing capacity; |\n| \u25cf | manufacturing and product quality issues related to scale-up of manufacturing; |\n| \u25cf | costs and validation of new equipment and facilities required for scale-up; |\n| \u25cf | the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms; |\n| \u25cf | termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; |\n| \u25cf | the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms; |\n| \u25cf | the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier; |\n| \u25cf | operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; |\n| \u25cf | carrier disruptions or increased costs that are beyond our control; and |\n| \u25cf | the failure to deliver products under specified storage conditions and in a timely manner. |",
            "type": "table"
        },
        {
            "id": 31,
            "context": "Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.Manufacturing of product candidates and conducting required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for product candidates or any approved products.We intend to rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we have limited influence over their actual performance. We will control only certain aspects of our CROs\u2019 activities. Nevertheless, we will be responsible for ensuring that each of our clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs will not relieve us of our regulatory responsibilities.We and our CROs will be required to comply with the FDA\u2019s or other regulatory agency\u2019s GCPs, for conducting, recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA and non-U.S. regulatory agencies enforce these GCPs through periodic inspections of trial sponsors, CROs, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or applicable non-U.S. regulatory agency may require us to perform additional clinical trials before approving any marketing applications for the relevant jurisdiction. Upon inspection, the FDA or applicable non-U.S. regulatory agency may determine that our clinical trials did not comply with GCPs. In addition, our clinical trials will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such products and any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.We intend to rely on other third parties to package, store and deliver drug products to the clinical trial sites for any clinical trials that we may conduct. Any performance failure on the part of these third parties could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.Risks Related to Our Intellectual PropertyIf we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, methods used to develop and manufacture our product candidates and methods for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. Our patent applications may fail to result in patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to patents and patent applications that we use in our business has been found; such prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do 28",
            "type": "paragraph"
        },
        {
            "id": 32,
            "context": "successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims.If the patent applications we hold or patents we have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or strength of protection is threatened, as applicable, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. A patent may be challenged through one or more of several administrative proceedings including post-grant challenges, re-examination or opposition before the USPTO or foreign patent offices. Any successful challenge of patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding, known as an interference, can be initiated to determine which applicant is entitled to the patent on that subject matter. Such an interference proceeding provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications, or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to require us to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license at all, or on commercially reasonable terms. Our defense of a patent or patent application in such a proceeding may not be successful and, even if successful, may result in substantial costs and distract our management and other employees.In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, including processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology are required to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA\u2019s disclosure policies may change in the future, if at all.Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.29",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management or employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys\u2019 fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.If we fail to obtain licenses or comply with our obligations in these agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.We are a party to intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various obligations on us.We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or of our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.Our defense in a lawsuit may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.30",
            "type": "paragraph"
        },
        {
            "id": 34,
            "context": "We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees\u2019 former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.Other Risks Related to Our Business Operations and IndustryOur future success depends on our ability to attract and retain key executives and to attract, retain and motivate qualified personnel.We are highly dependent on principal members of our executive team, and any reduction or loss of their services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit any executive or key employee or the loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.We may need to expand our organization and may experience difficulties in managing our growth, which could disrupt our operations.In the future we may expand our employee base to increase our managerial, scientific, operational, commercial, financial and other resources and we may hire more consultants and contractors. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure or give rise to operational mistakes, loss of business opportunities, loss of employees or reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional or nonintentional failures to comply with the regulations of the FDA and non-U.S. regulators, to provide accurate information to the FDA and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful 31",
            "type": "paragraph"
        },
        {
            "id": 35,
            "context": "| \u25cf | The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute requires mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others, including prescribers, patients, purchasers and formulary managers. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act penalties for which are described below. |\n| \u25cf | Federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act (\u201cFCA\u201d), which imposes criminal or civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties per false claim or statement. |\n| \u25cf | The civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. |\n| \u25cf | The federal Health Insurance Portability and Accountability Act of 1996 (\u201cHIPAA\u201d), which imposes civil and criminal penalties for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare. |\n| \u25cf | HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (\u201cHITECH\u201d), and its implementing regulations, which imposes certain requirements on certain types of individuals and entities, such as healthcare |",
            "type": "table"
        },
        {
            "id": 36,
            "context": "| providers, health plans and healthcare clearing houses, known as \u201ccovered entities,\u201d as well as their \u201cbusiness associates,\u201d independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity, relating to the privacy, security and transmission of individually identifiable health information. |\n| \u25cf | The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians, physician assistants, certain types of advance practice nurses and teaching hospitals, and further requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties; and |\n| \u25cf | Many state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. |",
            "type": "table"
        },
        {
            "id": 37,
            "context": "been signed into law. On December 22, 2017, former President Trump signed into law H.R. 1, \u201cAn Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018,\u201d informally titled the Tax Cuts and Jobs Act, which significantly revises the U.S. Internal Revenue Code of 1986, as amended (the \u201cCode\u201d). The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the \u201cindividual mandate.\u201d Additionally, on December 23, 2019, former President Trump signed a spending bill that repealed the implementation of certain ACA-mandated fees, including the so-called \u201cCadillac\u201d tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the \u201cindividual mandate\u201d was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is uncertain how any such challenges and the healthcare measures of the Biden administration will impact the ACA and our business.In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation\u2019s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, which started in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2031 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. The Medicare reductions were phased back in starting with a 1% reduction in effect from April 1, 2022 to June 30, 2022 before increasing to the full 2% reduction. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, also reduced Medicare payments to several categories of healthcare providers.Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Recently, healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (the \u201cIRA\u201d), in August 2022, which will, among other things, allow U.S. Department of Health and Human Services (\u201cHHS\u201d) to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in October 2023, the IRA will also penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges.The IRA also made changes to Medicare Part D, which provides prescription drug benefits for seniors and people with disabilities. Medicare Part D enrollees once had a gap in their coverage (between the initial coverage limit and the point at which catastrophic coverage begins) where Medicare did not cover their prescription drug costs, known as the coverage gap. However, beginning in 2019, Medicare Part D enrollees paid 25% of brand drug costs after they reached the initial coverage limit - the same percentage they were responsible for before they reached that limit - thereby closing the coverage gap from the enrollee\u2019s point of view. Most of the cost of closing the coverage gap is being borne by innovator companies and the government through subsidies. Each manufacturer of an approved drug or biologic is required to enter into a Medicare Part D coverage gap discount agreement and provide a 70% discount on those drugs dispensed to Medicare Part D enrollees in the coverage gap, in order for its drugs to be reimbursed by Medicare Part D. Beginning in 2025, the IRA eliminates the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees\u2019 prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. Although these discounts represent a lower percentage of enrollees\u2019 costs than the current discounts required below the out-of-pocket maximum (that is, in the coverage gap phase of Part D coverage), the new manufacturer contribution required above the out-of-pocket maximum could be considerable for very high-cost patients and the total contributions by manufacturers to a Part D enrollee\u2019s drug expenses may exceed those currently provided.34",
            "type": "paragraph"
        },
        {
            "id": 38,
            "context": "| \u25cf | impairment of our business reputation; |\n| \u25cf | withdrawal of clinical trial participants; |\n| \u25cf | costs due to related litigation; |\n| \u25cf | distraction of management\u2019s attention from our primary business; |\n| \u25cf | substantial monetary awards to patients or other claimants; |\n| \u25cf | the inability to commercialize our product candidates; and |\n| \u25cf | decreased demand for our product candidates, if approved for commercial sale. |",
            "type": "table"
        },
        {
            "id": 39,
            "context": "costs. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation, and a delay in development of our drug candidates.We have been, and may in the future be, adversely affected by health epidemics and pandemics, including COVID-19, which may significantly harm our business, prospects, financial condition and operating results.We face risks related to health epidemics and other outbreaks, including the global outbreak of the novel coronavirus and the disease caused by it, COVID-19. During 2020, the spread of the novel coronavirus led to disruption and volatility in the global capital markets. If such disruption and volatility recurs, there could be an increase to our cost of capital and an adverse effect on our ability to access the capital markets. In addition, efforts to contain the COVID-19 pandemic led to implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, stay-at-home or shelter-in-place orders, and business shutdowns. The extent to which a pandemic, epidemic or outbreak of an infectious disease impacts our operations, including our clinical trials, will depend on future occurrences, which are highly uncertain and cannot be predicted with confidence, including the duration of any outbreak and the actions to contain or treat its impact, among others. Any negative impact infectious diseases have on patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.Business interruptions could delay us in the process of developing our future products.We are vulnerable to natural disasters such as earthquakes and wildfires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.Risks Related to Us Being an Israeli CompanyShareholders may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws, against us or our executive officers and directors, or asserting U.S. securities laws claims in Israel.Service of process upon us in Israel or upon our non-U.S. resident directors and officers may be difficult to obtain within the United States and it may be difficult to enforce judgments obtained in the United States against our non-U.S. directors and executive officers. In addition, we have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our officers and directors in Israel.Moreover, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel or due to, among other reasons, absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel.Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders of U.S. corporations.Since we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our articles of association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders of U.S.-based corporations. In particular, a shareholder of an Israeli company, such as us, has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards us and other shareholders and to refrain from abusing its power in us, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to our articles of association, an increase of our authorized share capital, a merger, and approval of related party transactions that require 36",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "shareholder approval. A shareholder also has a general duty to refrain from taking advantage of other shareholders. In addition, a controlling shareholder (as defined below), or any shareholder who knows that it possesses the power to determine the outcome of a shareholders\u2019 vote, or who has the power to appoint or prevent the appointment of one of our office holders (as defined below), or who holds any other power in our regard, has a duty to act in fairness towards us. However, Israeli law does not define the substance of this duty of fairness. There is limited case law available to assist in understanding the implications of these provisions that govern shareholder behavior.Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders, and regulates other matters that may be relevant to these types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of Companies, and at least 30 days from the date that the shareholders of both merging companies approved the merger. In addition, the holder of a majority of each class of securities of the target company must approve a merger. Moreover, a full tender offer can only be completed if the acquirer receives at least 95% of the issued share capital (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer, except that if the total votes to reject the tender offer represent less than 2% of the company\u2019s issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender offer), and the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts the offer may not seek appraisal rights).Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to those of our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances, but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred. Additional tax considerations or exemptions from the foregoing may apply to certain non-Israeli tax resident shareholders.These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.Risks Related to Ownership of Our ADSs and Ordinary SharesWe do not know whether a market for our securities will be sustained and as a result it may be difficult for you to sell our securities held by you.Although our ADSs trade on Nasdaq, an active trading market for the ADSs may not be sustained. It may be difficult for you to sell your ADSs without depressing the market price for the ADSs. As a result of these and other factors, you may not be able to sell your ADSs. Further, an inactive market may also impair our ability to raise capital by issuing securities and may impair our ability to enter into strategic partnerships or acquire companies or products by using our equity as consideration.The requirements of being a publicly traded company may strain our resources and divert management\u2019s attention.As a publicly traded company, we have incurred, and will continue to incur, significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act (the \u201cDodd-Frank Act\u201d), as well as rules subsequently implemented by the SEC and Nasdaq under such acts have imposed various requirements on public companies. Shareholder activism, the current political environment and the current high level of government regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these 37",
            "type": "paragraph"
        },
        {
            "id": 41,
            "context": "| \u25cf | our failure to obtain the approvals necessary to commence clinical trials; |\n| \u25cf | results of clinical and preclinical studies; |\n| \u25cf | announcements of regulatory approval or the failure to obtain it, or changes or delays in the regulatory review process; |",
            "type": "table"
        },
        {
            "id": 42,
            "context": "| \u25cf | announcements of new products or product enhancements by us or others; |\n| \u25cf | adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; |\n| \u25cf | changes or developments in laws, regulations or decisions applicable to our product candidates or patents; |\n| \u25cf | any adverse changes to our relationship with manufacturers or suppliers; |\n| \u25cf | announcements concerning our competitors or healthcare industries in general; |\n| \u25cf | achievement of expected product sales and profitability or our failure to meet expectations; |\n| \u25cf | our commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual property infringement actions; |\n| \u25cf | any major changes in our board of directors, management or other key personnel; |\n| \u25cf | announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments; |\n| \u25cf | expiration or terminations of licenses, research contracts or other collaboration agreements; |\n| \u25cf | public concern as to the safety of our products that we, our licensors or others develop; |\n| \u25cf | success of research and development projects; |\n| \u25cf | developments concerning intellectual property rights or regulatory approvals; |\n| \u25cf | variations in our and our competitors\u2019 results of operations; |\n| \u25cf | changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or the ADSs are covered by analysts; |\n| \u25cf | future issuances of ordinary shares, ADSs or other securities; |\n| \u25cf | general market conditions and other factors, including factors unrelated to our operating performance, such as natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency), boycotts, adoption or expansion of government trade restrictions, and other business restrictions; and |\n| \u25cf | the other factors described in this \u201cRisk Factors\u201d section. |",
            "type": "table"
        },
        {
            "id": 43,
            "context": "product approvals. If we face such litigation, it could result in substantial costs, divert management\u2019s attention and resources, and have a material adverse effect on our business, operating results and prospects.Substantial future sales or perceived potential sales of our ordinary shares or ADSs in the public market could cause the price of our ADSs decline.Substantial sales of our ADSs on Nasdaq may cause the market price of our ADSs to decline. Sales by us or our security holders of substantial amounts of our ADSs or the perception that these sales may occur in the future, could cause a reduction in the market price of our shares ADSs. The issuance of any additional ordinary shares or any additional ADSs, or any securities that are exercisable for or convertible into our ordinary shares or ADSs, may have an adverse effect on the market price of our ADSs and will have a dilutive effect on our existing shareholders and holders of ADSs.Your percentage ownership in us may be diluted by future issuances of share capital, which could reduce your influence over matters on which shareholders vote.We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our shareholders may experience substantial dilution. Pursuant to our equity incentive plan, our management may grant options to our employees, directors and consultants. We may sell ordinary shares represented by ADSs, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, any of which may result in material dilution to our existing shareholders. New investors could also be issued securities with rights superior to those of our existing shareholders.We have not paid, and do not intend to pay, dividends on our ordinary shares and, therefore, unless our traded securities appreciate in value, our investors may not benefit from holding our securities.We have not paid any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. Moreover, the Israeli Companies Law, 5759-1999 (the \u201cCompanies Law\u201d) imposes certain restrictions on our ability to declare and pay dividends. As a result, investors in our ADSs or ordinary shares will not be able to benefit from owning these securities unless their market price becomes greater than the price paid by such investors and they are able to sell such securities. We cannot assure you that you will ever be able to resell our securities at a price in excess of the price paid.If we pay dividends or other distributions, an ADS holder may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited circumstances, you may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions, if any, in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly registered or distributed under an applicable exemption from registration. In these cases, the depositary may determine not to distribute such property and hold it as \u201cdeposited securities\u201d or may seek to effect a substitute dividend or distribution, including net cash proceeds from the sale of the dividends that the depositary deems an equitable and practicable substitute. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. In addition, the depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges to the extent the depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.40",
            "type": "paragraph"
        },
        {
            "id": 44,
            "context": "Holders of ADSs must act through the depositary to exercise their rights.Holders of the ADSs do not have the same rights as our shareholders and may only exercise the voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement for the ADSs. Under Israeli law and our articles of association, the minimum notice period required to convene a shareholders meeting is not less than 35 or 21 calendar days, depending on the proposals on the agenda for the shareholders meeting. When a shareholder meeting is convened, holders of the ADSs may not receive sufficient notice of a shareholders meeting to permit them to withdraw their ordinary shares to allow them to cast their vote with respect to any specific matter. In addition, the depositary and its agents may not be able to send voting instructions to holders of the ADSs or carry out their voting instructions in a timely manner. We will make all reasonable efforts to cause the depositary to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct the depositary to vote their ADSs. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of the ADSs may not be able to exercise their right to vote and they may lack recourse if their ADSs are not voted as they requested. In addition, in the capacity as a holder of ADSs, they will not be able to call a shareholders meeting.You may be subject to limitations on transfer of your ADSs.Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.",
            "type": "paragraph"
        },
        {
            "id": 45,
            "context": "Item 1B. Unresolved Staff Comments\nNone.\nItem 2. Properties We do not own any property, and we do not have any contracts or options to acquire or lease any property in the future. We are operating out of a virtual office, which is adequate for our present and planned future operations, as our corporate staff has been working remotely.",
            "type": "paragraph"
        },
        {
            "id": 46,
            "context": "Item 3. Legal Proceedings From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us.",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "Item 4. Mine Safety Disclosures\nNot applicable.\n42\nPART II\nItem 5. Market for Registrant\u2019s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\nMarket Information\nOur ADSs are currently listed on The Nasdaq Capital Market under the symbol \u201cQNRX,\u201d with each ADS representing one ordinary share.\nHolders As of March 13, 2024, our ADSs were held by 7 holders of record, and our ordinary shares were held by 5 holders of record. Bank of New York Mellon (\u201cBNY\u201d) is the depositary for our ADR program, and Computershare Trust Company, N.A. is our transfer agent. The number of record holders was determined from the records of our depositary and transfer agent and does not include beneficial owners of ADSs or ordinary shares whose shares are held in the names of various securities brokers, dealers and registered clearing agencies.",
            "type": "paragraph"
        },
        {
            "id": 48,
            "context": "Dividends We have never declared or paid any dividends on our ordinary shares. We do not anticipate paying any dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand our business. Our board of directors has sole discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our directors may deem relevant. The Companies Law imposes restrictions on our ability to declare and pay dividends.",
            "type": "paragraph"
        },
        {
            "id": 49,
            "context": "Equity Compensation Plan Table\nThe information included in our Equity Compensation Plan Table under Item 12 of Part III of this Annual Report is hereby incorporated by reference into this Item 5 of Part II of the Annual Report.\n\u200b\nItem 6. [Reserved]\n\u200b\n43\nItem 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and related notes to those statements included in this Annual Report. Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (\u201cGAAP\u201d), reflect the operations of Quoin Pharmaceuticals Inc. (\u201cQuoin Inc.\u201d) since inception and include the accounts of Quoin Ltd. since the closing of the Merger (as defined below). In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. \u201cRisk Factors\u201d and the section entitled \u201cCautionary Note Regarding Forward-Looking Statements and Summary of Risk Factors.\u201d",
            "type": "paragraph"
        },
        {
            "id": 50,
            "context": "Overview We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. Our initial focus is on the development of products, using our proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. Our first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare\u00ae technology, is under development as a potential treatment for Netherton Syndrome (\u201cNS\u201d), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (\u201cU.S.\u201d) under an open Investigational New Drug (\u201cIND\u201d) application with the Food and Drug Administration (\u201cFDA\u201d). We are also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (\u201cRDEB\u201d). In addition, we entered into Research Agreements with the Queensland University of Technology (\u201cQUT\u201d), under which we have obtained an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma.",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "Our objective is to develop and commercialize proprietary therapeutic drug products. To this effect, we intend to develop and seek marketing approvals from the FDA and other worldwide regulatory bodies for rare and orphan diseases. To achieve these objectives, we plan to: We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly, we will need to raise additional capital prior to the commercialization of QRX003 or any other product candidate. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our operating activities through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to continue our operations. See \u201cLiquidity and Capital Resources\u201d.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "ADS Ratio Change and Ordinary Share Reverse Split Effective August 1, 2022, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing four hundred (400) ordinary shares to 1 ADS representing five thousand (5,000) ordinary shares, which resulted in a one for 12.5 reverse split of the issued and outstanding ADSs. Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "44 split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. Except as specifically provided, all ordinary share, ADS and related option and warrant information presented herein, including our financial statements and accompanying footnotes, has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes.Key Events MergerOn October 28, 2021, Cellect completed the business combination with Quoin Inc. in accordance with the terms of the Merger Agreement, by and among Cellect, Quoin Inc. and Merger Sub, which was a wholly-owned subsidiary of Cellect, pursuant to which Merger Sub merged with and into Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect. Immediately after completion of the Merger, Cellect changed its name to \u201cQuoin Pharmaceuticals, Ltd.\u201dWe have accounted for the transaction as a reverse recapitalization with Quoin Inc. as the accounting acquirer. Because Quoin Inc. is the accounting acquirer, its historical financial statements became our historical financial statements and such assets and liabilities continued to be recorded at their historical carrying values. The impact of the recapitalization has been retroactively applied to all periods presented.In addition, on October 28, 2021, Cellect sold the entire share capital of its subsidiary, Cellect Biotherapeutics Ltd., which essentially included all of Cellect\u2019s then existing net assets, to EnCellX Inc. (\u201cEnCellX\u201d), a newly formed U.S. privately held company based in San Diego, CA (the \u201cShare Transfer\u201d), pursuant to an Amended and Restated Share Transfer Agreement. We have no interests in EnCellX subsequent to the closing of the Merger.Clinical DevelopmentQuoin\u2019s lead asset, QRX003, is currently in late-stage clinical development in the U.S. under an open IND application with the FDA. Five clinical sites in the U.S. have been opened for our initial study, patients are actively being screened and recruited into the study and dosing commenced in December 2022. This study originally was designed as a randomized, double blinded assessment of two different doses of QRX003 versus a placebo vehicle in 18 adult NS patients. The test materials are applied once daily, over a twelve-week period, to pre-selected areas of the patient\u2019s body. Based on discussions with the FDA, a number of different clinical endpoints are being assessed in the study, including but not limited to, an Investigators Global Assessment (IGA), Patient\u2019s Global Assessment (PaGA) and Pruritis.In November 2022, we submitted a protocol for our second clinical study in NS patients to the FDA under our currently open IND (the \u201cOpen Label Study\u201d). This study was cleared by the FDA to initiate in December 2022. This study originally was designed to be conducted in ten adult NS patients who are currently receiving, and will continue to do so throughout the study, off-label systemic therapy, primarily systemic biologic therapy. This is an open-label study with no placebo control and is being conducted at the same clinical sites as our other ongoing study. Both of our NS clinical studies are running concurrently and utilize the same clinical trial sites and investigators.While there is no assurance regarding the final results of the open label study, on October 24, 2023, we released positive initial clinical results obtained from the first six evaluable subjects in our open-label study. As a result of this positive initial data and the absence of any safety concerns from both studies, on November 8, 2023 we submitted a number of protocol amendments to the FDA, under our open IND, with a view to optimizing both studies and potentially leading to even better clinical outcomes and a more rapid regulatory approval. These protocol amendments included eliminating the lower dose from the double-blinded study, modifying the dosing frequency from once-daily to twice-daily and increasing the number of subjects from 18 to 30. For the open-label study, the number of subjects was increased from 10 to 20 and dosing was modified from once-daily to twice-daily. On December 13, 2023, we announced that we were cleared by the FDA to implement these protocol amendments.45",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "Agreements with Altium Growth Fund, LP and Warrant ExercisesOn October 28, 2021, we completed the private placement transaction with Altium Growth Fund, LP (\u201cAltium\u201d or the \u201cInvestor\u201d) for an aggregate purchase price of approximately $17.0 million (comprised of the set off of approximately $5.0 million of bridge notes from bridge financing earlier in 2021 (the \u201cBridge Notes\u201d), and approximately $12.0 million in cash) (the \u201cPrimary Financing\u201d), which resulted in the net proceeds of approximately $10.1 million. We issued 28,508 ADSs to the Investor.We also issued to the Investor, effective as of March 13, 2022 (i) a Series A Warrant to purchase 28,508 ADSs (the \u201cSeries A Warrant\u201d) (ii) a Series B Warrant to purchase 28,508 ADSs (the \u201cSeries B Warrant\u201d) and (iii) a Series C Warrant to purchase 15,931 ADSs (the \u201cSeries C Warrant\u201d and, together with the Series A Warrant and the Series B Warrant, the \u201cInvestor Warrants\u201d). The exercise price for the Investor Warrants is $597 per ADS, with the Series A Warrant having a five-year maturity, and the Series B Warrant and the Series C Warrant having a two-year maturity.We had the right to require the mandatory exercise of the Series C Warrant, subject to an effective registration statement being in place for the resale of the shares underlying such warrant and the satisfaction of equity market conditions, as defined in the Series C Warrant. In the period from April 22, 2022 to June 30, 2022, the Investor exercised the Series B Warrant in full pursuant to the alternate cashless exercise rights of such warrant, resulting in the issuance of a total of 28,508 ADSs to the Investor. The market related conditions to require the mandatory exercise of the Series C Warrant were not met during the period up to July 14, 2022.On July 14, 2022, we entered into an agreement with Quoin Inc. and Altium (the \u201cAltium Agreement\u201d), pursuant to which the parties agreed to, among other things, (i) amend certain terms of the Series A Warrant and the Investor Exchange Warrants previously issued to Altium to reduce the exercise price to $0.00 per ADS with respect to a total of 33,333 ADSs, (ii) cancel the Series C Warrant and the remaining portion of the Series A Warrant previously issued to Altium, and (iii) terminate the Purchase Agreements, pursuant to which the warrants were previously issued to Altium. The incremental fair value of the modified warrants was approximately $491,000, which was charged against the gross proceeds of the 2022 Offering (see below) as the modification was done in contemplation of the offering. As of August 2, 2022, Altium exercised all of its warrants to purchase ADSs at $0.00 per ADS exercise price, and we issued a total of 33,333 ADSs to Altium.Noteholder Warrant ExercisesCommencing in October 2020, Quoin Inc. issued promissory notes (the \u201c2020 Notes\u201d) to five noteholders, including our directors, Messrs. Langer and Culverwell (collectively, the \u201c2020 Noteholders\u201d). The 2020 Notes were issued at a 25% original issue discount with an aggregate face value of $1,213,313 with interest at a rate of 20% per annum. The 2020 Notes were mandatorily convertible into ADSs based on the valuation negotiated in the Primary Financing. The 2020 Noteholders also received warrants exercisable at any time after the issuance date for a number of shares of Quoin Inc.\u2019s common stock equal to 100% of the \u201cas if converted\u201d shares as if the 2020 Notes principal and interest were convertible at the lowest price any securities are sold, convertible, or exercisable into in the Primary Financing or the next round of financing (whichever is lower). At the closing of the Merger, ADSs were issued to the 2020 Noteholders upon the conversion of the principal of the 2020 Notes. In addition, effective as of March 13, 2022, Quoin Ltd. exchanged Quoin Inc. warrants held by the 2020 Noteholders for warrants on substantially the same terms as the Investor Exchange Warrants, exercisable for 2,449 ADSs, in the aggregate, at the exercise price of $597 per ADS (the \u201cNoteholder Warrants\u201d). The Noteholder Warrants became exercisable immediately upon issuance and expire five years from March 13, 2022. The exercise price of the warrants held by the 2020 Noteholders was also reduced to $0.00 as of July 14, 2022 as a result of the Altium Agreement. The change in the exercise price of the Noteholder Warrants resulted in a deemed dividend of approximately $65,000. From July to September 2022, the 2020 Noteholders exercised all their warrants to purchase ADSs at $0.00 per ADS exercise price, and a total of 2,449 ADSs were issued to such noteholders.Public OfferingsOn August 9, 2022 (the \u201c2022 Closing Date\u201d), we completed an offering (the \u201c2022 Offering\u201d) of 184,167 ordinary shares represented by 184,167 ADSs at a purchase price of $60.00 per ADS and a pre-funded warrant (the \u201c2022 Pre-Funded Warrant\u201d) to purchase 95,833 ordinary shares represented by 95,833 ADSs at a per pre-funded warrant price of $59.9988, with each ADS and 2022 Pre-Funded Warrant accompanied by an ordinary warrant (the \u201c2022 Common Warrant\u201d), for aggregate gross proceeds of $16.8 million, resulting in net proceeds of approximately $14.9 million, after deducting the placement agent\u2019s fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the subsequent exercise of the 2022 Common Warrants. Each 2022 Common Warrant had an exercise price of $60.00 per ADS and was to expire on the fifth anniversary of the 2022 Closing Date. On the 2022 Closing Date, the holder of the 2022 Pre-Funded Warrant exercised its Pre-Funded Warrant in full.46",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "On February 24, 2023 (the \u201c2023 Closing Date\u201d), we completed an offering (the \u201c2023 Offering\u201d) of 412,500 ordinary shares represented by 412,500 ADSs at a purchase price of $12.00 per ADS and a pre-funded warrant (the \u201c2023 Pre-Funded Warrant\u201d) to purchase 170,833 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $11.9988, with each ADS and 2023 Pre-Funded Warrant accompanied by an ordinary warrant (the \u201c2023 Common Warrant\u201d) for aggregate gross proceeds of $7.0 million, resulting in net proceeds of approximately $5.8 million, after deducting the placement agent\u2019s fees and offering expenses paid by us, and excluding the proceeds, if any, from the subsequent exercise of the 2023 Common Warrants. Each 2023 Common Warrant has an exercise price of $12.00 per ADS and expires on the fifth anniversary of the 2023 Closing Date. On the 2023 Closing Date, the holder of the 2023 Pre-Funded Warrant exercised its Pre-Funded Warrant in full.In connection with the 2023 Offering, we entered into an Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares, dated February 24, 2023 (collectively, the \u201c2023 Warrant Amendments\u201d), with each of the purchasers (the \u201c2022 Purchasers\u201d) who participated in both the 2022 Offering and the 2023 Offering. The 2023 Warrant Amendments amended certain terms of the common warrants issued to such 2022 Purchasers in the 2022 Offering. Specifically, the 2023 Warrant Amendments reduced the exercise price of such warrants to $13.20 and extended the term during which those warrants could remain exercisable until February 24, 2028.On March 7, 2024, (the \u201c2024 Closing Date\u201d) we completed an offering (the \u201c2024 Offering\u201d) of the following securities (i) 811,250 ordinary shares represented by ADSs, (ii) 4,062,500 Series D warrants (the \u201cSeries D Warrants\u201d) to purchase 4,062,500 ordinary shares represented by ADSs, (iii) 4,062,500 Series E warrants (the \u201cSeries E Warrants\u201d and together with the Series D Warrants, the \u201c2024 Warrants\u201d) to purchase 4,062,500 ordinary shares represented by ADSs, and (iv) 3,251,250 pre-funded warrants (the \u201c2024 Pre-Funded Warrants\u201d) to purchase 3,251,250 ordinary shares represented by ADSs for aggregate gross proceeds of approximately $6.5 million, resulting in net proceeds of approximately $5.6 million, after deducting the placement agent\u2019s fees and offering expenses paid by us. Each ADS (or 2024 Pre-Funded Warrant to purchase one ADS in lieu thereof) was sold together with a Series D Warrant to purchase one ADS and a Series E Warrant to purchase one ADS. The ADSs and accompanying 2024 Warrants were sold at a combined public offering price of $1.60 and the 2024 Pre-Funded Warrants and accompanying 2024 Warrants were sold at a combined public offering price of $1.5999, which is equal to the combined purchase price per ADS and accompanying 2024 Warrants, minus the exercise price of each 2024 Pre-Funded Warrant of $0.0001. The Series D Warrants and the Series E Warrants have an exercise price of $1.60 per share, are exercisable immediately following the closing of the 2024 Offering and expire in two years and five years, respectively, from the closing of the 2024 Offering.In connection with the 2024 Offering, we entered into a Securities Purchase Agreement (the \u201c2024 Purchase Agreement\u201d) dated March 4, 2024, with certain institutional investors signatory thereto, pursuant to which we agreed to issue and sell to such investors, certain of the ADSs, 2024 Pre-Funded Warrants and 2024 Warrants sold in the 2024 Offering. Pursuant to the terms of the 2024 Purchase Agreement, we agreed, subject to certain exceptions, (i) to not enter into variable rate financings for a period of 180 days following the closing of the 2024 Offering, and (ii) to not enter into any equity financings for 90 days from the closing of the 2024 Offering.On March 7, 2024, we also entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 638,834 ADSs (the \u201cPrior Warrants\u201d) to, among other things, reduce the exercise price of such Prior Warrants to $1.60 and to extend the current expiration date of the Prior Warrants until March 7, 2029.Alumni Equity Line and Purchase AgreementOn January 25, 2024, we entered into a Purchase Agreement (the \u201cAlumni Purchase Agreement\u201d) with Alumni Capital LP (\u201cAlumni\u201d). Pursuant to the Alumni Purchase Agreement, we have the right to sell to Alumni up to $8,000,000 (the \u201cCommitment Amount\u201d) of newly issued ordinary shares that are represented by ADS (the \u201cPurchase Notice Securities\u201d), subject to certain conditions and limitations, from time to time during the term of the Alumni Purchase Agreement. We do not have the right to commence any sales of ordinary shares represented by ADSs to Alumni under the Alumni Purchase Agreement until the date, which we refer to as the Commencement Date, that all of the conditions set forth in the Alumni Purchase Agreement have been satisfied, including that the registration statement we agreed to file with the Securities and Exchange Commission (\u201cSEC\u201d) pursuant to the Alumni Purchase Agreement is declared effective by the SEC, and our shareholders have approved of the issuance of ADSs under the Alumni Purchase Agreement. If shareholder approval of the issuance of ADSs under the Purchase Agreement is not obtained by April 30, 2024, we may terminate the Alumni Purchase Agreement by written notice to Alumni and neither party shall have any obligation or liability to the other party.47",
            "type": "paragraph"
        },
        {
            "id": 56,
            "context": "| \u25cf | employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses, share-based compensation, overhead related expenses and travel related expenses for our research and development personnel; |\n| \u25cf | expenses incurred under agreements with CROs, as well as consultants that support the implementation of the clinical studies described above; |\n| \u25cf | manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch; |",
            "type": "table"
        },
        {
            "id": 57,
            "context": "| \u25cf | formulation, research and development expenses related to QRX003; and other product candidates we may choose to develop; and |\n| \u25cf | costs for sponsored research. |\n| \u25cf | the number of trials required for approval; |\n| \u25cf | the per patient trial costs; |\n| \u25cf | the number of patients that participate in the trials; |\n| \u25cf | the number of sites included in the trials; |\n| \u25cf | the countries in which the trial is conducted; |\n| \u25cf | the length of time required to enroll eligible patients; |\n| \u25cf | the number of doses that patients receive; |\n| \u25cf | the drop-out or discontinuation rates of patients; |\n| \u25cf | the potential additional safety monitoring or other studies requested by regulatory agencies; |\n| \u25cf | the duration of patient follow-up; |\n| \u25cf | the timing and receipt of regulatory approvals; and |\n| \u25cf | the efficacy and safety profile of our product candidates. |",
            "type": "table"
        },
        {
            "id": 58,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year ended December 31, | \u200b | \u200b | \u200b |\n| \u200b | 2023 | 2022 | Change |\n| Operating Expenses | \u200b | \u200b | \u200b |\n| General and administrative | \u200b | $ | 6,070,517 | \u200b | $ | 6,584,868 | \u200b | $ | (514,351) |\n| Research and development | \u200b | 3,307,987 | \u200b | 2,672,836 | \u200b | 635,151 |\n| Total operating expenses | \u200b | 9,378,504 | \u200b | 9,257,704 | \u200b | 120,800 |\n| Other (income) and expenses | \u200b | \u200b | \u200b |\n| Forgiveness of trade payable | \u200b | \u2014 | \u200b | (416,000) | \u200b | 416,000 |\n| Warrant liability (income) expense | \u200b | \u2014 | \u200b | (77,237) | \u200b | 77,237 |\n| Unrealized income | \u200b | \u200b | 2,683 | \u200b | \u200b | (1,307) | \u200b | \u200b | 3,990 |\n| Realized and accrued interest income | \u200b | (694,614) | \u200b | (95,745) | \u200b | (598,869) |\n| Interest and financing expense | \u200b | \u200b | \u2014 | \u200b | \u200b | 714,081 | \u200b | \u200b | (714,081) |\n| Total other expense | \u200b | (691,931) | \u200b | 123,792 | \u200b | (815,723) |\n| Net loss | \u200b | $ | (8,686,573) | \u200b | $ | (9,381,496) | \u200b | $ | 694,923 |",
            "type": "table"
        },
        {
            "id": 59,
            "context": "| \u25cf | the scope, timing, rate of progress and costs of our drug development efforts, preclinical development activities, the timing of laboratory testing and clinical trials for our product candidates; |\n| \u25cf | the number and scope of clinical programs we decide to pursue; |\n| \u25cf | the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates; |\n| \u25cf | the scope and costs of development and commercial manufacturing activities; |\n| \u25cf | the cost and timing associated with commercializing our product candidates, if they receive marketing approval; |\n| \u25cf | the extent to which we acquire or in-license other product candidates and technologies; |\n| \u25cf | the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; |\n| \u25cf | our ability to establish and maintain collaborations on favorable terms, if at all; |\n| \u25cf | our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval; |",
            "type": "table"
        },
        {
            "id": 60,
            "context": "| \u25cf | our implementation of operational, financial and management systems; and |\n| \u25cf | the costs associated with being a public company. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year ended December 31, |\n| \u200b | 2023 | 2022 |\n| Net cash used in operating activities | \u200b | $ | (7,864,429) | \u200b | $ | (8,480,732) |\n| Net cash provided by (used in) investing activities | \u200b | 2,188,316 | \u200b | (10,149,121) |\n| Net cash provided by financing activities | \u200b | 5,216,683 | \u200b | 14,007,708 |\n| Net change in cash and cash equivalents | \u200b | $ | (459,430) | \u200b | $ | (4,622,145) |",
            "type": "table"
        },
        {
            "id": 61,
            "context": "Research and Development CommitmentsIn October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the \u201cLicense Agreement\u201d) with Skinvisible Pharmaceuticals, Inc. (\u201cSkinvisible\u201d), under which Skinvisible granted us an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. We made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the \u201cLicense Fee\u201d). In addition, we agreed to pay Skinvisible a single digit royalty percentage of our net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. We also agreed to pay Skinvisible 25% of any revenues we receive as royalties in the event that we sublicense any licensed products to a third party. The License Agreement also requires that we make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.In November 2020, Quoin Inc. entered into a Master Service Agreement with Therapeutics Inc. for the management of the preclinical and clinical development of QRX003 for Netherton Syndrome. The initial term of the agreement was three years with automatic one year extensions, and the agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. An additional work order was entered into in December 2022 for a second QRX003 clinical study at an expected estimated cost of approximately $830,000. In the years ended December 31, 2023 and 2022, we incurred research and development costs under these agreements of approximately $1.5 million and $1.2 million, respectively. During the year ended December 31, 2023, we received a credit of approximately $278,000 applied to prior expenses incurred during the period of March 2023 to July 2023.In November 2021, we entered into a research agreement with Queensland University of Technology (QUT) for a pre-clinical research program for the development of a product to treat Netherton Syndrome of approximately $250,000. In May 2022, we entered into a second research agreement with QUT for the development of a product to treat Scleroderma of approximately $610,000. Each agreement remains in place until the completion of the research program, which in each case was initially anticipated to be 18 months from execution. For the years December 31, 2023 and 2022, we incurred research and development costs related to these agreements of approximately $361,000 and $353,000 respectively. Critical Accounting EstimatesCritical accounting estimates are those that, in management\u2019s view, are most important to the portrayal of a company\u2019s financial condition and results of operations and most demanding on their calls on judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. We believe our most critical accounting estimates relate to:Research and DevelopmentResearch and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. We accrue for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, we may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.Stock based compensation:We recognize compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.Since we have a limited history of trading as a public company, our expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. We utilize the simplified method to estimate the expected term. 53",
            "type": "paragraph"
        },
        {
            "id": 62,
            "context": "| \u25cf | Significant changes in the manner of our use of the acquired assets or the strategy for our overall business, |\n| \u25cf | Significant underperformance relative to expected historical or projected development milestones, |\n| \u25cf | Significant negative regulatory or economic trends, and |\n| \u25cf | Significant technological changes which could render the platform technology obsolete. |",
            "type": "table"
        },
        {
            "id": 63,
            "context": "Item 7A. Quantitative and Qualitative Disclosures About Market Risk\nWe are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.\nItem 8. Financial Statements and Supplementary Data\nThe information required by this Item is set forth in the consolidated financial statements and notes thereto in Item 15 of Part IV of this Annual Report.\nItem 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure\nNot applicable.\nItem 9A. Controls and Procedures\nDisclosure Controls and Procedures We maintain disclosure controls and procedures, which are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation, as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15e under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "Management\u2019s Annual Report on Internal Control over Financial Reporting Our management, including our Chief Executive Officer and Chief Financial Officer, are responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "54\n\n| \u25cf | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions; |\n| \u25cf | provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles; |\n| \u25cf | provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and |\n| \u25cf | provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements. |",
            "type": "table"
        },
        {
            "id": 66,
            "context": "Item 9B. Other Information During the fourth quarter of 2023, none of our directors or executive officers adopted or terminated any \u201cRule 10b5-1 trading arrangement\u201d or \u201cnon-Rule 10b5-1 trading arrangement\u201d (as each term is defined in Item 408(a) of Registration S-K).",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "Item 10. Directors, Executive Officers and Corporate Governance. Set forth below is certain information regarding the members of our board of directors (the \u201cBoard\u201d or the \u201cBoard of Directors\u201d) and our executive officers. Each director is entitled to serve until the 2024 annual meeting of shareholders and until a successor is duly elected and qualified or until his or her earlier retirement, resignation or removal.",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Name | Age | Position(s) |\n| Dr. Michael Myers | 62 | Chairman of the Board and Chief Executive Officer |\n| Denise Carter | 55 | Director and Chief Operating Officer |\n| Joseph Cooper(1)(3) | 66 | Director |\n| James Culverwell(1)(2) | 67 | Director |\n| Dr. Dennis H. Langer(2) | 72 | Director |\n| Natalie Leong(1)(3) | 38 | Director |\n| Michael Sember(2) | \u200b | 74 | \u200b | Director |\n| Gordon Dunn | 59 | Chief Financial Officer |",
            "type": "table"
        },
        {
            "id": 69,
            "context": "Set forth below is a summary of the business experience of each of our directors and executive officers. Dr. Michael Myers, Chief Executive Officer and Director. Dr. Myers is the co-founder of Quoin Inc. and has served as Chairman and Chief Executive Officer of Quoin Inc. since its inception in 2018. Dr. Myers has served as Chairman and Chief Executive Officer of Quoin Ltd. since October 28, 2021. Dr. Myers has over 36 years of industry experience in the drug delivery and specialty pharmaceutical sectors. From 2003 to October 2015, he served as Chief Executive Officer of Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), a biotherapeutics pharmaceutical company, and was responsible for taking that company public in 2014. From 2001 to 2002, he served as President of the drug delivery division of West Pharmaceutical Services, Inc., a publicly traded company and a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. From 1996 to 1999, Dr. Myers served as the President of Pharmaceutical Operations for Fuisz Technologies (Biovail), a developer of food and drug delivery systems and technologies. From 2000 to 2001, Dr. Myers served as Executive Vice President and Chief Commercial Officer of Flamel Technologies (n/k/a Avadel Pharmaceuticals PLC, a publicly traded company and a specialty pharmaceutical company. From 1987 to 1995, Dr. Myers served as the Head of Pharmaceutical Development for Elan Corporation, a biotechnology drug company. Since 2023, Dr. Myers has served as a director of Cranial Devices, a clinical stage medical device company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company. Dr. Myers earned his Ph.D. in Chemistry from University College Cork, Ireland. We believe Dr. Myers is qualified to serve on our Board due to his extensive knowledge as one of Quoin Inc.\u2019s co-founders and Chief Executive Officer, and his extensive clinical development, commercial and management experience with both public and private life sciences companies.",
            "type": "paragraph"
        },
        {
            "id": 70,
            "context": "Denise Carter, Chief Operating Officer and Director. Ms. Carter is the co-founder of Quoin Inc. and has served as a director and Chief Operating Officer of Quoin Inc. since its inception in 2018. Ms. Carter has served as a director and Chief Operating Officer of Quoin Ltd. since October 28, 2021. Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. From June 2003 to October 2015, Ms. Carter held various positions at Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), including President of Innocoll Pharmaceuticals and Executive Vice President of Business Development and Corporate Affairs of Innocoll AG. From 2001 to 2003, Ms. Carter was the Vice President of Business Development of the drug delivery division of West Pharmaceuticals, Inc., a publicly traded company. From 2000 to 2001, she was the Senior Director of Business Development of Eurand, a specialty pharmaceutical company. From 1996 to 1999, Ms. Carter was the Director of Business Development and Alliance Management of Fuisz Technologies (Biovail). From 1999 to 2000, Ms. Carter was the Director of Business Development of Cardinal Health, Inc., a multi-national health care service company. Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary. We believe Ms. Carter is qualified to serve on our Board due to her extensive knowledge as one of Quoin Inc.\u2019s co-founders and Chief Operating Officer, and her extensive business development, sales and marketing and fund raising experience in the life sciences industry.",
            "type": "paragraph"
        },
        {
            "id": 71,
            "context": "56 Joseph Cooper, Director. Mr. Cooper has served as a director of Quoin Inc. since May 2021. Mr. Cooper has served as a director of Quoin Ltd. since October 28, 2021. Mr. Cooper has significant experience in finance, operation, corporate development and general management roles within the pharmaceutical and healthcare industry. Since July 2023, Mr. Cooper has served as Chief Financial Officer for Hydrinity Skin Sciences, a medical aesthetics company. From 2012 to 2023, Mr. Cooper served as the President of Boulder Cove LC, a pharmaceutical and healthcare consulting company. From September 2019 to December 2022, Mr. Cooper served as the Chief of Strategy and Corporate Development for Resonea, Inc., a digital health company. From August 2018 to December 2019, Mr. Cooper served as the Chief Business Officer of NuvOx Pharmaceuticals, a clinical stage pharmaceutical company. From January 2015 to August 2018, Mr. Cooper served as Chief Financial and Operating Officer for First Place, AZ, a non-profit healthcare services organization. From 1996 to 2010, Mr. Cooper served as the Executive Vice President of Corporate and Product Development of Medicis Pharmaceutical Corp., a publicly traded pharmaceutical and medical aesthetics company. Since January 2018, Mr. Cooper has served as a director of Sonoran Biosciences, a specialty pharmaceutical company. From 2006 to 2007, Mr. Cooper served as a director of Bioenvision, a publicly traded pharmaceutical company. Mr. Cooper holds an MBA from the WP Carey School of Business at Arizona State University and a BA from Northeastern Illinois University. We believe Mr. Cooper is qualified to serve on our Board due to his extensive executive and board experience with pharmaceutical and healthcare companies.James Culverwell, Director. Mr. Culverwell has served as a director of Quoin Inc. since April 2021. Mr. Culverwell has served as a director of Quoin Ltd. since October 28, 2021. Since May 2013, Mr. Culverwell has served as the Chief Executive Officer and is currently Chairman of the Board of Directors of HOX Therapeutics, a prostate cancer research company. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fund raising services for life science companies. From 1992 to 2004, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. From 1982 to 1992, Mr. Culverwell was Director of Healthcare Equity Research at ABN Amro Bank N.V., a private banking company. Since February 2022, Mr. Culverwell has served as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP), a cancer treatment development company. Since January 2005, Mr. Culverwell has served as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems, a high throughput molecular diagnostics company. From April 2016 to September 2019, Mr. Culverwell served as a director and Audit Committee Chairman of Amryt Pharma PLC, a publicly traded company and a commercial-stage biopharmaceutical company. From February 2013 to July 2017, Mr. Culverwell served as a director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen. We believe Mr. Culverwell is qualified to serve on our Board due to his extensive experience serving on the audit and compensation committees for multiple public and private life sciences and healthcare companies.Dennis H. Langer, M.D., J.D., Director. Dr. Langer has served as a director of Quoin Inc. since 2019. Dr. Langer has served as a director of Quoin Ltd. Since October 28, 2021. From 2005 to 2010, Dr. Langer served as the Managing Partner at Phoenix IP Ventures, LLC, a private equity and venture capital fund specializing in life sciences companies. From 2004 to 2005, Dr. Langer was the President, North America for Dr. Reddy\u2019s Laboratories, Inc., a multi-national pharmaceutical company. Dr. Langer was with GlaxoSmithKline, a multi-national pharmaceutical and biotechnology company, from 1994-2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. From 1991 to 1994, he served as President and Chief Executive Officer at Neose Technologies, Inc., a clinical stage biopharmaceutical company. From 2004 to June 2022, Dr. Langer served as a director of Myriad Genetics, Inc., a publicly traded company and a genetic testing and precision medicine company. From 2021 to June 2022, Dr. Langer served as a director of Brooklyn ImmunoTherapeutics, Inc. (n/k/a Eterna Therapeutics Inc.), a publicly traded company and a biotechnology company. From 2007 to 2019, Dr. Langer served as a director of Dicerna Pharmaceuticals Inc., a publicly traded company and a biopharmaceutical company. Dr. Langer serves on the Dean\u2019s Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University. We believe Dr. Langer is qualified to serve on our Board due to his extensive experience as an executive and board member of public and private life sciences and healthcare companies.Natalie Leong, Director. Ms. Leong has served as a director of Quoin Inc. since April 2021. Ms. Leong has served as a director of Quoin Ltd. since October 28, 2021. Since January 2023, Ms. Leong has been the Senior Vice President of Product Management for B.S.D. Capital, Inc. (d/b/a Lendistry), a minority-led small business lender. Ms. Leong was the Head of Finance and Product Strategy (October 2019 \u2013 October 2020) and subsequently Head of Product Management (October 2020 \u2013 November 2022) for LoanStreet Inc., a financial SaaS company. From May 2016 to July 2019, Ms. Leong served as the Lead for the Asset Liability Committee for the US at RBC Capital Markets. In addition, from August 2018 to October 2019, she served as the Lead for Global Originations FP&A for RBC Capital Markets. From October 2011 to May 2016, Ms. Leong worked as the Vice President of Capital Insights at National Australia Bank. From February 2008 to October 2011, Ms. Leong served as a Senior Auditor at National Australia Bank. Ms. Leong earned her MBA at The Wharton School, University of Pennsylvania. She earned a B.Comm degree (Finance and Economics) and a B.A. degree 57",
            "type": "paragraph"
        },
        {
            "id": 72,
            "context": "(French and Literature) from the University of Melbourne in 2007. We believe Ms. Leong is qualified to serve on our Board of directors due to her extensive financial and business management experience.Michael Sember, Director. Mr. Sember has served as a director of Quoin Inc. since May 2021. Mr. Sember has served as a director of Quoin Ltd. since October 28, 2021. Since 2007, he has served as a Principal of Accela Advisors, a biopharmaceutical consulting firm specializing in strategic planning, business development and coaching for startups. From January 2018 to October 2020, From 2022 until 2023, Mr. Sember served as the Chief Executive Officer of RaeSedo, Inc, a startup therapeutics company spin out of the University of Arizona. Mr. Sember served as the Chief Executive Officer of Regulonix Holding, Inc., a drug development company. From October 2015 to March 2019, he served as the Mentor in Residence to companies formed from inventions discovered at the University of Arizona. From 2013 to 2015, Mr. Sember was the Corporate Turnaround Specialist and Chief Executive Officer of Palyon Medical Corporation, a drug delivery system company. From 1991 to 2002, Mr. Sember was Executive Vice President of Corporate Business Development for \u00c9lan Corporation, responsible for strategic collaborations and mergers and acquisitions. From 1973 to 1991, Mr. Sember served as the Senior director of Global Program Management at Marion Laboratories (later Marion Merrell Dow). From 2013 to 2015, Mr. Sember was the Chairman of the Board of Paylon Medical Corporation, a drug delivery system company. From 2012 to 2013, Mr. Sember was the Chairman of the Board of BioIndustry Organization of Southern Arizona, a non-profit trade group. Mr. Sember earned a Bachelor of Science degree from the University of Pittsburgh and an MBA from Rockhurst University. We believe Mr. Sember is qualified to serve on our Board due to his broad executive and capital raising experience in the life sciences industry.Gordon Dunn, Chief Financial Officer. Mr. Dunn has served as Chief Financial Officer of Quoin Ltd. since November 1, 2021. Mr. Dunn has over 30 years of finance experience. He served as Chief Financial Officer of Health Technologies Ltd. (d/b/a Qured), a UK-based healthcare provider, from March 2020 to October 2021, and as Chief Financial Officer of U-Research, an online company information platform, from July 2017 to March 2020. Mr. Dunn also served as Chief Financial Officer of Anton Corporation, a film and media finance company, from September 2016 to July 2017, and as Chief Financial Officer of Innocoll AG from 2012 to 2016. Prior to these roles, he had deep experience in investment banking and private equity, serving as Portfolio Manager of NewSmith Asset Management, a private equity fund from 2004 to 2014, and as Director of Investment Banking and Co-Head of Private Equity at Merrill Lynch, in addition to other roles, from 1994 to 2003. Mr. Dunn was an associate at Morrison & Foerster LLP from 1991 to 1993. Mr. Dunn earned his JD from New York University School of Law and a BA from Stanford University.Delinquent Section 16(a) ReportsSection 16(a) of the Exchange Act and the regulations promulgated thereunder require our executive officers, directors and persons who beneficially own more than 10% of our common stock to file forms with the SEC to report their ownership of the Company\u2019s shares and any changes in ownership. We have reviewed all forms filed electronically with the SEC during, and with respect to, 2023. Based on that review and written information given to us by all of our directors and executive officers, we believe that all of our directors, executive officers and holders of more than 10% of our stock filed on a timely basis all reports that they were required to file under Section 16(a) during fiscal 2023, except for a late Form 3 filed on March 7, 2023 for Michael Sember.Code of EthicsWe have adopted a Code of Ethics and Business Conduct (the \u201cCode of Ethics\u201d) that applies to all of our directors, officers and employees, including our principal executive officer and our principal financial and accounting officer. A copy of our Code of Ethics has been posted to the \u201cInvestors\u2014Corporate Governance\u201d section of our website www.quoinpharma.com, and it is attached as an exhibit to this Annual Report. If we make any amendment to the Code of Ethics or grant any waivers, including any implicit waiver, from a provision of the Code of Ethics, we will disclose the nature of such amendment or waiver on our website www.quoinpharma.com. to the extent required by the rules and regulations of the SEC. The information on the website is not and should not be considered part of this Form 10-K and is not incorporated by reference in this Form 10-K.Board of DirectorsThe Board of Directors has established three standing committees: the Audit Committee, the Compensation Committee and the Nominating and Governance Committee.Audit CommitteeThe Audit Committee of the Board of Directors consists of Joseph Cooper, James Culverwell, and Natalie Leong, with Mr. Culverwell chairing the committee.58",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "| \u25cf | overseeing our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; |\n| \u25cf | recommending the engagement or termination of the person filling the office of our internal auditor; |\n| \u25cf | recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; |\n| \u25cf | determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; |\n| \u25cf | determining the approval process for transactions that are \u2018non-negligible\u2019 (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, which determination may be based on annually pre-determined criteria; |\n| \u25cf | determining whether to approve certain related party transactions (including transactions in which an office holder (as defined below) has a personal interest and whether such transaction is extraordinary or material under the Companies Law); |\n| \u25cf | examining the work plan of the internal auditor before its submission to our board of directors and proposing amendments thereto or, upon a decision of the board of directors, acting as the corporate body to approve such work plan; |\n| \u25cf | examining our internal controls and internal auditor\u2019s performance, including whether the internal auditor has sufficient resources and tools at his disposal to fulfill his responsibilities; |\n| \u25cf | examining the scope of our independent auditor\u2019s work and compensation and submitting a recommendation with respect thereto to our board of directors; and |\n| \u25cf | establishing procedures for the handling of employees\u2019 complaints as to the management of our business and the protection to be provided to such employees. |\n| \u25cf | recommending to our board of directors a policy regarding the terms of engagement of the company\u2019s office holders, to which we refer as a \u201ccompensation policy\u201d; |",
            "type": "table"
        },
        {
            "id": 74,
            "context": "| \u25cf | recommending whether the compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years); |\n| \u25cf | recommending to the board of directors updates to the compensation policy from time to time; |\n| \u25cf | assessing implementation of the compensation policy; |\n| \u25cf | resolving whether to approve arrangements with respect to the terms of office and employment of office holders, which require the approval of the compensation committee pursuant to the Companies Law; |\n| \u25cf | exempting, under certain circumstances, a transaction with our Chief Executive Officer from the approval of our shareholders.; |\n| \u25cf | making other determinations that the Companies Law assigns to a compensation committee; |\n| \u25cf | reviewing and recommending for approval by the board of directors the overall compensation policies with respect to our Chief Executive Officer and other executive officers; |\n| \u25cf | reviewing and recommending for approval by the board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers; |\n| \u25cf | evaluating the performance of our Chief Executive Officer and other executive officers in light of such goals and objectives; |\n| \u25cf | reviewing and approving the granting of options and other incentive awards, including the exercise of authorities delegated by the board of directors regarding the grant of equity incentives under our equity compensation plans; |\n| \u25cf | reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors; |\n| \u25cf | overseeing our compliance with SEC and Nasdaq rules related to shareholder approval of certain executive compensation matters and equity compensation plans; |\n| \u25cf | considering and implementing policies with respect to oversight, assessment and management of risks associated with our compensation polices; and |\n| \u25cf | reviewing and establishing appropriate insurance coverage for our office holders. |\n| \u25cf | such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or |\n| \u25cf | the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation policy and who vote against the policy does not exceed two percent (2%) of the aggregate voting rights in the Company. |",
            "type": "table"
        },
        {
            "id": 75,
            "context": "| \u25cf | the education, skills, experience, expertise and accomplishments of the relevant office holder; |\n| \u25cf | the office holder\u2019s position and responsibilities; |\n| \u25cf | prior compensation agreements with the office holder; |\n| \u25cf | the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost to the average and median salary of such employees of the company, as well as the impact of disparities between them on the work relationships in the company; |\n| \u25cf | if the terms of employment include variable components \u2014 the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and |\n| \u25cf | if the terms of employment include severance compensation \u2014 the term of employment or office of the office holder, the terms of the office holder\u2019s compensation during such period, the company\u2019s performance during such period, the office holder\u2019s individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company. |\n| \u25cf | with regards to variable components: |\n| \u25cf | with the exception of office holders who report to the chief executive officer, a means of determining the variable components on the basis of long-term performance and measurable criteria; provided that the company may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based on non-measurable criteria, or if such amount is not higher than three months\u2019 salary per annum, taking into account such office holder\u2019s contribution to the company; |\n| \u25cf | the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their payment, or in the case of equity-based compensation, at the time of grant; |\n| \u25cf | a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of the office holder\u2019s terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company\u2019s financial statements; |",
            "type": "table"
        },
        {
            "id": 76,
            "context": "| \u25cf | evaluating our corporate leadership structure, and reviewing important issues and developments in corporate governance, and developing appropriate recommendations for the Board; and |\n| \u25cf | overseeing and assisting our board in reviewing and recommending nominees for election as directors and members of committees of our board. |\n| \u25cf | information on the advisability of a given action brought for the office holder\u2019s approval or performed by virtue of his or her position; and |\n| \u25cf | all other important information pertaining to any such action. |\n| \u25cf | refrain from any conflict of interest between the performance of the office holder\u2019s duties to the company and his or her other duties or personal affairs; |\n| \u25cf | refrain from any activity that is competitive with the company; |\n| \u25cf | refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and |\n| \u25cf | disclose to the company any information or documents relating to the company\u2019s affairs which the office holder received as a result of his or her position as an office holder. |",
            "type": "table"
        },
        {
            "id": 77,
            "context": "| \u25cf | an amendment to the company\u2019s articles of association; |\n| \u25cf | an increase of the company\u2019s authorized share capital; |\n| \u25cf | a merger; or |\n| \u25cf | interested party transactions that require shareholder approval. |",
            "type": "table"
        },
        {
            "id": 78,
            "context": "| \u25cf | a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator\u2019s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company\u2019s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the above mentioned events and amount or criteria; |\n| \u25cf | reasonable litigation expenses, including legal fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; |\n| \u25cf | reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third-party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent; |\n| \u25cf | expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and |\n| \u25cf | expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder pursuant to certain provisions of the Israeli Economic Competition Law, 5758-1988. |\n| \u25cf | a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; |\n| \u25cf | a breach of the duty of care to the company or to a third-party, including a breach arising out of the negligent conduct of the office holder; |\n| \u25cf | a financial liability imposed on the office holder in favor of a third-party; |\n| \u25cf | a financial liability imposed on the office holder in favor of a third-party harmed by a breach in an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and |",
            "type": "table"
        },
        {
            "id": 79,
            "context": "| \u25cf | expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law. |\n| \u25cf | a breach of the duty of loyalty, except with respect to insurance coverage or indemnification, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; |\n| \u25cf | a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; |\n| \u25cf | an act or omission committed with intent to derive illegal personal benefit; or |\n| \u25cf | a fine, monetary sanction, or forfeit levied against the office holder. |\n| \u25cf | at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, vote in favor of the inconsistent provisions of the compensation package, excluding abstentions; or |\n| \u25cf | the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the inconsistent provisions of the compensation package does not exceed two percent (2%) of the aggregate voting rights in the Company. |",
            "type": "table"
        },
        {
            "id": 80,
            "context": "Executive officers other than the chief executive officer\u200bThe Companies Law requires the compensation of a public company\u2019s executive officers (other than the chief executive officer and who do not also serve as a director) be approved in the following order: (i) the compensation committee, (ii) the company\u2019s board of directors, and (iii) if such compensation arrangement is inconsistent with the company\u2019s stated compensation policy, the company\u2019s shareholders (by a special vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy).\u200bHowever, there are exceptions to the foregoing approval requirements with respect to such non-director executive officers. If the shareholders of the company do not approve the compensation of such a non-director executive officer, the compensation committee and board of directors may override the shareholders\u2019 disapproval for such non-director executive officer provided that the compensation committee and the board of directors each document the basis for their decision to override the disapproval of the shareholders and approve the compensation.\u200bAn amendment to an existing compensation arrangement with a non-director executive officer requires only the approval of the compensation committee, if the compensation committee determines that the amendment is immaterial. However, if such non-director executive officer is subordinate to the chief executive officer, an immaterial amendment to an existing compensation arrangement shall not require the approval of the compensation committee if (i) such amendment is approved by the chief executive officer, (ii) the company\u2019s compensation policy allows for such immaterial amendments to be approved by the chief executive officer and (iii) the engagement terms are consistent with the company\u2019s compensation policy.\u200bChief Executive officer\u200bUnder the Companies Law, the compensation of a public company\u2019s chief executive officer is required to be approved by: (i) the company\u2019s compensation committee, (ii) the company\u2019s board of directors and (iii) the company\u2019s shareholders (by a special vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy). However, if the shareholders of the company do not approve the compensation arrangement with a chief executive officer who does not serve as a director, the compensation committee and board of directors may override the shareholders\u2019 decision provided that they each document the basis for their decision and the compensation is in accordance with the company\u2019s compensation policy. The approval of each of the compensation committee and board of directors should be in accordance with the company\u2019s compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy).\u200bIn the case of a new chief executive officer, the compensation committee may waive the shareholder approval requirement with regard to the compensation of a candidate for the chief executive officer position if the compensation committee determines that: (i) the compensation arrangement is consistent with the company\u2019s compensation policy, (ii) the chief executive officer candidate did not have, on the date of his appointment or during the two-year period preceding his appointment, an \u201caffiliation\u201d (including an employment relationship, a business or professional relationship or control) with the company or a controlling shareholder of the company or a relative thereof and (iii) subjecting the approval of the engagement to a shareholder vote would impede the company\u2019s ability to employ the chief executive officer candidate. However, if the chief executive officer candidate will serve as a member of the board of directors, such candidate\u2019s compensation terms as chief executive officer must be approved in accordance with the rules applicable to approval of compensation of directors.67",
            "type": "paragraph"
        },
        {
            "id": 81,
            "context": "Item 11. Executive Compensation\nSummary Compensation Table The following table sets forth information concerning the compensation awarded to, earned by, or paid to our Chief Executive Officer, Chief Operating Officer and Chief Financial Officer (collectively referred to as \u201cnamed executive officers\u201d or \u201cCovered Office Holders\u201d) during the years ended December 31, 2023 and 2022.",
            "type": "paragraph"
        },
        {
            "id": 82,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Option | All Other | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Salary | \u200b | Bonus(1) | Awards(2) | \u200b | Compensation(3) | \u200b | Total(4) |\n| Name and Principal Position | Year | ($) | \u200b | ($) | \u200b | ($) | \u200b | ($) | \u200b | ($) |\n| Dr. Michael Myers | \u200b | 2023 | \u200b | 602,250 | \u200b | \u2014 | \u200b | 292,263 | \u200b | 59,550 | \u200b | 954,063 |\n| Chief Executive Officer | \u200b | 2022 | \u200b | 550,000 | \u200b | 247,500 | \u200b | 1,112,187 | \u200b | 57,112 | \u200b | 1,966,799 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Denise Carter | \u200b | 2023 | \u200b | 481,800 | \u200b | \u2014 | \u200b | 292,266 | \u200b | 56,000 | \u200b | 830,066 |\n| Chief Operating Officer | \u200b | 2022 | \u200b | 440,000 | \u200b | 198,000 | \u200b | 1,112,187 | \u200b | 55,215 | \u200b | 1,805,402 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Gordon Dunn(4) | \u200b | 2023 | \u200b | 394,200 | \u200b | \u2014 | \u200b | 184,635 | \u200b | \u2014 | \u200b | 578,835 |\n| Chief Financial Officer | \u200b | 2022 | \u200b | 360,000 | \u200b | 162,000 | \u200b | 926,822 | \u200b | 1,385 | \u200b | 1,450,207 |",
            "type": "table"
        },
        {
            "id": 83,
            "context": "\u200b\n68\n\n| (3) | Represents amounts paid as office and automobile allowance to Mr. Myers and Ms. Carter under their respective employment agreements, as well as the employer matching contribution to the executive\u2019s 401(k) plan contributions under our Section 401(k) retirement plan (the \u201cSection 401(k) Plan\u201d), broken down as follows: |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Office | \u200b | Car | \u200b | 401(k) | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Allowance | \u200b | Allowance | \u200b | Contributions | \u200b | Total |\n| \u200b | \u200b | ($) | ($) | ($) | ($) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Michael Myers | \u200b | 2023 | \u200b | 30,000 | \u200b | 18,000 | \u200b | 11,550 | \u200b | 59,550 |\n| \u200b | \u200b | 2022 | \u200b | 30,000 | \u200b | 18,000 | \u200b | 9,112 | \u200b | 57,112 |\n| Denise Carter | \u200b | 2023 | \u200b | 30,000 | \u200b | 18,000 | \u200b | 8,000 | \u200b | 56,000 |\n| \u200b | \u200b | 2022 | \u200b | 30,000 | \u200b | 18,000 | \u200b | 7,215 | \u200b | 55,215 |\n| Gordon Dunn | \u200b | 2023 | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 |\n| \u200b | \u200b | 2022 | \u200b | \u2014 | \u200b | \u2014 | \u200b | 1,385 | \u200b | 1,385 |",
            "type": "table"
        },
        {
            "id": 84,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Number of | Number of |\n| \u200b | \u200b | Securities | \u200b | Securities | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Underlying | \u200b | Underlying | \u200b | Option | \u200b | \u200b |\n| \u200b | \u200b | Unexercised | \u200b | Unexercised | \u200b | Exercise | \u200b | Option |\n| \u200b | \u200b | Options (#) | \u200b | Options (#) | \u200b | Price(2) | \u200b | Expiration |\n| Name | \u200b | Exercisable | \u200b | Unexercisable(1) | \u200b | ($) | \u200b | Date |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Dr. Michael Myers | 1,786 | 5,357 | \u200b | 210.00 | \u200b | 04/12/2032 |\n| \u200b | \u200b | \u2014 | \u200b | 80,965 | \u200b | 5.75 | \u200b | 10/26/2033 |\n| Denise Carter | 1,786 | 5,357 | \u200b | 210.00 | \u200b | 04/12/2032 |\n| \u200b | \u200b | \u2014 | \u200b | 80,966 | \u200b | 5.75 | \u200b | 10/26/2033 |\n| Gordon Dunn | \u200b | 1,488 | \u200b | 4,465 | \u200b | 210.00 | \u200b | 04/12/2032 |\n| \u200b | \u2014 | 51,149 | \u200b | 5.75 | \u200b | 10/26/2033 |\n| (1) | Represents the number of ADSs issuable upon the exercise of options. The 2022 options vest in four equal annual installments beginning on April 12, 2023. The 2023 options vest in in three annual installments of 20% and a fourth annual installment of 40% beginning on October 26, 2024. |\n| (2) | Represents the exercise price per ADS. |",
            "type": "table"
        },
        {
            "id": 85,
            "context": "Potential Payments Upon Termination or in Connection With a Change of ControlEmployment AgreementsPursuant to each of the Myers Agreement and the Carter Agreement, Dr. Myers and Ms. Carter, respectively, are entitled to the following benefits upon termination of their employment:\u25cfTermination for any reason: Upon the termination of such executive\u2019s employment for any reason, such executive will receive (i) his or her Base Salary (as defined in the Myers Agreement or the Carter Agreement, as applicable) through the Exit Date (as defined in the Myers Agreement or the Carter Agreement, as applicable), (ii) any Bonuses (as defined in the Myers Agreement or the Carter Agreement, as applicable) to which he or she is entitled and has already earned for the prior fiscal year, and (iii) any other accrued or vested benefits or reimbursements through the Exit Date to which such executive is entitled to contractually or by operation of law.\u25cfTermination upon death or Disability: In the event of the executive\u2019s termination due to his or her death or Disability (as defined in the Myers Agreement or the Carter Agreement, as applicable), then, in addition to the payments set forth above, the executive will receive his or her pro rata portion of the Bonus such executive would have been entitled to receive for the fiscal year in which the Exit Date occurs, based upon the percentage of the fiscal year that elapsed through the Exit Date. Additionally, in the event of termination due to Disability, the executive will receive, for a period of 24 months following the Exit Date, such executive monthly COBRA premium.\u25cfTermination without Cause or for Good Reason: In addition to the payments set forth in the first bullet above, if Dr. Myers or Ms. Carter is terminated by the Company without Cause (as defined in the Myers Agreement or the Carter Agreement, as applicable), or Dr. Myers or Ms. Carter terminates his or her employment for Good Reason (as defined in the Myers Agreement or the Carter Agreement, as applicable), he or she will be entitled to receive (i) his or her Base Salary for 2 years from the Exit Date and 2 times the current years\u2019 Bonus, and (ii) continuation of such executive\u2019s medical benefits for 2 years from the Exit Date (unless the executive becomes employed elsewhere during such 2 year period and is eligible to receive comparable medical benefits).As a condition precedent to receiving any of the foregoing benefits, Dr. Myers and/or Ms. Carter, as applicable, must first sign a Release (as defined in the Myers Agreement or the Carter Agreement, as applicable).Mr. Dunn, pursuant to the Dunn Agreement, is also entitled to the following benefits upon termination of his employment:\u25cfGarden Leave: During any period of notice to terminate Mr. Dunn\u2019s employment, Mr. Dunn will continue to be entitled to his basic salary and contractual benefits in the usual course.\u25cfPayment in lieu of notice: Upon the termination of Mr. Dunn\u2019s employment at any time, Mr. Dunn will receive payment equal to his basic salary as of the termination date which he would have been entitled to receive under the Dunn Agreement during the notice period referred to in the bullet below, less income tax and national insurance contributions. Payment in lieu of notice will not include (i) any bonus or commission payments that might otherwise have been paid to Mr. Dunn during the period for which such payment in lieu of notice is made, (ii) benefits Mr. Dunn would have been entitled to during such time, and (iii) holiday entitlement that would have accrued during such time.\u25cfTermination: Subject to successful completion of the probationary employment period as set forth in the Dunn Agreement, and except in connection with certain \u201cfor cause\u201d events, as set forth in Section 20.2 of the Dunn Agreement, the Company may terminate Mr. Dunn\u2019s employment by giving at least 12 months\u2019 prior written notice, and is obligated to continue paying Mr. Dunn his basic salary and other benefits during such notice period.The foregoing descriptions of the Myers Agreement, the Carter Agreement and the Dunn Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of the Myers Agreement, the Carter Agreement and the Dunn Agreement, copies of which are included as exhibits to this Annual Report.Option AwardsUnder the Plan, upon termination of employment for any reason, other than in the event of death or disability or for \u201dCause\u201d (as defined in the Plan), all unvested options will expire and all vested options at time of termination will generally be exercisable for 71",
            "type": "paragraph"
        },
        {
            "id": 86,
            "context": "| \u25cf | each non-employee director receives an annual base retainer of $75,000; |\n| \u25cf | each committee chairperson receives an additional retainer of $15,000 for his or her service as a chairperson; and |\n| \u25cf | each member of a standing committee receives an additional retainer of $5,000 for such service on a standing committee. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Fees Earned or | Option |\n| \u200b | \u200b | Paid in Cash | \u200b | Awards(1) | \u200b | Total |\n| Name | \u200b | ($) | \u200b | ($) | \u200b | ($) |\n| Joseph Cooper | 85,000 | \u200b | 27,622 | \u200b | 112,622 |\n| James Culverwell | 95,000 | \u200b | 27,622 | \u200b | 122,622 |\n| Dr. Dennis H. Langer | 90,000 | \u200b | 27,622 | \u200b | 117,622 |\n| Natalie Leong | 95,000 | \u200b | 27,622 | \u200b | 122,622 |\n| Michael Sember | 80,000 | \u200b | 27,622 | \u200b | 107,622 |\n| (1) | Represents the grant date fair value of option awards granted to each of our non-employee directors on October 26, 2023, calculated in accordance with FASB ASC Topic 718. These options have an exercise price of $5.75 per ADS and vest in four equal annual installments beginning on October 26, 2024. The option values were calculated using a Black-Scholes Model for pricing options. See Note 7 to Consolidated Financial Statements included in this Annual Report for all relevant valuation assumptions used to determine the grant date fair value of these options. As of December 31, 2023 the aggregate number of outstanding options held by each of our non-employee directors was 8,724 ADSs. |",
            "type": "table"
        },
        {
            "id": 87,
            "context": "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters\nSecurity Ownership of Certain Beneficial Owners and Management\nThe following table sets forth information relating to the beneficial ownership of our ordinary shares as of March 13, 2024 by: Beneficial ownership is determined in accordance with the rules of the SEC and generally means sole or shared power to vote or direct the voting or to dispose or direct the disposition of any ordinary shares. Unless otherwise indicated in the footnotes to this table, we believe that each of the persons named in this table has sole voting and investment power with respect to the shares indicated as being beneficially owned.",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "72\n\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Amount and Nature of Beneficial | Percentage |\n| Name and Address of Beneficial Owner | \u200b | Ownership | \u200b | of Class |\n| Directors and Named Executive Officers: | \u200b | \u200b | \u200b | \u200b |\n| Dr. Michael Myers(1) | \u200b | 12,930 | \u200b | * |\n| Denise Carter(2) | \u200b | 12,929 | \u200b | * |\n| Joseph Cooper(3) | \u200b | 715 | \u200b | * |\n| James Culverwell(4) | \u200b | 1,032 | \u200b | * |\n| Dr. Dennis Langer(5) | \u200b | 1,065 | \u200b | * |\n| Natalie Leong(6) | \u200b | 715 | \u200b | * |\n| Michael Sember(7) | \u200b | 715 | \u200b | * |\n| Gordon Dunn(8) | \u200b | 2,977 | \u200b | * |\n| All directors and officers as a group (8 persons) (9) | \u200b | 33,078 | \u200b | * |\n| (1) | Consists of (i) 9,358 ordinary shares held directly and (ii) 3,572 ordinary shares issuable upon the exercise of options. |\n| (2) | Consists of (i) 9,357 ordinary shares held directly and (ii) 3,572 ordinary shares issuable upon exercise of options. |\n| (3) | Represents 715 ordinary shares issuable upon exercise of options. |\n| (4) | Consists of (i) 317 ordinary shares held directly and (ii) 715 ordinary shares issuable upon exercise of options. |\n| (5) | Consists of (i) 350 ordinary shares held directly and (ii) 715 ordinary shares issuable upon exercise of options. |\n| (6) | Represents 715 ordinary shares issuable upon exercise of options. |\n| (7) | Represents 715 ordinary shares issuable upon exercise of options. |\n| (8) | Represents 2,977 ordinary shares issuable upon exercise of options. |\n| (9) | Consists of (i) 19,382 ordinary shares held directly and (ii) 13,696 ordinary shares issuable upon the exercise of options. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | Number of securities |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | remaining available for |\n| \u200b | \u200b | Number of securities | \u200b | Weighted-average | \u200b | future issuance under equity |\n| \u200b | \u200b | to be issued upon exercise | \u200b | exercise price of | \u200b | compensation plans |\n| \u200b | \u200b | of outstanding options, | \u200b | outstanding options, | \u200b | (excluding securities reflected |\n| Plan category | \u200b | warrants and rights(1) | \u200b | warrants and rights(2) | \u200b | in column (a) |\n| \u200b | (a) | \u200b | (b) | (c) |\n| Equity compensation plans approved by security holders | 278,011 | \u200b | $ | 25.34 | 41,386 |\n| Equity compensation plans not approved by security holders | \u2014 | \u200b | \u2014 | \u2014 |\n| Total | 278,011 | \u200b | $ | 25.34 | 41,386 |\n| (1) | Represents the number of ADSs issuable upon the exercise of options. |\n| (2) | Represents the weighted-average exercise price of outstanding options exercisable into ADSs. |",
            "type": "table"
        },
        {
            "id": 89,
            "context": "Item 13. Certain Relationships and Related Transactions, and Director Independence\nDirector Independence\nThe Board determined that Joseph Cooper, James Culverwell, Dr. Dennis Langer, Natalie Leong, and Michael Sember, qualify as independent directors, as such term is defined under Nasdaq listing rules.\nCertain Relationships and Related Transactions In 2021, Quoin Inc. paid $100,000 of consulting expenses to a company controlled by Dennis Langer, our director, and approximately $8,000 and $48,000 and $12,000 were paid in 2021, 2022, and 2023, respectively, to Dr. Myers\u2019 son, who was consulting Quoin Inc. on research and development matters from time to time. As of March 31, 2023, Dr. Myers\u2019 son no longer provides consulting services to Quoin.",
            "type": "paragraph"
        },
        {
            "id": 90,
            "context": "Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid by Dr. Myers and Ms. Carter to third parties on behalf of Quoin Inc., were not paid by Quoin Inc. to Dr. Myers and Ms. Carter, and were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to repay the above-described non-interest-bearing indebtedness. We repaid $125,000,$300,000 and $300,000 of such indebtedness to Dr. Myers and $160,000, $300,000 and $300,000 to Ms. Carter in 2021, 2022 and 2023, respectively. As of December 31, 2023, approximately $1,959,000 and $1,565,000 of such indebtedness was outstanding to Dr. Myers and Ms. Carter, respectively.",
            "type": "paragraph"
        },
        {
            "id": 91,
            "context": "Commencing in October 2020, Quoin Inc. issued promissory notes (the \u201c2020 Notes\u201d) to five noteholders, including our directors, Messrs. Langer and Culverwell (collectively, \u201c2020 Noteholders\u201d). The 2020 Notes were issued at a 25% original issue discount with an aggregate face value of $1,213,313 with an interest at a rate of 20% per annum. The 2020 Noteholders also received warrants exercisable at any time after the issuance date. At the closing of the Merger in October 2021, 432 ADSs were issued to the 2020 Noteholders upon the conversion of the principal of the 2020 Notes, of which 52 ADSs were issued to Mr. Langer and 47 ADSs were issued to Mr. Culverwell. In December 2021, we concluded that the calculation of ADSs due to the 2020 Noteholders did not account for accrued interest due when the ADSs were issued. We reached cash settlements with two 2020 Noteholders, who are not our directors, to account for this. Based on the terms of these cash settlements, we estimate the liability to the remaining three 2020 Noteholders, including our directors, to be $1,146,000 as of December 31, 2023 and 2022. The exercise price of the warrants held by the 2020 Noteholders was reduced to $0.00 as of July 14, 2022 as a result of agreement with Quoin\u2019s investor. The change in the exercise price of the Noteholder Warrants resulted in a deemed dividend of approximately $65,000. From July to September 2022, the 2020 Noteholders exercised all their warrants to purchase ADSs at $0.00 per ADS exercise price, and a total of 2,449 ADSs were issued to such noteholders, of which 298 ADSs were issued to Mr. Langer and 270 ADSs were issued to Mr. Culverwell.",
            "type": "paragraph"
        },
        {
            "id": 92,
            "context": "\u200b\n74\nItem 14. Principal Accountant Fees and Services The Company\u2019s shareholders appointed Friedman LLP (\u201cFriedman\u201d) as the Company\u2019s independent registered public accounting firm for the year ended December 31, 2021. Based on information provided by Friedman, effective September 1, 2022, Friedman combined with Marcum LLP (\u201cMarcum\u201d). Marcum has served as the Company\u2019s independent registered public accounting firm since September 1, 2022.",
            "type": "paragraph"
        },
        {
            "id": 93,
            "context": "The following table sets forth the aggregate accounting fees paid by us to Marcum and Friedman for all services, including audit services, for the years ended December 31, 2023 and 2022, as applicable.\n\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended | Year Ended |\n| \u200b | \u200b | December 31, 2023 | \u200b | December 31, 2022 |\n| Type of Fees (a) (in thousands) | \u200b | \u200b |\n| Audit Fees | \u200b | $ | 244 | \u200b | $ | 258 |\n| Audit-Related Fees | \u200b | \u200b | \u2014 | \u200b | \u2014 |\n| Tax Fees | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| All Other Fees | \u200b | \u200b | \u2014 | \u200b | \u2014 |\n| Total | \u200b | $ | 244 | \u200b | $ | 258 |",
            "type": "table"
        },
        {
            "id": 94,
            "context": "\u200b\nAudit Fees. Audit fees refer to the aggregate fees, including expenses, for the audit of our annual financial statements and review of financial statements included in our quarterly reports and other services that are normally provided in connection with statutory and regulatory filings or engagements.\nAudit-Related Fees. Audit-Related fees refer to the aggregate fees, including expenses, for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements not reported under \u201cAudit Fees\u201d above.\nTax Fees. Our independent registered public accounting firm did not provide any tax services during the periods.\nAll Other Fees. Our independent registered public accounting firm did not provide any \u201cother services\u201d during the periods.\nPre-Approval Policy Our audit committee has a pre-approval policy for the engagement of our independent registered public accounting firm to perform audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and tax services, if any, that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee.",
            "type": "paragraph"
        },
        {
            "id": 95,
            "context": "\u200b\n75\nPART IV\u200b\nItem 15.\nExhibit and Financial Statement Schedules\n\u200b\n(a)(1) Financial Statements\nAs part of this Annual Report, the consolidated financial statements are listed in the accompanying index to financial statements on page F-1.\n(a)(2) Financial Statement Schedules.\nAll financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.\n(a)(3) Exhibits.\nThe following is a list of exhibits filed as part of this Annual Report.\n\n| Exhibit No. | Exhibit Description |\n| 2.1 | \u200b | Agreement and Plan of Merger and Reorganization, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC, Inc. and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021). |\n| 2.2 | \u200b | Amendment made as of September 24, 2021, to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC, Inc., and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 99.2 to Form 6-K filed with the SEC on September 27, 2021). |\n| 2.3 | \u200b | Amended and Restated Share Transfer Agreement, dated May 27, 2021 by and between Cellect Biotechnology Ltd. and EnCellX Inc. (incorporated by reference to Exhibit 2.2 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on June 16, 2021). |\n| 2.4 | \u200b | Amendment made as of September 26, 2021, to the Amended and Restated Share Transfer Agreement dated as of May 27, 2021, by and between EnCellX, Inc. and Cellect Biotechnology Ltd. (incorporated by reference to Exhibit 99.3 to Form 6-K filed with the SEC on September 27, 2021). |\n| 2.5 | \u200b | Securities Purchase Agreement, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., Quoin Pharmaceuticals, Inc. and the investors named on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.4 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021). |\n| 2.6 | \u200b | Securities Purchase Agreement, dated as of March 24, 2021, by and among Quoin Pharmaceuticals, Inc. and the investors listed on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.6 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021). |\n| 2.7 | \u200b | Amendment Agreement, dated as of September 17, 2021, by and among Quoin Pharmaceuticals, Inc., Cellect Biotechnology, Ltd., and Altium Growth Fund, L.P. (incorporated by reference to Exhibit 99.1 of the Form 6-K filed with the Securities and Exchange Commission on September 17, 2021). |\n| 2.8 | \u200b | Letter Agreement, dated September 17, 2021, between Quoin Pharmaceuticals, Inc. and Cellect Biotechnology, Ltd. (incorporated by reference to Exhibit 99.2 of the Form 6-K filed with the Securities and Exchange Commission on September 17, 2021). |\n| 2.9 | \u200b | Second Amendment Agreement, dated as of March 13, 2022, by and among Quoin Pharmaceuticals, Inc., Quoin Pharmaceuticals Ltd., and Altium Growth Fund, L.P. (incorporated by reference to Exhibit 4.1 to Form 6\u2013K filed with the SEC on March 28, 2022). |\n| 2.10 | \u200b | Waiver Agreement, dated June 6, 2022, by and among Quoin Pharmaceuticals Ltd., Quoin Pharmaceuticals, Inc. and Altium Growth Fund, LP (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on June 6, 2022). |\n| 2.11 | \u200b | Agreement, dated July 14, 2022, by and among Quoin Pharmaceuticals, Inc., Quoin Pharmaceuticals Ltd. and Altium Growth Fund, LP (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on July 15, 2022). |\n| 2.12 | \u200b | Letter of Agreement among Cellect Biotechnology Ltd, Dr. Shai Yarkoni and EnCellX, Inc. (incorporated by reference to Exhibit 2.5 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on July 16, 2021). |\n| 2.13 | \u200b | Form of Representative Agreement among Cellect Biotechnology Ltd, Eyal Leibovitz, as Representative, and EnCellX, Inc. (incorporated by reference to Exhibit 2.6 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on August 6, 2021). |\n| 3.1 | \u200b | Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on February 28, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on February 8, 2022). |",
            "type": "table"
        },
        {
            "id": 96,
            "context": "76\n\n| 3.2 | \u200b | Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on April 12, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022). |\n| 3.3 | \u200b | Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on November 3, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on September 21, 2022). |\n| 3.4 | \u200b | Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on October 26, 2023 (incorporated by reference to Annex A included in the proxy statement filed with the SEC on September 12, 2023). |\n| 4.1 | \u200b | Form of Deposit Agreement between Cellect Biotechnology Ltd. (n/k/a Quoin Pharmaceuticals Ltd.), The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder (incorporated by reference to Exhibit 4.1 to Registration Statement on Form F-1/A as filed with the SEC on July 26, 2016). |\n| 4.2 | \u200b | Specimen American Depositary Receipt (included in Exhibit 2.1). |\n| 4.3 | \u200b | Form of Contingent Value Rights Agreement, by and among Cellect Biotechnology, Ltd., Eyal Leibovitz in the capacity of Representative and Computershare, Inc. in the capacity of Rights Agent (incorporated by reference to Exhibit 4.14 to Registration Statement on Form F-4 filed with the SEC on August 6, 2021). |\n| 4.4 | \u200b | Registration Rights Agreement, dated as of March 24, 2021, by and between Cellect Biotechnology Ltd. and the investors listed on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.5 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021). |\n| 4.5 | \u200b | Form of Primary Warrants for the Purchase Agreement (incorporated by reference to Exhibit B to Exhibit 10.4 to Form 6-K filed with the SEC on March 24, 2021). |\n| 4.6 | \u200b | Form of Exchange Warrant (incorporated by reference to Exhibit 99.1 to Form 6-K filed with the SEC on September 17, 2021). |\n| 4.7 | \u200b | Form of Series A Warrant (incorporated by reference to Exhibit 2.5 to Form 20-F filed with the SEC on April 13, 2022). |\n| 4.8 | \u200b | Form of Series B Warrant (incorporated by reference to Exhibit 2.6 to Form 20-F filed with the SEC on April 13, 2022). |\n| 4.9 | \u200b | Form of Series C Warrant (incorporated by reference to Exhibit 2.7 to Form 20-F filed with the SEC on April 13, 2022). |\n| 4.10 | \u200b | Form of Warrant Agent Agreement between Cellect Biotechnology Ltd. and Computershare Inc., as warrant agent, including the form of Warrant (incorporated by reference to Exhibit 4.6 of the Registration Statement on Form F-1 filed with the SEC on February 7, 2019). |\n| 4.11 | \u200b | Form of Securities Purchase Agreement, dated August 5, 2022 (incorporated by reference to Exhibit 4.11 of the Registration Statement on Form F-1/A filed with the SEC on August 4, 2022). |\n| 4.12 | \u200b | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.12 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022). |\n| 4.13 | \u200b | Form of Common Warrant (incorporated by reference to Exhibit 4.13 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022). |\n| 4.14 | \u200b | Form of Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on February 28, 2023). |\n| 4.15 | \u200b | Form of Securities Purchase Agreement, dated February 22, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023). |\n| 4.16 | \u200b | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023). |\n| 4.17 | \u200b | Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023). |\n| 4.18 | \u200b | Placement Agency Agreement by and between A.G.P. / Alliance Global Partners and Quoin Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023 |\n| 4.19 | \u200b | Description of Registrant\u2019s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. |\n| 4.20 | \u200b | Form of Pre-Funded Warrant issued in the 2024 Offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 4.21 | \u200b | Form of Series D Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 4.22 | \u200b | Form of Series E Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 4.23 | \u200b | Form of Amendment to Warrants to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 10.1# | \u200b | Compensation Policy for Executives and Directors of Quoin Pharmaceuticals Ltd, adopted on April 12, 2022 (incorporated by reference to Annex B included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022). |\n| 10.2# | \u200b | Amended and Restated Equity Incentive Plan of Quoin Pharmaceuticals Ltd., effective as of April 12, 2022 (incorporated by reference to Annex C included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022). |",
            "type": "table"
        },
        {
            "id": 97,
            "context": "| 10.3# | \u200b | Form of Indemnification and Release Agreement, entered into by and between Quoin Pharmaceuticals Ltd. and each of the officers and directors of Quoin Pharmaceuticals Ltd. as of April 12, 2022 (incorporated by reference to Annex D included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022). |\n| 10.4# | \u200b | Executive Employment Agreement, dated March 9, 2018, by and between Quoin Pharmaceuticals, Inc. and Dr. Michael Myers (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on October 29, 2021). |\n| 10.5# | \u200b | Executive Employment Agreement, dated March 9, 2018, by and between Quoin Pharmaceuticals, Inc. and Denise Carter (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on October 29, 2021). |\n| 10.6# | \u200b | Service Agreement, dated November 1, 2021, by and between Quoin Pharmaceuticals, Inc. and Gordon Dunn (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.7 | \u200b | Research Agreement, dated November 1, 2021, by and between Quoin Pharmaceuticals, Inc. and Queensland University of Technology (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.8 | \u200b | License and Distribution Agreement, dated November 5, 2021, by and between Quoin Pharmaceuticals, Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.3 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.9 | \u200b | Supply Agreement, dated September 15, 2021, by and between Quoin Pharmaceuticals, Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.4 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.10 | \u200b | License and Distribution Agreement, dated November 7, 2021, by and between Quoin Pharmaceuticals, Inc. and GenPharm Services FZ LLC (incorporated by reference to Exhibit 10.5 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.11 | \u200b | Supply Agreement, dated November 7, 2021, by and between Quoin Pharmaceuticals, Inc. and GenPharm Services FZ LLC (incorporated by reference to Exhibit 10.6 to Form 6-K filed with the SEC on November 23, 2021). |\n| 10.12 | \u200b | Distribution Agreement, dated December 15, 2021, by and between Quoin Pharmaceuticals, Inc. and Orpharm LLC (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on December 20, 2021). |\n| 10.13 | \u200b | License and Distribution Agreement, dated as of January 24, 2022 between the Company and E-Log Logistica LTDA (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on January 31, 2022). |\n| 10.14 | \u200b | License and Distribution Agreement, dated as of February 1, 2022, by and between Quoin Pharmaceuticals Ltd. and Er-Kim \u0130la\u00e7 Sanayi ve Ticaret A.\u015e, and the First Amendment to the License and Distribution Agreement, dated as of February 17, 2022, by and between Quoin Pharmaceuticals, Inc. and Er-Kim \u0130la\u00e7 Sanayi ve Ticaret A.\u015e (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.4 to Form 6-K filed with the SEC on March 8, 2022). |\n| 10.15 | \u200b | License and Distribution Agreement, dated as of February 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.5 to Form 6-K filed with the SEC on March 8, 2022). |\n| 10.16 | \u200b | Supply Agreement, dated as of February 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (incorporated by reference to Exhibit 10.6 to Form 6-K filed with the SEC on March 8, 2022). |\n| 10.17 | \u200b | License Agreement, dated June 14, 2022, by and between Quoin Pharmaceuticals, Inc. and WinHealth Investment (HK) Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on June 17, 2022). |\n| 10.18 | \u200b | License and Distribution Agreement, dated July 14, 2022, by and between Quoin Pharmaceuticals, Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on July 15, 2022). |\n| 10.19 | \u200b | Supply Agreement, dated July 14, 2022, by and between Quoin Pharmaceuticals, Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.3 to Form 6-K filed with the SEC on July 15, 2022). |\n| 10.20 | \u200b | Research Agreement, dated May 20, 2022, by and between Quoin Pharmaceuticals, Inc. and Queensland University of Technology, Australia (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on June 6, 2022). |\n| 10.21 | \u200b | Exclusive License Agreement, dated October 17, 2019, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.30 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.22 | \u200b | Exclusive License Agreement Renewal, dated May 8, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.31 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.23 | \u200b | First Amendment to the Exclusive License Agreement, dated July 31, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.32 to Form 20-F filed with the SEC on April 13, 2022). |",
            "type": "table"
        },
        {
            "id": 98,
            "context": "| 10.24 | \u200b | Second Amendment to the Exclusive License Agreement, dated September 30, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.33 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.25 | \u200b | Third Amendment to the Exclusive License Agreement, dated January 27, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.34 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.26 | \u200b | Fourth Amendment to the Exclusive License Agreement, dated April 19, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.35 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.27 | \u200b | Fifth Amendment to the Exclusive License Agreement, dated June 14, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.36 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.28 | \u200b | Quotation \u2013 Tech Transfer and Clinical Manufacture for QRX003 Topical Lotion, dated April 8, 2021, by Ferndale Contract Manufacturing to Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.37 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.29 | \u200b | Development and Supply Agreement, dated January 13, 2021, by and between TopChem Pharmaceuticals Limited and Quoin Pharmaceuticals Limited (incorporated by reference to Exhibit 4.38 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.30 | \u200b | Master Services Agreement, dated November 2, 2020, by and between Therapeutics, Inc. and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.39 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.31 | \u200b | Term Sheet for Agreement, dated October 29, 2019, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.40 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.32 | \u200b | Term Sheet for Agreement, dated January 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (re: QRX003) (incorporated by reference to Exhibit 4.41 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.33 | \u200b | Term Sheet for Agreement, dated January 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (re: QRX004) (incorporated by reference to Exhibit 4.42 to Form 20-F filed with the SEC on April 13, 2022). |\n| 10.34# | \u200b | Form of Non-Qualified Stock Option Award Agreement for directors (incorporated by reference to Exhibit 10.34 to Form F-1 filed with the SEC on August 3, 2022). |\n| 10.35# | \u200b | Form of Non-Qualified Stock Option Award Agreement for officers (incorporated by reference to Exhibit 10.35 to Form F-1 filed with the SEC on August 3, 2022). |\n| 10.36 | \u200b | License and Distribution Agreement, by and between Quoin Pharmaceuticals Inc. and Farma Mondo (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on September 13, 2023). |\n| 10.37 | \u200b | Purchase Agreement, dated January 25, 2024, by and between Quoin Pharmaceuticals Ltd. and Alumni Capital LP (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on January 30, 2024). |\n| 10.38 | \u200b | Securities Purchase Agreement dated March 4, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 10.39 | \u200b | Placement Agency Agreement dated March 4, 2024 (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024). |\n| 14.1 | \u200b | Code of Ethics. (incorporated by reference to Exhibit 14.1 to Form 10-K filed with the SEC on March 15, 2023). |\n| 21.1 | \u200b | Subsidiaries of Registrant (incorporated by reference to Exhibit 8.1 to Form 20-F filed with the SEC on April 13, 2022). |\n| 23.1* | \u200b | Consent of Marcum LLP, Certified Public Accountants |\n| 31.1* | \u200b | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934. |\n| 31.2* | \u200b | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934. |\n| 32.1* | \u200b | Certification of Chief Executive Officer pursuant to 18 U.S.C. \u00a7 1350. |\n| 32.2* | \u200b | Certification of Chief Financial Officer pursuant to 18 U.S.C. \u00a7 1350. |\n| 97.1* | \u200b | Clawback Policy |\n| 101* | \u200b | Information formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Shareholders\u2019 Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements. |\n| 104* | \u200b | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101) |",
            "type": "table"
        },
        {
            "id": 99,
            "context": "| Date: March 14, 2024 | QUOIN PHARMACEUTICALS LTD. |\n| \u200b | \u200b | \u200b |\n| \u200b | By: | /s/ Dr. Michael Myers |\n| \u200b | Name: | Dr. Michael Myers |\n| \u200b | Title: | Chief Executive Officer |\n| Signature | Title | Date |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Dr. Michael Myers | \u200b | Chairman and Chief Executive Officer | \u200b | March 14, 2024 |\n| Dr. Michael Myers | \u200b | (Principal Executive Officer) | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Gordon Dunn | \u200b | Chief Financial Officer | \u200b | \u200b |\n| Gordon Dunn | \u200b | (Principal Financial Officer and Principal Accounting Officer) | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Denise Carter | \u200b | \u200b | \u200b | \u200b |\n| Denise Carter | \u200b | Director and Chief Operating Officer | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Joseph Cooper | \u200b | \u200b | \u200b | \u200b |\n| Joseph Cooper | \u200b | Director | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ James Culverwell | \u200b | \u200b | \u200b | \u200b |\n| James Culverwell | \u200b | Director | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Dennis Langer | \u200b | \u200b | \u200b | \u200b |\n| Dennis Langer | \u200b | Director | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Natalie Leong | \u200b | \u200b | \u200b | \u200b |\n| Natalie Leong | \u200b | Director | \u200b | March 14, 2024 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Michael Sember | \u200b | \u200b | \u200b | \u200b |\n| Michael Sember | \u200b | Director | \u200b | March 14, 2024 |",
            "type": "table"
        },
        {
            "id": 100,
            "context": "| \u200b | Page |\n| Reports of Independent Registered Public Accounting Firm (PCAOB Firm ID: Marcum LLP # 688 ) | F-2 |\n| Consolidated Financial Statements | \u200b |\n| Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022 | F-4 |\n| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-5 |\n| Consolidated Statements of Shareholders\u2019 Equity for the years ended December 31, 2023 and 2022 | F-6 |\n| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-7 |\n| Notes to consolidated financial statements | F-8 \u2013 F-22 |",
            "type": "table"
        },
        {
            "id": 101,
            "context": "REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMTo the Shareholders and Board of Directors of Quoin Pharmaceuticals Ltd.Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of Quoin Pharmaceuticals Ltd. (the \u201cCompany\u201d) as of December 31, 2023 and 2022, the related consolidated statements of operations, shareholders\u2019 equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the \u201cfinancial statements\u201d). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.Basis for OpinionThese financial statements are the responsibility of the Company\u2019s management. Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (\u201cPCAOB\u201d) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company\u2019s internal control over financial reporting. Accordingly, we express no such opinion.Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.Critical Audit MattersThe critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.F-2\u200b\u200b",
            "type": "paragraph"
        },
        {
            "id": 102,
            "context": "| Critical Audit Matter Description | As discussed in Note 3 to the financial statements, the Company records costs for clinical trial activities based upon estimates of costs incurred through the balance sheet date for services performed by contract research organizations, clinical study sites and other vendors. |\n| \u200b | \u200b | \u200b |\n| \u200b | \u200b | Auditing the recognition of pre-clinical and clinical trial costs associated with contracted organizations is challenging due to the significant judgment required to determine the nature and level of services that have been received, including determining the progress to completion of specific tasks and activities conducted in relation to what has been invoiced and recorded. |\n| \u200b | \u200b | \u200b |\n| How We Addressed the Matter in Our Audit | \u200b | The primary procedures we performed to address this critical audit matter included: |\n| \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u25cfObtained an understanding of the design and operating effectiveness of internal controls for pre-clinical and clinical cost recognition. |\n| \u200b | \u200b | \u25cfTested the completeness and accuracy of the underlying data used in the estimates including, but not limited to, the estimated costs per project milestone and duration. |\n| \u200b | \u200b | \u25cfAssessed the reasonableness of the significant assumptions, corroborated the progress of the pre-clinical and clinical trials with the Company\u2019s operations personnel and to information obtained by the Company directly from third parties, and to information in contracts or statements of work including costs for those activities and project duration. |\n| \u200b | \u200b | \u25cfExamined subsequent invoicing received from such third parties. |",
            "type": "table"
        },
        {
            "id": 103,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, | \u200b | December 31, |\n| \u200b | 2023 | 2022 |\n| ASSETS | \u200b | \u200b |\n| Current assets: | \u200b | \u200b |\n| Cash and cash equivalents | \u200b | $ | 2,401,198 | \u200b | $ | 2,860,628 |\n| Investments | \u200b | \u200b | 8,293,663 | \u200b | \u200b | 9,992,900 |\n| Prepaid expenses and other current assets | \u200b | 591,034 | \u200b | 516,584 |\n| Total current assets | \u200b | 11,285,895 | \u200b | 13,370,112 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Prepaid expenses - long term | \u200b | 300,000 | \u200b | 383,390 |\n| Intangible assets, net | \u200b | 583,334 | \u200b | 704,561 |\n| Total assets | \u200b | $ | 12,169,229 | \u200b | $ | 14,458,063 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| LIABILITIES AND SHAREHOLDERS\u2019 EQUITY | \u200b | \u200b |\n| Current liabilities: | \u200b | \u200b |\n| Accounts payable | \u200b | $ | 526,523 | \u200b | $ | 605,600 |\n| Accrued expenses | \u200b | 1,308,706 | \u200b | 1,175,705 |\n| Accrued interest and financing expense | \u200b | 1,146,251 | \u200b | 1,146,251 |\n| Due to officers - short term | \u200b | 600,000 | \u200b | 600,000 |\n| Total current liabilities | \u200b | \u200b | 3,581,480 | \u200b | \u200b | 3,527,556 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Due to officers - long term | \u200b | \u200b | 2,923,733 | \u200b | \u200b | 3,523,733 |\n| Total liabilities | \u200b | $ | 6,505,213 | \u200b | $ | 7,051,289 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Commitments and contingencies | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Shareholders\u2019 equity: | \u200b | \u200b |\n| Ordinary shares, no par value per share, 100,000,000 and 8,333,334 ordinary shares authorized at December 31, 2023 and 2022, respectively - 987,220 ( 987,220 ADS\u2019s) ordinary shares issued and outstanding at December 31, 2023 and 403,887 ( 403,887 ADS\u2019s) at December 31, 2022 | \u200b | $ | \u2014 | \u200b | $ | \u2014 |\n| Treasury stock, - 0 - ordinary shares issued at December 31, 2023 and 45 ordinary shares issued at December 31, 2022 | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 2,932,000 ) |\n| Additional paid in capital | \u200b | 51,867,336 | \u200b | 47,855,521 |\n| Accumulated deficit | \u200b | ( 46,203,320 ) | \u200b | ( 37,516,747 ) |\n| Total shareholders\u2019 equity | \u200b | 5,664,016 | \u200b | 7,406,774 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Total liabilities and shareholders\u2019 equity | \u200b | $ | 12,169,229 | \u200b | $ | 14,458,063 |",
            "type": "table"
        },
        {
            "id": 104,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Years Ended December 31, |\n| \u200b | 2023 | 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Operating expenses | \u200b | \u200b | \u200b | \u200b |\n| General and administrative | \u200b | $ | 6,070,517 | \u200b | $ | 6,584,868 |\n| Research and development | \u200b | 3,307,987 | \u200b | 2,672,836 |\n| Total operating expenses | \u200b | 9,378,504 | \u200b | \u200b | 9,257,704 |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Other (income) and expenses | \u200b | \u200b |\n| Forgiveness of accounts payable | \u200b | \u2014 | \u200b | ( 416,000 ) |\n| Warrant liability (income) expense | \u200b | \u2014 | \u200b | ( 77,237 ) |\n| Unrealized loss (gain) | \u200b | \u200b | 2,683 | \u200b | \u200b | ( 1,307 ) |\n| Realized and accrued interest income | \u200b | \u200b | ( 694,614 ) | \u200b | \u200b | ( 95,745 ) |\n| Interest and financing expense | \u200b | \u2014 | \u200b | 714,081 |\n| Total other (income) expense | \u200b | ( 691,931 ) | \u200b | 123,792 |\n| Net loss | \u200b | $ | ( 8,686,573 ) | \u200b | $ | ( 9,381,496 ) |\n| Deemed dividend on warrant modification | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 65,266 ) |\n| Net loss attributable to shareholders | \u200b | $ | ( 8,686,573 ) | \u200b | $ | ( 9,446,762 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Loss per ADS | \u200b | \u200b |\n| Loss per ADS | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Basic | \u200b | $ | ( 9.64 ) | \u200b | $ | ( 46.81 ) |\n| Fully-diluted | \u200b | $ | ( 9.64 ) | \u200b | $ | ( 46.81 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Weighted average number of ADS\u2019s outstanding | \u200b | \u200b |\n| Basic | \u200b | 900,919 | \u200b | 201,826 |\n| Fully-diluted | \u200b | \u200b | 900,919 | \u200b | \u200b | 201,826 |",
            "type": "table"
        },
        {
            "id": 105,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Additional | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Ordinary | \u200b | \u200b | \u200b | No Par | \u200b | Treasury | \u200b | Paid in | \u200b | Accumulated | \u200b | \u200b | \u200b |\n| \u200b | Shares | ADS\u2019s | Value | Stock | Capital | Deficit | Total |\n| Balance at December 31, 2021 | \u200b | 55,913 | \u200b | 55,913 | \u200b | $ | \u2014 | \u200b | $ | ( 2,932,000 ) | \u200b | $ | 31,659,017 | \u200b | $ | ( 28,069,985 ) | \u200b | $ | 657,032 |\n| Net loss | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | ( 9,381,496 ) | \u200b | ( 9,381,496 ) |\n| Stock based compensation | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | 764,007 | \u200b | \u2014 | \u200b | 764,007 |\n| Issuance of ADS and Pre-Funded Warrants, net | 280,000 | \u200b | 280,000 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | 14,877,332 | \u200b | \u2014 | \u200b | 14,877,332 |\n| Cashless exercise of warrants | 64,292 | \u200b | 64,292 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 |\n| Settlement of accrued expenses | 3,682 | \u200b | 3,682 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | 193,537 | \u200b | \u2014 | \u200b | 193,537 |\n| Reclassification of warrant liability upon issuance of Exchange warrant | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 296,362 | \u200b | \u200b | \u2014 | \u200b | \u200b | 296,362 |\n| Deemed dividend on warrant modifcation | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | 65,266 | \u200b | ( 65,266 ) | \u200b | \u2014 |\n| Balance at December 31, 2022 | \u200b | 403,887 | \u200b | 403,887 | \u200b | $ | \u2014 | \u200b | $ | ( 2,932,000 ) | \u200b | $ | 47,855,521 | \u200b | $ | ( 37,516,747 ) | \u200b | $ | 7,406,774 |\n| Net loss | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 8,686,573 ) | \u200b | \u200b | ( 8,686,573 ) |\n| Stock based compensation | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 1,094,549 | \u200b | \u200b | \u2014 | \u200b | \u200b | 1,094,549 |\n| Retirement of Treasury Stock | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 2,932,000 | \u200b | \u200b | ( 2,932,000 ) | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| Issuance of ADS and Pre-Funded Warrants, net | \u200b | 583,333 | \u200b | 583,333 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 5,849,266 | \u200b | \u200b | \u2014 | \u200b | \u200b | 5,849,266 |\n| Balance at December 31, 2023 | \u200b | 987,220 | \u200b | 987,220 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 51,867,336 | \u200b | $ | ( 46,203,320 ) | \u200b | $ | 5,664,016 |",
            "type": "table"
        },
        {
            "id": 106,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Years Ended December 31, |\n| \u200b | 2023 | 2022 |\n| Cash flows used in operating activities: | \u200b | \u200b | \u200b | \u200b |\n| Net loss | $ | ( 8,686,573 ) | \u200b | $ | ( 9,381,496 ) |\n| Change in fair value of warrant liability | \u200b | \u2014 | \u200b | ( 77,237 ) |\n| Stock based compensation | \u200b | 1,094,549 | \u200b | 764,007 |\n| Forgiveness of trade payable | \u200b | \u2014 | \u200b | ( 416,000 ) |\n| Amortization of intangibles | \u200b | \u200b | 103,706 | \u200b | \u200b | 104,043 |\n| Asset impairment | \u200b | \u200b | 17,521 | \u200b | \u200b | \u2014 |\n| Increase in accrued interest and financing expense | \u200b | \u200b | \u2014 | \u200b | \u200b | 714,081 |\n| Unrealized gain and accrued interest on investments | \u200b | \u200b | ( 489,079 ) | \u200b | \u200b | ( 93,779 ) |\n| Changes in assets and liabilities: | \u200b | \u200b |\n| Increase in accounts payable and accrued expenses | \u200b | 53,924 | \u200b | ( 217,806 ) |\n| Decrease in prepaid expenses & other assets | \u200b | 41,523 | \u200b | 123,455 |\n| Net cash used in operating activities | $ | ( 7,864,429 ) | \u200b | $ | ( 8,480,732 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash flows provided by (used in) investing activities: | \u200b | \u200b |\n| Purchase of investments | \u200b | $ | ( 18,090,684 ) | \u200b | $ | ( 9,899,121 ) |\n| Proceeds from maturity of investments | \u200b | \u200b | 20,279,000 | \u200b | \u200b | \u2014 |\n| Payment for license acquisition | \u200b | \u2014 | \u200b | ( 250,000 ) |\n| Net cash provided by (used in) investing activities | $ | 2,188,316 | \u200b | $ | ( 10,149,121 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash flows provided by financing activities: | \u200b | \u200b |\n| Payments of deferred financing costs | $ | ( 32,583 ) | \u200b | $ | 42,045 |\n| Payment of amounts due to officers | \u200b | ( 600,000 ) | \u200b | ( 599,999 ) |\n| Payment of interest on \u201cBridge Notes\u201d | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 311,670 ) |\n| Proceeds from sale of equity securities, net | \u200b | 5,849,266 | \u200b | 14,877,332 |\n| Net cash provided by financing activities | $ | 5,216,683 | \u200b | $ | 14,007,708 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net change in cash and cash equivalents: | \u200b | ( 459,430 ) | \u200b | ( 4,622,145 ) |\n| Cash and cash equivalents - beginning of year | \u200b | 2,860,628 | \u200b | 7,482,773 |\n| Cash and cash equivalents - end of year | $ | 2,401,198 | \u200b | $ | 2,860,628 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Supplemental information - Non cash items: | \u200b | \u200b | \u200b | \u200b |\n| Reclassification of warrant liability to equity upon issuance of \u201cExchange warrants\u201d | \u200b | $ | \u2014 | \u200b | $ | 296,362 |\n| Deemed dividend on warrant modification | \u200b | $ | \u2014 | \u200b | $ | 65,266 |\n| Offering expenses associated with warrant modification | \u200b | $ | 238,231 | \u200b | $ | 491,601 |\n| Settlement of accrued expenses | \u200b | $ | \u2014 | \u200b | $ | 193,537 |",
            "type": "table"
        },
        {
            "id": 107,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 NOTE 1 \u2013 ORGANIZATION AND BUSINESS Quoin Pharmaceuticals Ltd. (\u201cQuoin Ltd.,\u201d or the \u201cCompany\u201d), formerly known as Cellect Biotechnology Ltd. (\u201cCellect\u201d), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (\u201cQuoin Inc.\u201d). Quoin Inc. was incorporated in Delaware on March 5, 2018. On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the \u201cMerger\u201d). Immediately after completion of the Merger, Cellect changed its name to \u201cQuoin Pharmaceuticals Ltd.\u201dThe Company is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Company\u2019s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Company\u2019s first lead product, QRX003, is a topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare\u00ae technology, is under development as a potential treatment for Netherton Syndrome (\u201cNS\u201d), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (\u201cU.S.\u201d) under an open Investigational New Drug (\u201cIND\u201d) application with the Food and Drug Administration (\u201cFDA\u201d). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (\u201cRDEB\u201d). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (\u201cQUT\u201d), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma. To date, no products have been commercialized and no revenue has been generated. \u200b NOTE 2 - LIQUIDITY RISKS AND OTHER UNCERTAINTIESThe Company has incurred net losses every year since inception and has an accumulated deficit of approximately $ 46.2 million at December 31, 2023. The Company has historically funded its operations through debt and equity financings. At December 31, 2023, the Company had cash balances totaling $ 2.4 million and investments of $ 8.3 million. On March 7, 2024, the Company completed an offering of ordinary shares represented by ADSs and pre-funded warrants to purchase ordinary shares represented by ADSs with each ADS and pre-funded warrant accompanied by warrants to purchase ordinary shares represented by ADSs, for aggregate gross proceeds of approximately $ 6.5 million, before offering costs (See Note 18). The Company believes that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these consolidated financial statements.Additional financing will still be required to complete the research and development of the Company\u2019s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Company\u2019s business, results of operations and financial condition.Other risks and uncertainties:The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements.The Company\u2019s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Company\u2019s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.There can be no assurance that the Company\u2019s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. F-8",
            "type": "paragraph"
        },
        {
            "id": 108,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company\u2019s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug product for clinical development.On April 5, 2023, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) notifying the Company that the closing bid price per ADS was below the required minimum of $ 1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company had a period of one hundred eighty (180) calendar days, or until October 2, 2023 (the \u201cCompliance Period\u201d), to regain compliance with Nasdaq\u2019s minimum bid price requirement. On August 1, 2023, the Company received a letter from Nasdaq stating that the Company\u2019s closing bid price per ADS was at $ 1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed.\u200b NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation:The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (\u201cU.S. GAAP\u201d), which have been consistently applied. All intercompany accounts and transactions have been eliminated in consolidation.Effective July 18, 2023, the ratio of American Depositary Shares (\u201cADSs\u201d) evidencing ordinary shares changed from 1 ADS representing five thousand ( 5,000 ) ordinary shares to 1 ADS representing sixty thousand ( 60,000 ) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Company completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand ( 60,000 ) ordinary shares to 1 ADS representing one ( 1 ) ordinary share. All ordinary share, ADSs and related option and warrant information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the aforementioned ordinary share reverse split and ADS ratio changes. Use of estimates:The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations. Cash and cash equivalents:The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. F-9",
            "type": "paragraph"
        },
        {
            "id": 109,
            "context": "| \u25cf | Significant changes in the manner of our use of the acquired assets or the strategy for our overall business, |\n| \u25cf | Significant underperformance relative to expected historical or projected development milestones, |\n| \u25cf | Significant negative regulatory or economic trends, and |\n| \u25cf | Significant technological changes which could render the platform technology obsolete. |",
            "type": "table"
        },
        {
            "id": 110,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered. Income taxes:The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company\u2019s income tax returns. As of December 31, 2023 and 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively. Stock based compensation:The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.Since the Company has a limited history of trading as a public company, the Company\u2019s expected stock volatility is based on a weighting of its historical volatility along with a group of a publicly traded set of peer companies. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future. Fair value of financial instruments:The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (\u201cASC Topic 820\u201d). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Earnings (loss) per share:The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of \u201cbasic\u201d and \u201cdiluted\u201d earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to shareholders by the weighted average shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential shares are excluded if their effect is anti-dilutive. F-11",
            "type": "paragraph"
        },
        {
            "id": 111,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 For the year ended December 31, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,081 ADS and outstanding stock options to purchase 278,011 ADS. For the year ended December 31, 2022, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 280,735 ADS and outstanding stock options to purchase 25,595 ADS. The inclusion of these warrants and stock options for both 2023 and 2022 in the denominator would be anti-dilutive. Recent Accounting Pronouncements:In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The standard is intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. The new standard will be effective for the Company for the fiscal year beginning January 1, 2025. While the new standard does require further disaggregation of the income tax footnote, the Company currently does not expect the adoption of the new standard to have a material effect on its consolidated financial statements. \u200b NOTE 4 \u2013 ACCRUED INTEREST AND FINANCING EXPENSEOn October 2, 2020, Quoin Inc. issued promissory notes (the \u201c2020 Notes\u201d) to certain investors (\u201c2020 Noteholders\u201d). The 2020 Notes were mandatorily convertible into 432 ADSs, subject to adjustment and were converted in 2021. The ADSs issued to the 2020 Noteholders did not include accrued interest. Two of the five 2020 Noteholders received their amount due during the year ended December 31, 2022 and the Company\u2019s estimate of the liability to the remaining three 2020 Noteholders was estimated to be $ 1,146,000 as of December 31, 2023 and December 31, 2022. There was no interest expense during the year ended December 31, 2023.The holders also received warrants exercisable at any time after the issuance date for 2,449 ADSs at an initial exercise price of $ 597 per ADS. At the time of grant, the Company determined that these warrants met the criteria to be recorded as a liability instrument. Effective March 13, 2022, each holder agreed to exchange these warrants for warrants on the substantially same terms as the Investor Exchange Warrants (See Note 5) with the same number of shares issuable upon the exercise of the original warrant and the same exercise price with a contractual term of 5 years (the \u201cNoteholder Warrants\u201d).The Noteholder Warrants have been determined to have equity classification. The change in the fair value of the warrants through the exchange date was included in other income (expense) in the accompanying statement of operations, and then reclassified from liability to additional paid in capital. On July 14, 2022, as a result of the Altium Agreement (see Note 5), the exercise price of the Noteholder Warrants was reduced to $ 0 and the 2020 Noteholders subsequently exercised all of their warrants. The change in the exercise price of the Noteholder Warrants resulted in a deemed dividend of approximately $ 65,000 recorded during the year ended December 31, 2022. From July to September 2022, the 2020 Noteholders exercised all their warrants to purchase ADSs at $ 0.00 per ADS exercise price, and the Company issued a total of 2,449 ADSs to such noteholders. NOTE 5 \u2013 FINANCINGIn connection with the Merger Agreement and the Securities Purchase Agreement with Altium Growth Fund LLP (the \u201cInvestor\u201d) (described below), during March to May 2021 Quoin Inc. issued three tranches of bridge notes (the \u201cBridge Notes\u201d) in the aggregate principal amount of $ 5.0 million. The Bridge notes had a maturity date of the earliest to occur of: (i) December 25, 2021, (ii) the date on which the Company\u2019s equity was registered under the Exchange Act or is exchanged for equity so registered or (iii) immediately prior to the closing of the Merger. The Bridge Notes were offset against the purchase price under the Securities Purchase Agreement related to the Primary Financing and converted into 8,385 ADSs upon the closing of the Primary Financing in October 2021.The Bridge Notes were issued with warrants to purchase a number of shares of Quoin Inc.\u2019s common stock equal to the aggregate principal amount of the Bridge Notes. Upon the closing of the financing in October 2021, the warrants were exchanged for warrants to purchase 8,256 ADSs at a fixed per share exercise price of $ 597 with a five year maturity (\u201cInvestor Exchange Warrants\u201d). On July 14, 2022, the Company and the Investor entered into an agreement amending the terms of the Investor Exchange Warrants. See below, \u201cAgreements with Altium Growth Fund, LP and Warrant Exercises\u201d. F-12",
            "type": "paragraph"
        },
        {
            "id": 112,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 On October 28, 2021, the Company completed the private placement transaction with the Investor for an aggregate purchase price of approximately $ 17.0 million (comprised of the set off from approximately $ 5.0 million of Bridge Notes, and approximately $ 12.0 million in cash) (the \u201cPrimary Financing\u201d), which resulted in the net proceeds of approximately $ 10.1 million.The Company also issued to the Investor, effective as of March 13, 2022 (i) Series A Warrant to purchase 28,508 ADSs (the \u201cSeries A Warrant\u201d) (ii) Series B Warrant to purchase 28,508 ADSs (the \u201cSeries B Warrant\u201d) and (iii) Series C Warrant to purchase 15,931 ADSs (\u201cSeries C Warrant\u201d and, together with the Series A Warrant and Series B Warrant, the \u201cInvestor Warrants\u201d). The exercise price for the Investor Warrants was$ 597 per ADS, with Series A Warrant having a five-year maturity, and Series B Warrant and Series C Warrant having a two-year maturity.The Company had the right to require the mandatory exercise of the Series C Warrant, subject to an effective registration statement being in place for the resale of the shares underlying such warrants and the satisfaction of equity market conditions, as defined in the Series C Warrant. In the period from April 22, 2022 to June 30, 2022, the Investor exercised the Series B Warrant in full pursuant to the alternate cashless exercise rights of such warrant, resulting in the issuance of a total of 28,508 ADSs to the Investor. The market related conditions to require the mandatory exercise of the Series C Warrant were not met during the period up to July 14, 2022.Agreements with Altium Growth Fund, LP and Warrant ExercisesOn July 14, 2022, the Company, Quoin Inc. and Altium entered into an agreement (the \u201cAltium Agreement\u201d), pursuant to which the parties agreed to, among other things, (i) amend certain terms of the Series A Warrant and Investor Exchange Warrants previously issued to Altium to reduce the exercise price from $ 597 to $ 0.00 per ADS with respect to a total of 33,333 ADSs, (ii) cancel the Series C Warrant and the remaining portion of the Series A Warrant previously issued to Altium, and (iii) terminate the Purchase Agreements, pursuant to which the warrants were previously issued to Altium. The incremental fair value of the modified warrants was approximately $ 491,000 , which was accounted for as an offering expense as part of the 2022 Offering (see Note 14) as the modification was done in contemplation of such offering. As of August 2, 2022, Altium exercised all of its outstanding warrants to purchase ADSs at $ 0.00 per ADS exercise price and the Company issued a total of 33,333 ADSs to Altium. The exercise price of the Noteholder Warrants (See Note 4) was also reduced from $ 597 to $ 0.00 as of July 14, 2022 as a result of the Altium Agreement. \u200b NOTE 6 - FAIR VALUE OF FINANCIAL INSTRUMENTSThe Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs. F-13",
            "type": "paragraph"
        },
        {
            "id": 113,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| December 31, 2023 | Level 1 | Level 2 | Level 3 | Total |\n| US Treasury Bills | $ | 8,293,663 | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 8,293,663 |\n| Total US Treasury Bills Asset | $ | 8,293,663 | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 8,293,663 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| December 31, 2022 | Level 1 | Level 2 | Level 3 | Total |\n| US Treasury Bills | \u200b | $ | 9,992,900 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 9,992,900 |\n| Total US Treasury Bills Asset | \u200b | $ | 9,992,900 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 9,992,900 |\n| \u200b | \u200b | \u200b | \u200b |\n| \u200b | 2020 Note |\n| \u200b | \u200b | Warrants |\n| Beginning Balance January 1, 2022 | \u200b | $ | 373,599 |\n| Change in Fair value of warrants | \u200b | \u200b | ( 77,237 ) |\n| Reclassification of warrant liability to an equity instrument | \u200b | \u200b | ( 296,362 ) |\n| Ending Balance December 31, 2022 | \u200b | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 114,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Weighted | Weighted |\n| \u200b | \u200b | \u200b | \u200b | Average | \u200b | Average |\n| \u200b | \u200b | ADS Underlying | \u200b | Exercise | \u200b | Contractual |\n| \u200b | \u200b | Options | \u200b | Price | \u200b | Terms |\n| Outstanding at December 31, 2021 | 479 | \u200b | $ | 7,640.88 | 0.33 |\n| Granted | \u200b | 25,595 | \u200b | \u200b | 210.00 | \u200b | \u2014 |\n| Forfeited/Cancelled | \u200b | ( 479 ) | \u200b | \u200b | 7,640.00 | \u200b | \u2014 |\n| Outstanding at December 31, 2022 | \u200b | 25,595 | \u200b | $ | 210.00 | \u200b | 9.28 |\n| Granted | 252,416 | \u200b | \u200b | 6.62 | \u2014 |\n| Forfeited/Cancelled | \u2014 | \u200b | \u200b | \u2014 | \u2014 |\n| Outstanding at December 31, 2023 | 278,011 | \u200b | $ | 25.34 | 9.68 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Exercisable options at December 31, 2023 | 7,382 | \u200b | $ | 210.00 | 8.38 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Expected volatility | \u200b | 110.6 | % | \u200b | 106.0 | % |\n| Risk-free interest rate | \u200b | 4.8 | % | \u200b | 2.7 | % |\n| Expected dividend yield | \u200b | 0.0 | % | \u200b | 0.0 | % |\n| Expected life of options in years | \u200b | 6.4 | \u200b | \u200b | 6.9 | \u200b |\n| Exercise Price | \u200b | $ | 6.62 | \u200b | $ | 210.00 | \u200b |\n| Fair value of common stock | \u200b | $ | 4.31 | \u200b | $ | 184.56 | \u200b |\n| Estimate fair value of option | \u200b | $ | 3.60 | \u200b | $ | 155.04 | \u200b |",
            "type": "table"
        },
        {
            "id": 115,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Prepaid R&D costs | \u200b | $ | 447,979 | \u200b | $ | 383,390 |\n| Prepaid insurance | \u200b | 401,972 | \u200b | 508,084 |\n| Prepaid expense | \u200b | 8,500 | \u200b | 8,500 |\n| Deferred offering costs (note 18) | \u200b | \u200b | 32,583 | \u200b | \u200b | \u2014 |\n| Total | \u200b | $ | 891,034 | \u200b | $ | 899,974 |\n| Less: Short-term portion | \u200b | \u200b | ( 591,034 ) | \u200b | \u200b | ( 516,584 ) |\n| Long-term portion | \u200b | $ | 300,000 | \u200b | $ | 383,390 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Research contract expenses (note 13) | \u200b | $ | 358,287 | \u200b | $ | 105,071 |\n| Payroll (note 12) | \u200b | \u200b | 804,156 | \u200b | \u200b | 788,169 |\n| Payroll taxes (note 12) | \u200b | \u200b | 93,989 | \u200b | \u200b | 159,593 |\n| Professional fees | \u200b | \u200b | 50,534 | \u200b | \u200b | 44,278 |\n| Other expenses | \u200b | 1,740 | \u200b | 78,594 |\n| Total | \u200b | $ | 1,308,706 | \u200b | $ | 1,175,705 |",
            "type": "table"
        },
        {
            "id": 116,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Acquired technology \u2013 Polytherapeutics | \u200b | $ | \u2014 | \u200b | $ | 40,433 |\n| Technology license \u2013 Skinvisible | \u200b | 1,000,000 | \u200b | 1,000,000 |\n| Total cost | \u200b | 1,000,000 | \u200b | 1,040,433 |\n| Accumulated amortization | \u200b | ( 416,666 ) | \u200b | ( 335,872 ) |\n| Net book value | \u200b | $ | 583,334 | \u200b | $ | 704,561 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, | \u200b | December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Salaries and other compensation | \u200b | $ | 3,523,733 | \u200b | $ | 4,108,500 |\n| Invoices paid on behalf of the Company | \u200b | \u2014 | \u200b | 15,232 |\n| Total | \u200b | $ | 3,523,733 | \u200b | $ | 4,123,732 |\n| Less: Short-term portion | \u200b | \u200b | ( 600,000 ) | \u200b | \u200b | ( 600,000 ) |\n| Long-term portion | \u200b | $ | 2,923,733 | \u200b | $ | 3,523,733 |",
            "type": "table"
        },
        {
            "id": 117,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 NOTE 13 \u2013 RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTSResearch and consulting agreementIn November 2020, Quoin Inc. entered into a Master Service Agreement with Therapeutics Inc. for the management of the preclinical and clinical development of QRX003 for Netherton Syndrome. The initial term of the agreement was three years with automatic one year extensions, and the agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $ 4.4 million. An additional work order was entered into in December 2022 for a second QRX003 clinical study at an expected estimated cost of approximately $ 830,000 . In the years ended December 31, 2023 and 2022, the Company incurred a research and development expense under these agreements of approximately $ 1.5 million and $ 1.2 million respectively. During the year ended December 31, 2023, the Company received a credit of approximately $ 278,000 applied to prior expenses incurred during the period of March 2023 to July 2023.In November 2021, the Company entered into a research agreement with Queensland University of Technology (QUT) for a pre-clinical research program for the development of a product to treat Netherton Syndrome of approximately $ 250,000 . In May 2022, the Company entered into a second research agreement with QUT for the development of a product to treat Scleroderma of approximately $ 610,000 . Each agreement remains in place until the completion of the research program, which in each case was initially anticipated to be 18 months from execution. For the years December 31, 2023 and 2022, the Company incurred research and development costs related to these agreements of approximately $ 361,000 and $ 353,000 respectively.Consulting agreement:Quoin Inc. entered into a consulting agreement with an Investor Relations (IR) firm, which provides for a monthly fee of $ 14,000 . The agreement had an automatic annual renewal clause and has been in effect since November 2017. The Company owed the IR firm $ 584,000 as of December 31, 2021, which was included in accrued expenses in the accompanying balance sheet. In March 2022, the Company entered into a settlement agreement with the IR firm reducing the liability to $ 168,000 and recognized $ 416,000 as other income in the accompanying consolidated statement of operations. For the years ended December 31, 2023 and 2022, the Company incurred expenses of $ 0 and $ 112,000 , respectively. As of December 31, 2023 and December 31, 2022 the Company has $- 0 - and $ 56,000 in accrued balances, respectively.Performance milestones and RoyaltiesSee Note 10 for asset and in-licensed technology commitments. \u200b NOTE 14 \u2013 SHAREHOLDERS\u2019 EQUITYHistorical authorized shares amounts in this Note 14 were not retroactively adjusted to reflect the number of ordinary shares and ADSs resulting from the ordinary share reverse split and ADS ratio changes discussed herein.On April 12, 2022, the Company held a Special General Meeting, at which the Company\u2019s shareholders approved, among other items, to increase the Company\u2019s registered share capital from 12,500,000,000 ordinary shares (without any nominal value) to 50,000,000,000 ordinary shares (without any nominal value). Effective August 1, 2022, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing four hundred ( 400 ) ordinary shares to 1 ADS representing five thousand ( 5,000 ) ordinary shares, which resulted in a one for 12.5 reverse split of the issued and outstanding ADSs. Subsequent thereto, on November 3, 2022, the Company held its Annual General Meeting, at which the Company\u2019s shareholders approved, among other items, an increase in the registered share capital of the Company from 50,000,000,000 ordinary shares without any nominal value each to 500,000,000,000 ordinary shares (without any nominal value). F-18",
            "type": "paragraph"
        },
        {
            "id": 118,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 On or about July 18, 2023, the Company changed the ratio of ADSs evidencing ordinary shares from one ADS representing five thousand ( 5,000 ) ordinary shares to one ADS representing sixty thousand ( 60,000 ) ordinary shares (the \u201cRatio Change\u201d). The Ratio Change resulted in a one for twelve split of issued and outstanding ADSs, however it had no effect on the Ordinary Shares.On October 26, 2023, the Company held its Annual General Meeting (\u201c2023 Meeting\u201d), at which the Company\u2019s shareholders approved, among other items, an increase in the Company\u2019s registered share capital from 500,000,000,000 ordinary shares, no par value, to 6,000,000,000,000 ordinary shares, no par value. Moreover, at the 2023 Meeting, the Company\u2019s shareholders approved a reverse share split (\u201cReverse Split\u201d) of the Company\u2019s ordinary shares on a date to be determined by the Board, at a ratio of 1 -for- 60,000 . On November 5, 2023, the Board approved November 8, 2023 as the effective date of the Reverse Split. Effective as of November 8, 2023, the number of authorized ordinary shares through the Reverse Split was reduced to 100,000,000 ordinary shares, combining every 60,000 outstanding ordinary shares into one ordinary share, with each ADS representing one ordinary share.Each holder of a Company\u2019s ordinary share has one vote for each ordinary share held on all matters submitted to a vote of shareholders at each shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholders\u2019 resolutions shall be approved by a simple majority vote.In November 2023 the company retired 45 ordinary shares of treasury stock.Under Israeli law, the Company may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent the Company from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that the Company does not have retained earnings or earnings generated over the two most recent years legally available for distribution, the Company may seek the approval of the court in order to distribute a dividend. The court may approve our request if it determines that there is no reasonable concern that the payment of a dividend will prevent the Company from satisfying existing and foreseeable obligations as they become due.On August 9, 2022, the Company completed the 2022 Offering of 184,167 ordinary shares represented by 184,167 ADSs at a purchase price of $ 60.00 per ADS and pre-funded warrants (the \u201c2022 Pre-Funded Warrants\u201d) to purchase 93,833 ordinary shares represented by 93,833 ADSs at a per pre-funded warrant price of $ 59.998 , with each ADS and 2022 Pre-Funded Warrant accompanied by an ordinary warrant (the \u201c2022 Common Warrant\u201d), for aggregate gross proceeds of $ 16.8 million, resulting in net proceeds of approximately $ 14.9 million. Each 2022 Common Warrant had an exercise price of $ 60.00 per ADS and was to expire on the fifth anniversary of the Closing Date. On the Closing Date, the holder of 2022 Pre-Funded Warrants sold in the 2022 Offering exercised its Pre-Funded Warrants in full. The 2022 Common Warrant exercise price and expiration date were subsequently amended for investors who participated in both the 2022 Offering and 2023 Offering (Note 5).Quoin Inc. entered into three consulting agreements with Axella Research LLC (\u201cAxella\u201d) to provide regulatory and pre- clinical/clinical services to the Company with respect to QRX003 and QRX004. The combined fees of the three agreements are approximately $ 270,000 , payable as milestones were met. The Company incurred accrued expenses of approximately $ 194,000 in relation to Axella consulting agreements as of December 31, 2021. In August 2022 the Company issued 3,682 ADSs to one of Axella\u2019s principals to settle the outstanding liability in full. The Company has no ongoing relationship with Axella Research and no further services will be provided.On February 24, 2023 (the \u201c2023 Closing Date\u201d), the Company completed an offering (the \u201c2023 Offering\u201d) of 412,500 ordinary shares represented by 412,500 ADSs at a purchase price of $ 12.00 per ADS and a pre-funded warrant (the \u201cPre-Funded Warrant\u201d) to purchase 170,833 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $ 11.9988 , with each ADS and Pre-Funded Warrant accompanied by an ordinary warrant (the \u201cCommon Warrant\u201d) for aggregate gross proceeds of $ 7.0 million, resulting in net proceeds of approximately $ 5.8 million, after deducting the placement agent\u2019s fees and offering expenses. Each Common Warrant has an exercise price of $ 12.00 per ADS and expires on the fifth anniversary of the 2023 Closing Date. On the 2023 Closing Date, the F-19",
            "type": "paragraph"
        },
        {
            "id": 119,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Weighted | \u200b |\n| \u200b | \u200b | ADSs | \u200b | Average | \u200b |\n| \u200b | \u200b | Underlying | \u200b | Exercise Price | \u200b |\n| \u200b | \u200b | Warrants | \u200b | Per ADS | \u200b |\n| Outstanding at December 31, 2021 | \u200b | 11,440 | \u200b | $ | 664.68 | * |\n| Granted Common Warrants | \u200b | 448,779 | \u200b | \u200b | 134.52 | ** |\n| Terminated | \u200b | ( 19,362 ) | \u200b | \u200b | 597.00 | * |\n| Exercised - Cashless and Pre Funded Warrants | \u200b | ( 160,122 ) | \u200b | \u200b | \u2014 | \u200b |\n| Outstanding at December 31, 2022 | \u200b | 280,735 | \u200b | $ | 64.20 | ** |\n| Granted Common Warrants | \u200b | 583,346 | \u200b | \u200b | 12.00 | \u200b |\n| Granted Pre-Funded Warrants | \u200b | 170,833 | \u200b | \u200b | \u2014 | \u200b |\n| Exercised Pre-Funded Warrants | \u200b | ( 170,833 ) | \u200b | \u200b | \u2014 | \u200b |\n| Outstanding and exercisable at December 31, 2023 | \u200b | 864,081 | \u200b | $ | 16.13 | \u200b |\n| * | Note that the exercise price of certain warrants was reduced from $ 597 to $ 0 on July 14, 2022 and to refer to Note 5 |\n| ** | Note that the exercise price of certain warrants were reduced from $ 60.00 to $ 13.20 per ADS for Common Warrants issued in the 2022 Offering to investors who participated in both the Company\u2019s 2022 Offering and 2023 Offering, see above. |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| (table in thousands) | 2023 | 2022 |\n| Net operating losses | \u200b | $ | 4,276 | \u200b | $ | 3,334 |\n| Accrued Expenses and Other | \u200b | \u200b | 175 | \u200b | \u200b | 189 |\n| R&D Credit Carryforward | \u200b | \u200b | 321 | \u200b | \u200b | 76 |\n| Stock Compensation | \u200b | \u200b | 289 | \u200b | \u200b | 178 |\n| R&D Capitalization | \u200b | \u200b | 1,104 | \u200b | \u200b | 581 |\n| Intangibles | \u200b | \u200b | 51 | \u200b | \u200b | 34 |\n| Total gross deferred tax assets/(liabilities) | \u200b | $ | 6,216 | \u200b | $ | 4,392 |\n| Less valuation allowance | \u200b | \u200b | ( 6,216 ) | \u200b | \u200b | ( 4,392 ) |\n| Net deferred tax assets/(liabilities) | \u200b | $ | \u2014 | \u200b | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 120,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| (table in thousands) | \u200b | 2023 | \u200b | 2022 |\n| Federal Statutory Rate | $ | ( 1,824 ) | $ | ( 1,970 ) |\n| Permanent Differences | \u200b | 167 | \u200b | 153 |\n| Research and Development | \u200b | ( 195 ) | \u200b | ( 76 ) |\n| State Income Tax | \u200b | 79 | \u200b | 388 |\n| Change in Valuation Allowance | \u200b | 1,824 | \u200b | 347 |\n| Deferred True Up | \u200b | ( 51 ) | \u200b | 1,158 |\n| Effective Tax | \u200b | $ | \u2014 | \u200b | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 121,
            "context": "QUOIN PHARMACEUTICALS LTD. Notes to Consolidated Financial StatementsDecember 31, 2023 and 2022 NOTE 18 - SUBSEQUENT EVENTSAlumni Equity Line and Purchase AgreementOn January 25, 2024, the Company entered into a purchase agreement (the \u201cAlumni Purchase Agreement\u201d) with Alumni Capital LP (\u201cAlumni\u201d). Pursuant to the Alumni Purchase Agreement, the Company has the right to sell to Alumni up to $ 8,000,000 (the \u201cCommitment Amount\u201d) of newly issued ordinary shares that are represented by ADS, subject to certain conditions and limitations, from time to time during the term of the Alumni Purchase Agreement. The Company has agreed to issue purchase notices for an aggregate of at least $ 4,000,000 of the Commitment Amount pursuant to the Alumni Purchase Agreement. If shareholder approval of the issuance of ADSs under the Purchase Agreement is not obtained by April 30, 2024, the Company may terminate the Alumni Purchase Agreement by written notice to Alumni and neither party shall have any obligation or liability to the other party. There is no upper limit on the price per share that Alumni could be obligated to pay for the ADSs under the Alumni Purchase Agreement; provided, however at no time can the purchase price be below a floor price of $ 1.00 per share (subject to adjustment as provided in the Alumni Purchase Agreement). As consideration for Alumni\u2019s irrevocable commitment to purchase ADSs under the Alumni Purchase Agreement, the Company agreed to issue to Alumni, at the times set forth in the Alumni Purchase Agreement a number of ADSs with a value at the time of issuance not to exceed $ 240,000 in the aggregate (the \u201cCommitment Securities\u201d). The Company may pay cash in lieu of issuing all or any portion of the Commitment Securities. In connection with the 2024 Offering, the Company agreed not to sell any ADSs to Alumni under the Alumni Purchase Agreement for a period of 180 days from the closing date of the 2024 Offering. Public OfferingOn March 7, 2024, (the \u201c2024 Closing Date\u201d) the Company completed an offering (the \u201c2024 Offering\u201d) of the following securities (i) 811,250 ordinary shares represented by ADSs, (ii) 4,062,500 Series D warrants (the \u201cSeries D Warrants\u201d) to purchase 4,062,500 ordinary shares represented by ADSs, (iii) 4,062,500 Series E warrants (the \u201cSeries E Warrants\u201d and together with the Series D Warrants, the \u201c2024 Warrants\u201d) to purchase 4,062,500 ordinary shares represented by ADSs, and (iv) 3,251,250 pre-funded warrants (the \u201c2024 Pre-Funded Warrants\u201d) to purchase 3,251,250 ordinary shares represented by ADSs for aggregate gross proceeds of approximately $ 6.5 million, resulting in net proceeds of approximately $ 5.6 million, after deducting the placement agent\u2019s fees and offering expenses paid by us. Each ADS (or 2024 Pre-Funded Warrant to purchase one ADS in lieu thereof) was sold together with a Series D Warrant to purchase one ADS and a Series E Warrant to purchase one ADS. The ADSs and accompanying 2024 Warrants were sold at a combined public offering price of $ 1.60 and the 2024 Pre-Funded Warrants and accompanying 2024 Warrants were sold at a combined public offering price of $ 1.5999 , which is equal to the combined purchase price per ADS and accompanying 2024 Warrants, minus the exercise price of each 2024 Pre-Funded Warrant of $ 0.0001 .The Series D and Series E warrants have an exercise price of $ 1.60 per share, are exercisable immediately following the 2024 Closing Date and expire in two years and five years , respectively, from the closing of the 2024 Offering.In connection with the 2024 Offering, the Company entered into a Securities Purchase Agreement (the \u201c2024 Purchase Agreement\u201d) dated March 4, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the ADSs, 2024 Pre-Funded Warrants and 2024 Warrants sold in the 2024 Offering. Pursuant to the terms of the 2024 Purchase Agreement, the Company agreed, subject to certain exceptions, (i) to not enter into variable rate financings for a period of 180 days following the closing of the 2024 Offering, and (ii) to not enter into any equity financings for 90 days from closing of the 2024 Offering.On March 7, 2024, the Company also entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 638,834 ADSs (the \u201cPrior Warrants\u201d) to, among other things, reduce the exercise price of such Prior Warrants to $ 1.60 and to extend the current expiration date of the Prior Warrants until March 7, 2029. \u200bF-22",
            "type": "paragraph"
        }
    ],
    "html_tables": [
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;\"><tr><td style=\"vertical-align:bottom;width:51.04%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0pt 5pt;\"><b style=\"font-weight:bold;\">Patents</b></p></td><td style=\"vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Trademarks</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:51.04%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\">U.S. Patent No. 7,674,471 (exp. March 10, 2024) and U.S. Patent No. 8,318,818 (exp. July 10, 2025) directed to Invisicare\u00ae technology licensed from Skinvisible.</p></td><td style=\"vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\">U.S. Trademark Registration No. 6918421 for word mark \u201cRARE DISEASES ARE ONLY RARE IF YOU DON\u2019T LIVE WITH ONE\u201d filed by Quoin Pharmaceuticals, Inc.</p></td></tr><tr style=\"height:14.1pt;\"><td rowspan=\"2\" style=\"vertical-align:bottom;width:51.04%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\">U.S.and PCT patent applications directed to adjunctive therapy for NS with QRX003 filed by Quoin Pharmaceuticals Inc.</p></td><td style=\"vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\">U.S. Trademark Registration No. 7071539 for design and words \u201cQuoin Pharmaceuticals\u201d filed by Quoin Pharmaceuticals, Inc.</p></td></tr><tr style=\"height:14.1pt;\"><td style=\"display:none;vertical-align:bottom;width:51.04%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\"><span style=\"margin-left:0pt;margin-right:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 5.75pt 0pt 5.75pt;\">U.S. Trademark Application No. 98/184,357 for word mark \u201cQELTIQ\u201d filed by Quoin Pharmaceuticals, Inc.</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">preclinical laboratory tests, </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">in vitro</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> and</span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\"> in vivo</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> preclinical studies and formulation and stability studies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the submission to the FDA of an application for human clinical testing, which is known as an IND application;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the submission to the FDA of a new drug application (\u201cNDA\u201d) for a drug; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP (\u201ccGMP\u201d) requirements to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the approval by the FDA of an NDA.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">continue and/or initiate clinical development of our product candidates, including\u2014QRX003\u2014a topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare</span><sup style=\"font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;\">\u00ae</sup><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> technology, which is under clinical development as a potential treatment for Netherton Syndrome (\u201cNS\u201d);</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">further enhance our internal control systems;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">initiate the development of additional product candidates for other rare disease indications;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">acquire or in-license other products and technologies and advance those product candidates into clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">seek marketing approvals for our product candidates that successfully complete clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">hire additional clinical, regulatory, research, executive and administrative personnel; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">create additional infrastructure to support our operations and our product development and planned future commercialization efforts.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">completing our research and preclinical development of product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">initiating and completing clinical trials for product candidates with favorable results;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">seeking, obtaining, and maintaining marketing approvals for product candidates that successfully complete clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">establishing and maintaining supply and manufacturing relationships with third parties;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">launching and commercializing product candidates for which we may obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">maintaining, protecting and expanding our intellectual property portfolio; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">attracting, hiring and retaining qualified personnel.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">significantly delay, scale back or discontinue the development or commercialization of any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">successfully implementing preclinical studies which may be predictive of clinical outcomes;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">successful enrollment in clinical trials and completion of those trials with favorable results;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtaining and maintaining patent and trade secret protection for current and future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">successfully commercializing our products, if approved, including successfully establishing a sales force, marketing and distribution infrastructure, whether alone or in collaboration with others.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our research methodology may be unsuccessful in identifying potential product candidates; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unsuitable for administration in patients in clinical trials, unlikely to receive marketing approval or unmarketable.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in reaching an agreement with the FDA or other regulatory authorities on final trial design, including selection of dose and clinical outcome assessments and related efficacy endpoints</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in obtaining from the FDA, or comparable foreign regulatory authority, authorization to administer an investigational new drug product to humans through the submission or acceptance of an IND or similar foreign application;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in reaching agreement on acceptable terms with prospective contract research organizations (\u201cCROs\u201d) and clinical trial sites;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our inability to adhere to clinical trial requirements directly or with third parties such as CROs;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">clinical trial site or CRO non-compliance with good clinical practices (\u201cGCPs\u201d), good laboratory practices, or other regulatory requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability or failure of clinical trial sites to adhere to the clinical trial protocol;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in obtaining required IRB approval at each clinical trial site, or an IRB reversing such approval resulting in the suspension or termination of a trial at that;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in recruiting and retaining suitable patients to participate in a trial particularly for a rare disease such as NS;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">clinical sites dropping out of a trial to the detriment of enrollment;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">time required to add new clinical sites; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">be delayed in obtaining marketing approval for our future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">not obtain marketing approval at all;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtain approval for indications or patient populations that are not as broad as originally intended or desired;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">have the product removed from the market after obtaining marketing approval.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory authorities may withdraw, suspend, or limit their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory authorities may require the addition of labeling statements, such as black box warnings or contraindications;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we may be required to change the way the product is administered or conduct additional clinical trials or post-marketing surveillance;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we could be sued and held liable for harm caused to patients; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our reputation may suffer.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory authorities disagreeing with the design or implementation of our clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">unfavorable or unclear results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we may be unable to demonstrate that a product candidate\u2019s clinical and other benefits outweigh its safety risks;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a New Drug Application (\u201cNDA\u201d) or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such authorities may find deficiencies in the manufacturing processes, testing systems or facilities of our third-party manufacturers with which we contract for clinical and commercial supplies; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulations of such authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">issue a warning or untitled letter asserting that we are in violation of the law;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">seek an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">suspend or withdraw regulatory approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">suspend any ongoing clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refuse to approve a pending NDA or supplements to an NDA submitted by us;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">seize product or require a product recall; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refuse to allow us to enter into supply contracts, including government contracts.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">develop therapeutics that are superior to other products in the market;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">attract qualified scientific, product development and commercial personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtain patent and/or other proprietary protection for our product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtain required regulatory approvals; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">demonstration of clinical safety and efficacy compared to other products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the prevalence and severity of any AEs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">limitations or warnings contained in the FDA-approved label for such products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">availability of alternative treatments;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">pricing and cost-effectiveness;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the effectiveness of our, or any of our collaborators\u2019, sales and marketing strategies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to obtain hospital or payor formulary approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the willingness of patients to pay out-of-pocket in the absence of third-party coverage.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">different regulatory requirements for drug approvals in foreign countries;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reduced protection for intellectual property rights;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the inability to meet any product specifications and quality requirements consistently;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a delay or inability to procure or expand sufficient manufacturing capacity;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">manufacturing and product quality issues related to scale-up of manufacturing;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">costs and validation of new equipment and facilities required for scale-up;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">carrier disruptions or increased costs that are beyond our control; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the failure to deliver products under specified storage conditions and in a timely manner.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute requires mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others, including prescribers, patients, purchasers and formulary managers. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act penalties for which are described below.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act (\u201cFCA\u201d), which imposes criminal or civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties per false claim or statement.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The federal Health Insurance Portability and Accountability Act of 1996 (\u201cHIPAA\u201d), which imposes civil and criminal penalties for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (\u201cHITECH\u201d), and its implementing regulations, which imposes certain requirements on certain types of individuals and entities, such as healthcare </span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"></td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">providers, health plans and healthcare clearing houses, known as \u201ccovered entities,\u201d as well as their \u201cbusiness associates,\u201d independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity, relating to the privacy, security and transmission of individually identifiable health information.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians, physician assistants, certain types of advance practice nurses and teaching hospitals, and further requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Many state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">impairment of our business reputation;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">withdrawal of clinical trial participants;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">costs due to related litigation;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">distraction of management\u2019s attention from our primary business;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the inability to commercialize our product candidates; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">decreased demand for our product candidates, if approved for commercial sale.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our failure to obtain the approvals necessary to commence clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">results of clinical and preclinical studies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">announcements of regulatory approval or the failure to obtain it, or changes or delays in the regulatory review process;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">announcements of new products or product enhancements by us or others;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes or developments in laws, regulations or decisions applicable to our product candidates or patents;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">any adverse changes to our relationship with manufacturers or suppliers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">announcements concerning our competitors or healthcare industries in general;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">achievement of expected product sales and profitability or our failure to meet expectations;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual property infringement actions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">any major changes in our board of directors, management or other key personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expiration or terminations of licenses, research contracts or other collaboration agreements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">public concern as to the safety of our products that we, our licensors or others develop;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">success of research and development projects;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">developments concerning intellectual property rights or regulatory approvals;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">variations in our and our competitors\u2019 results of operations;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or the ADSs are covered by analysts;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">future issuances of ordinary shares, ADSs or other securities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">general market conditions and other factors, including factors unrelated to our operating performance, such as natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency), boycotts, adoption or expansion of government trade restrictions, and other business restrictions; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the other factors described in this \u201cRisk Factors\u201d section.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses, share-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expenses incurred under agreements with CROs, as well as consultants that support the implementation of the clinical studies described above;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">formulation, research and development expenses related to QRX003; and other product candidates we may choose to develop; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">costs for sponsored research.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of trials required for approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the per patient trial costs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of patients that participate in the trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of sites included in the trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the countries in which the trial is conducted;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the length of time required to enroll eligible patients;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number of doses that patients receive;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the duration of patient follow-up;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the timing and receipt of regulatory approvals; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the efficacy and safety profile of our product candidates.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year ended December 31,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Change</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">Operating Expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">General and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 6,070,517</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 6,584,868</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (514,351)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,307,987</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,672,836</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 635,151</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Total operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 9,378,504</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 9,257,704</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 120,800</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">Other (income) and expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Forgiveness of trade payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (416,000)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 416,000</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Warrant liability (income) expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (77,237)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 77,237</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Unrealized income</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,683</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (1,307)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,990</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Realized and accrued interest income</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (694,614)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (95,745)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (598,869)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Interest and financing expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 714,081</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (714,081)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Total other expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (691,931)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 123,792</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (815,723)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">Net loss</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (8,686,573)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (9,381,496)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 694,923</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the scope, timing, rate of progress and costs of our drug development efforts, preclinical development activities, the timing of laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the number and scope of clinical programs we decide to pursue;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the scope and costs of development and commercial manufacturing activities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the extent to which we acquire or in-license other product candidates and technologies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our implementation of operational, financial and management systems; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs associated with being a public company.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:29.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Net cash used in operating activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (7,864,429)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (8,480,732)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Net cash provided by (used in) investing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,188,316</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (10,149,121)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Net cash provided by financing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,216,683</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 14,007,708</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">Net change in cash and cash equivalents</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (459,430)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"white-space:pre-wrap;\"> (4,622,145)</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant changes in the manner of our use of the acquired assets or the strategy for our overall business,</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant underperformance relative to expected historical or projected development milestones,</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant negative regulatory or economic trends, and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant technological changes which could render the platform technology obsolete.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Age</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Position(s)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Michael Myers</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">62</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Chairman of the Board and Chief Executive Officer</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Denise Carter </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">55</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director and Chief Operating Officer</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Joseph Cooper<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(1)(3)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">66</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">James Culverwell<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(1)(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">67</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Dennis H. Langer<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">72</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Natalie Leong<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(1)(3)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">38</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Michael Sember<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">74</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Director</p></td></tr><tr><td style=\"vertical-align:bottom;width:43.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Gordon Dunn</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">59</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:43.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Chief Financial Officer</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">overseeing our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending the engagement or termination of the person filling the office of our internal auditor; </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">determining the approval process for transactions that are \u2018non-negligible\u2019 (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, which determination may be based on annually pre-determined criteria;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">determining whether to approve certain related party transactions (including transactions in which an office holder (as defined below) has a personal interest and whether such transaction is extraordinary or material under the Companies Law);</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">examining the work plan of the internal auditor before its submission to our board of directors and proposing amendments thereto or, upon a decision of the board of directors, acting as the corporate body to approve such work plan;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">examining our internal controls and internal auditor\u2019s performance, including whether the internal auditor has sufficient resources and tools at his disposal to fulfill his responsibilities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">examining the scope of our independent auditor\u2019s work and compensation and submitting a recommendation with respect thereto to our board of directors; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">establishing procedures for the handling of employees\u2019 complaints as to the management of our business and the protection to be provided to such employees.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending to our board of directors a policy regarding the terms of engagement of the company\u2019s office holders, to which we refer as a \u201ccompensation policy\u201d;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending whether the compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recommending to the board of directors updates to the compensation policy from time to time;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">assessing implementation of the compensation policy;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">resolving whether to approve arrangements with respect to the terms of office and employment of office holders, which require the approval of the compensation committee pursuant to the Companies Law;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">exempting, under certain circumstances, a transaction with our Chief Executive Officer from the approval of our shareholders.;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">making other determinations that the Companies Law assigns to a compensation committee;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and recommending for approval by the board of directors the overall compensation policies with respect to our Chief Executive Officer and other executive officers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and recommending for approval by the board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">evaluating the performance of our Chief Executive Officer and other executive officers in light of such goals and objectives;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and approving the granting of options and other incentive awards, including the exercise of authorities delegated by the board of directors regarding the grant of equity incentives under our equity compensation plans;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">overseeing our compliance with SEC and Nasdaq rules related to shareholder approval of certain executive compensation matters and equity compensation plans;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">considering and implementing policies with respect to oversight, assessment and management of risks associated with our compensation polices; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reviewing and establishing appropriate insurance coverage for our office holders.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation policy and who vote against the policy does not exceed two percent (2%) of the aggregate voting rights in the Company.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the education, skills, experience, expertise and accomplishments of the relevant office holder;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the office holder\u2019s position and responsibilities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">prior compensation agreements with the office holder;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost to the average and median salary of such employees of the company, as well as the impact of disparities between them on the work relationships in the company;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">if the terms of employment include variable components \u2014 the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">if the terms of employment include severance compensation \u2014 the term of employment or office of the office holder, the terms of the office holder\u2019s compensation during such period, the company\u2019s performance during such period, the office holder\u2019s individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">with regards to variable components:</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">with the exception of office holders who report to the chief executive officer, a means of determining the variable components on the basis of long-term performance and measurable criteria; provided that the company may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based on non-measurable criteria, or if such amount is not higher than three months\u2019 salary per annum, taking into account such office holder\u2019s contribution to the company;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their payment, or in the case of equity-based compensation, at the time of grant;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of the office holder\u2019s terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company\u2019s financial statements;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">evaluating our corporate leadership structure, and reviewing important issues and developments in corporate governance, and developing appropriate recommendations for the Board; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">overseeing and assisting our board in reviewing and recommending nominees for election as directors and members of committees of our board.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">information on the advisability of a given action brought for the office holder\u2019s approval or performed by virtue of his or her position; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">all other important information pertaining to any such action.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refrain from any conflict of interest between the performance of the office holder\u2019s duties to the company and his or her other duties or personal affairs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refrain from any activity that is competitive with the company;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disclose to the company any information or documents relating to the company\u2019s affairs which the office holder received as a result of his or her position as an office holder.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">an amendment to the company\u2019s articles of association;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">an increase of the company\u2019s authorized share capital;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a merger; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">interested party transactions that require shareholder approval.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator\u2019s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company\u2019s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the above mentioned events and amount or criteria;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reasonable litigation expenses, including legal fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third-party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder pursuant to certain provisions of the Israeli Economic Competition Law, 5758-1988.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a breach of the duty of care to the company or to a third-party, including a breach arising out of the negligent conduct of the office holder;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a financial liability imposed on the office holder in favor of a third-party;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a financial liability imposed on the office holder in favor of a third-party harmed by a breach in an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a breach of the duty of loyalty, except with respect to insurance coverage or indemnification, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">an act or omission committed with intent to derive illegal personal benefit; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a fine, monetary sanction, or forfeit levied against the office holder.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, vote in favor of the inconsistent provisions of the compensation package, excluding abstentions; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the inconsistent provisions of the compensation package does not exceed two percent (2%) of the aggregate voting rights in the Company.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">All Other </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Salary</b>\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Bonus</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(1)</sup>\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Compensation</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(3)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(4)</sup>\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name and Principal Position</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0<b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><i style=\"font-style:italic;\">Dr. Michael Myers</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 602,250</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 292,263</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 59,550</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 954,063</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Chief Executive Officer</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 550,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 247,500</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,112,187</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 57,112</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,966,799</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\"><i style=\"font-style:italic;\">Denise Carter</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 481,800</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 292,266</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 56,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 830,066</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Chief Operating Officer</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 440,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 198,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,112,187</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 55,215</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,805,402</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\"><i style=\"font-style:italic;\">Gordon Dunn</i><sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(4)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 394,200</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 184,635</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 578,835</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Chief Financial Officer</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 360,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 162,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 926,822</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,385</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,450,207</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(3)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents amounts paid as office and automobile allowance to Mr. Myers and Ms. Carter under their respective employment agreements, as well as the employer matching contribution to the executive\u2019s 401(k) plan contributions under our Section 401(k) retirement plan (the \u201cSection 401(k) Plan\u201d), broken down as follows:</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Office</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Car</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">401(k)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Allowance</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Allowance</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Contributions</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Michael Myers</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 30,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 11,550</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 59,550</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 30,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 9,112</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 57,112</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Denise Carter</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 30,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 8,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 56,000</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 30,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 7,215</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 55,215</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Gordon Dunn</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:55.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">\u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,385</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,385</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Underlying</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Unexercised</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Unexercised</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Options (#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Options (#)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Price</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Expiration</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exercisable</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Unexercisable</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(1)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Michael Myers</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,786</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,357</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 210.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">04/12/2032</p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 80,965</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5.75</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">10/26/2033</p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Denise Carter</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,786</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,357</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 210.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">04/12/2032</p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 80,966</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5.75</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">10/26/2033</p></td></tr><tr><td style=\"vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Gordon Dunn</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,488</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,465</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 210.00</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">04/12/2032</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:56.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 51,149</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5.75</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">10/26/2033</p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents the number of ADSs issuable upon the exercise of options. The 2022 options vest in four equal annual installments beginning on April 12, 2023. The 2023 options vest in in three annual installments of 20% and a fourth annual installment of 40% beginning on October 26, 2024.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents the exercise price per ADS.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">each non-employee director receives an annual base retainer of $75,000;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">each committee chairperson receives an additional retainer of $15,000 for his or her service as a chairperson; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">each member of a standing committee receives an additional retainer of $5,000 for such service on a standing committee.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Fees Earned or</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Option</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Paid in Cash</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Awards</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(1)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">($)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Joseph Cooper</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 85,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27,622</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 112,622</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">James Culverwell</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 95,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27,622</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 122,622</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Dennis H. Langer</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 90,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27,622</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 117,622</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Natalie Leong</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 95,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27,622</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 122,622</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Michael Sember</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 80,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 27,622</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 107,622</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents the grant date fair value of option awards granted to each of our non-employee directors on October 26, 2023, calculated in accordance with FASB ASC Topic 718. These options have an exercise price of $5.75 per ADS and vest in four equal annual installments beginning on October 26, 2024. The option values were calculated using a Black-Scholes Model for pricing options. See Note 7 to Consolidated Financial Statements included in this Annual Report for all relevant valuation assumptions used to determine the grant date fair value of these options. </span><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;\">As of December 31, 2023 the aggregate number of outstanding options held by each of our non-employee directors was 8,724 ADSs</span><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:63.39%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Amount and Nature of Beneficial </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Percentage </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Name and Address of Beneficial Owner</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Ownership</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">of Class</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><i style=\"font-style:italic;\">Directors and Named Executive Officers:</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Michael Myers<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(1)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 12,930</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Denise Carter<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 12,929</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Joseph Cooper<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(3)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 715</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">James Culverwell<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(4)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,032</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Dennis Langer<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(5)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,065</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Natalie Leong<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(6)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 715</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Michael Sember<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(7)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 715</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Gordon Dunn<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\">(8)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,977</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">All directors and officers as a group (8 persons)<sup style=\"font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;\"> (9)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 33,078</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"> <span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\">*</p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Consists of (i) 9,358 ordinary shares held directly and (ii) 3,572 ordinary shares issuable upon the exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Consists of (i) 9,357 ordinary shares held directly and (ii) 3,572 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(3)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents 715 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(4)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Consists of (i) 317 ordinary shares held directly and (ii) 715 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(5)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Consists of (i) 350 ordinary shares held directly and (ii) 715 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(6)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents 715 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(7)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents 715 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(8)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents 2,977 ordinary shares issuable upon exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(9)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Consists of (i) 19,382 ordinary shares held directly and (ii) 13,696 ordinary shares issuable upon the exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:46.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of securities</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">remaining available for</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Number of securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Weighted-average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">future issuance under equity</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">to be issued upon exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">exercise price of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">compensation plans</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">of outstanding options,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">outstanding options,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">(excluding securities reflected</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Plan category</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">warrants and rights</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(1)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">warrants and rights</b><sup style=\"font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(2)</sup></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">in column (a)</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">(a)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">(b)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">(c)</p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Equity compensation plans approved by security holders</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 278,011</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 25.34</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 41,386</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Equity compensation plans not approved by security holders</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:46.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 278,011</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 25.34</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:18.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 41,386</span></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(1)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents the number of ADSs issuable upon the exercise of options.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(2)</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Represents the weighted-average exercise price of outstanding options exercisable into ADSs.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year Ended</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year Ended</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, 2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Type of Fees </b><sup style=\"font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;\">(a)</sup><b style=\"font-weight:bold;\"> </b>(in thousands)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Audit Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 244</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 258</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Audit-Related Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Tax Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">All Other Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 244</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 258</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.087963104%;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:8.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 5pt;\"><b style=\"font-weight:bold;\">Exhibit No.</b></p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:89.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exhibit Description</b></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.1</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021017552/ea138297ex10-1_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Agreement and Plan of Merger and Reorganization, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC, Inc. and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.2</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021049924/ea147939ex99-2_cellect.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment made as of September 24, 2021, to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., CellMSC, Inc., and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 99.2 to Form 6-K filed with the SEC on September 27, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.3</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000119380521000886/e620681_ex2-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amended and Restated Share Transfer Agreement, dated May 27, 2021 by and between Cellect Biotechnology Ltd. and EnCellX Inc. (incorporated by reference to Exhibit 2.2 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on June 16, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.4</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021049924/ea147939ex99-3_cellect.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment made as of September 26, 2021, to the Amended and Restated Share Transfer Agreement dated as of May 27, 2021, by and between EnCellX, Inc. and Cellect Biotechnology Ltd. (incorporated by reference to Exhibit 99.3 to Form 6-K filed with the SEC on September 27, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.5</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021017552/ea138297ex10-4_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Securities Purchase Agreement, dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., Quoin Pharmaceuticals, Inc. and the investors named on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.4 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.6</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021017552/ea138297ex10-6_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Securities Purchase Agreement, dated as of March 24, 2021, by and among Quoin Pharmaceuticals, Inc. and the investors listed on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.6 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.7</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021048656/ea147559ex99-1_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment Agreement, dated as of September 17, 2021, by and among Quoin Pharmaceuticals, Inc., Cellect Biotechnology, Ltd., and Altium Growth Fund, L.P. (incorporated by reference to Exhibit 99.1 of the Form 6-K filed with the Securities and Exchange Commission on September 17, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.8</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021048656/ea147559ex99-2_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Letter Agreement, dated September 17, 2021, between Quoin Pharmaceuticals, Inc. and Cellect Biotechnology, Ltd. (incorporated by reference to Exhibit 99.2 of the Form 6-K filed with the Securities and Exchange Commission on September 17, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.9</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922038338/tm2210177d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Second Amendment Agreement, dated as of March 13, 2022, by and among Quoin Pharmaceuticals, Inc., Quoin Pharmaceuticals Ltd., and Altium Growth Fund, L.P. (incorporated by reference to Exhibit 4.1 to Form 6\u2013K filed with the SEC on March 28, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.10</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922068318/tm2217757d1_ex10-2.htm#Exhibit:https://www.sec.gov/Archives/edgar/data/1671502/000110465922068318/tm2217757d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Waiver Agreement, dated June 6, 2022, by and among Quoin Pharmaceuticals Ltd., Quoin Pharmaceuticals, Inc. and Altium Growth Fund, LP (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on June 6, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.11</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922080005/tm2221137d1_ex10-1.htm#Exhibit:https://www.sec.gov/Archives/edgar/data/1671502/000110465922080005/tm2221137d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Agreement, dated July 14, 2022, by and among Quoin Pharmaceuticals, Inc., Quoin Pharmaceuticals Ltd. and Altium Growth Fund, LP (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on July 15, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.12</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000119380521001035/e620802_ex2-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Letter of Agreement among Cellect Biotechnology Ltd, Dr. Shai Yarkoni and EnCellX, Inc. (incorporated by reference to Exhibit 2.5 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on July 16, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">2.13</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000119380521001121/e620839_ex2-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Representative Agreement among Cellect Biotechnology Ltd, Eyal Leibovitz, as Representative, and EnCellX, Inc. (incorporated by reference to Exhibit 2.6 to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on August 6, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">3.1</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922012886/tm225712d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on February 28, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on February 8, 2022).</span></a></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.087963104%;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">3.2</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on April 12, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">3.3</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922101995/tm2226355d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on November 3, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on September 21, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">3.4</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923099826/tm2325301-2_def14a.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on October 26, 2023 (incorporated by reference to Annex A included in the proxy statement filed with the SEC on September 12, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.1</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000114420416114563/v444964_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Deposit Agreement between Cellect Biotechnology Ltd. (n/k/a Quoin Pharmaceuticals Ltd.), The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder (incorporated by reference to Exhibit 4.1 to Registration Statement on Form F-1/A as filed with the SEC on July 26, 2016).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.2</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000114420416114563/v444964_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Specimen American Depositary Receipt (included in Exhibit 2.1).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.3</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000119380521001121/e620839_ex4-14.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Contingent Value Rights Agreement, by and among Cellect Biotechnology, Ltd., Eyal Leibovitz in the capacity of Representative and Computershare, Inc. in the capacity of Rights Agent (incorporated by reference to Exhibit 4.14 to Registration Statement on Form F-4 filed with the SEC on August 6, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.4</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021017552/ea138297ex10-5_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Registration Rights Agreement, dated as of March 24, 2021, by and between Cellect Biotechnology Ltd. and the investors listed on the Schedule of Buyers attached thereto (incorporated by reference to Exhibit 10.5 of the Form 6-K filed with the Securities and Exchange Commission on March 24, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.5</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021017552/ea138297ex10-4_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Primary Warrants for the Purchase Agreement (incorporated by reference to Exhibit B to Exhibit 10.4 to Form 6-K filed with the SEC on March 24, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.6</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021048656/ea147559ex99-1_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Exchange Warrant (incorporated by reference to Exhibit 99.1 to Form 6-K filed with the SEC on September 17, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.7</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex2d5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series A Warrant (incorporated by reference to Exhibit 2.5 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.8</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex2d6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series B Warrant (incorporated by reference to Exhibit 2.6 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.9</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex2d7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series C Warrant (incorporated by reference to Exhibit 2.7 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.10</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390019001810/ff12018a2ex4-6_cellectbio.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Warrant Agent Agreement between Cellect Biotechnology Ltd. and Computershare Inc., as warrant agent, including the form of Warrant (incorporated by reference to Exhibit 4.6 of the Registration Statement on Form F-1 filed with the SEC on February 7, 2019).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.11</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057822002035/qnrx-20211231xex4d11.htm#Exhibit:https://www.sec.gov/Archives/edgar/data/1671502/000141057822002035/qnrx-20211231xex4d11.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement, dated August 5, 2022 (incorporated by reference to Exhibit 4.11 of the Registration Statement on Form F-1/A filed with the SEC on August 4, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.12</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex4d12.htm#Exhibit:https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex4d12.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.12 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.13</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex4d13.htm#Exhibit:https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex4d13.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Warrant (incorporated by reference to Exhibit 4.13 of the Registration Statement on Form F-1 filed with the SEC on August 3, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.14</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_ex4-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.15</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Securities Purchase Agreement, dated February 22, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.16</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.17</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.18</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Placement Agency Agreement by and between A.G.P. / Alliance Global Partners and Quoin Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on February 28, 2023</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.19</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex4d19.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Description of Registrant\u2019s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.20</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Pre-Funded Warrant issued in the 2024 Offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.21</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex4-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series D Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.22</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex4-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Series E Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">4.23</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex4-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;\">Form of Amendment to Warrants to Purchase Ordinary Shares Represented by American Depositary Shares</span><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\"> (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.1#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Compensation Policy for Executives and Directors of Quoin Pharmaceuticals Ltd, adopted on April 12, 2022 (incorporated by reference to Annex B included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.2#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amended and Restated Equity Incentive Plan of Quoin Pharmaceuticals Ltd., effective as of April 12, 2022 (incorporated by reference to Annex C included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.087963104%;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.3#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex99-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Indemnification and Release Agreement, entered into by and between Quoin Pharmaceuticals Ltd. and each of the officers and directors of Quoin Pharmaceuticals Ltd. as of April 12, 2022 (incorporated by reference to Annex D included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.4#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021055261/ea149556ex10-1_quoinpharma.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Executive Employment Agreement, dated March 9, 2018, by and between Quoin Pharmaceuticals, Inc. and Dr. Michael Myers (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on October 29, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.5#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000121390021055261/ea149556ex10-2_quoinpharma.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Executive Employment Agreement, dated March 9, 2018, by and between Quoin Pharmaceuticals, Inc. and Denise Carter (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on October 29, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.6#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Service Agreement, dated November 1, 2021, by and between Quoin Pharmaceuticals, Inc. and Gordon Dunn (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.7</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Research Agreement, dated November 1, 2021, by and between Quoin Pharmaceuticals, Inc. and Queensland University of Technology (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.8</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated November 5, 2021, by and between Quoin Pharmaceuticals, Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.3 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.9</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Supply Agreement, dated September 15, 2021, by and between Quoin Pharmaceuticals, Inc. and AFT Pharmaceuticals Ltd. (incorporated by reference to Exhibit 10.4 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.10</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated November 7, 2021, by and between Quoin Pharmaceuticals, Inc. and GenPharm Services FZ LLC (incorporated by reference to Exhibit 10.5 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.11</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921143092/tm2133721d1_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Supply Agreement, dated November 7, 2021, by and between Quoin Pharmaceuticals, Inc. and GenPharm Services FZ LLC (incorporated by reference to Exhibit 10.6 to Form 6-K filed with the SEC on November 23, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.12</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465921151319/tm2135796d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Distribution Agreement, dated December 15, 2021, by and between Quoin Pharmaceuticals, Inc. and Orpharm LLC (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on December 20, 2021).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.13</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922009666/tm225017d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated as of January 24, 2022 between the Company and E-Log Logistica LTDA (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on January 31, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.14</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated as of February 1, 2022, by and between Quoin Pharmaceuticals Ltd. and Er-Kim \u0130la\u00e7 Sanayi ve Ticaret A.\u015e, and the First Amendment to the License and Distribution Agreement, dated as of February 17, 2022, by and between Quoin Pharmaceuticals, Inc. and Er-Kim \u0130la\u00e7 Sanayi ve Ticaret A.\u015e (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.4 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.15</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex10-5.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated as of February 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.5 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.16</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922031667/tm228708d1_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Supply Agreement, dated as of February 11, 2022, by and between Quoin Pharmaceuticals Ltd. and Neopharm (Israel) 1996 Ltd. (incorporated by reference to Exhibit 10.6 to Form 6-K filed with the SEC on March 8, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.17</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922072060/tm2218757d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License Agreement, dated June 14, 2022, by and between Quoin Pharmaceuticals, Inc. and WinHealth Investment (HK) Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on June 17, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.18</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922080005/tm2221137d1_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, dated July 14, 2022, by and between Quoin Pharmaceuticals, Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.2 to Form 6-K filed with the SEC on July 15, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.19</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922080005/tm2221137d1_ex10-3.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Supply Agreement, dated July 14, 2022, by and between Quoin Pharmaceuticals, Inc. and Endo Ventures Limited (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.3 to Form 6-K filed with the SEC on July 15, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.20</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922068318/tm2217757d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Research Agreement, dated May 20, 2022, by and between Quoin Pharmaceuticals, Inc. and Queensland University of Technology, Australia (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F) (incorporated by reference to Exhibit 10.1 to Form 6-K filed with the SEC on June 6, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.21</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d30.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Exclusive License Agreement, dated October 17, 2019, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.30 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.22</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d31.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Exclusive License Agreement Renewal, dated May 8, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.31 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.23</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d32.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to the Exclusive License Agreement, dated July 31, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.32 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.087963104%;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.24</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d33.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Second Amendment to the Exclusive License Agreement, dated September 30, 2020, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.33 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.25</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d34.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Third Amendment to the Exclusive License Agreement, dated January 27, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.34 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.26</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d35.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Fourth Amendment to the Exclusive License Agreement, dated April 19, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.35 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.27</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d36.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Fifth Amendment to the Exclusive License Agreement, dated June 14, 2021, by and between Quoin Pharmaceuticals, Inc. and Skinvisible Inc. (incorporated by reference to Exhibit 4.36 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.28</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d37.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Quotation \u2013 Tech Transfer and Clinical Manufacture for QRX003 Topical Lotion, dated April 8, 2021, by Ferndale Contract Manufacturing to Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.37 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.29</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d38.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Development and Supply Agreement, dated January 13, 2021, by and between TopChem Pharmaceuticals Limited and Quoin Pharmaceuticals Limited (incorporated by reference to Exhibit 4.38 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.30</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d39.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Master Services Agreement, dated November 2, 2020, by and between Therapeutics, Inc. and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.39 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.31</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d40.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Term Sheet for Agreement, dated October 29, 2019, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.40 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.32</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d41.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Term Sheet for Agreement, dated January 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (re: QRX003) (incorporated by reference to Exhibit 4.41 to Form 20-F filed with the SEC on April 13, 2022).</span></a> </p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.33</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex4d42.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Term Sheet for Agreement, dated January 11, 2020, by and between Axella Research, LLC and Quoin Pharmaceuticals, Inc. (re: QRX004) (incorporated by reference to Exhibit 4.42 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.34#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex10d34.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Non-Qualified Stock Option Award Agreement for directors (incorporated by reference to Exhibit 10.34 to Form F-1 filed with the SEC on August 3, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.35#</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057822002024/qnrx-20211231xex10d35.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Non-Qualified Stock Option Award Agreement for officers (incorporated by reference to Exhibit 10.35 to Form F-1 filed with the SEC on August 3, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.36</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/tm2325985d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Distribution Agreement, by and between Quoin Pharmaceuticals Inc. and Farma Mondo (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on September 13, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.37</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924008229/tm244426d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Purchase Agreement, dated January 25, 2024, by and between Quoin Pharmaceuticals Ltd. and Alumni Capital LP (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on January 30, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.38</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Securities Purchase Agreement dated March 4, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">10.39</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_ex1-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Placement Agency Agreement dated March 4, 2024 (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the SEC on March 8, 2024).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">14.1</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057823000267/qnrx-20221231xex14d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Code of Ethics. (incorporated by reference to Exhibit 14.1 to Form 10-K filed with the SEC on March 15, 2023).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">21.1</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/qnrx-20211231xex8d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Subsidiaries of Registrant (incorporated by reference to Exhibit 8.1 to Form 20-F filed with the SEC on April 13, 2022).</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">23.1*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex23d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Consent of Marcum LLP, Certified Public Accountants</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">31.1*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex31d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934.</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">31.2*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex31d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934.</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">32.1*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex32d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Chief Executive Officer pursuant to 18 U.S.C. \u00a7 1350.</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">32.2*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex32d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Chief Financial Officer pursuant to 18 U.S.C. \u00a7 1350.</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">97.1*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1671502/000141057824000198/qnrx-20231231xex97d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Clawback Policy</span></a></p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">101*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Information formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Shareholders\u2019 Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements.</p></td></tr><tr><td style=\"vertical-align:top;width:8.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;\">104*</p></td><td style=\"vertical-align:top;width:1.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:89.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;\"><tr><td style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Date: March 14, 2024</p></td><td colspan=\"2\" style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">QUOIN PHARMACEUTICALS LTD.</p></td></tr><tr><td style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:5.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:44.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:5.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">By:</p></td><td style=\"vertical-align:bottom;width:44.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Dr. Michael Myers</p></td></tr><tr><td style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:5.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Name:</p></td><td style=\"vertical-align:bottom;width:44.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Dr. Michael Myers</p></td></tr><tr><td style=\"vertical-align:bottom;width:50%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:5.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Title:</p></td><td style=\"vertical-align:bottom;width:44.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Chief Executive Officer</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Signature</b></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:50.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:50.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:18.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 2pt;\">/s/ Dr. Michael Myers</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Chairman and Chief Executive Officer</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Dr. Michael Myers</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">(Principal Executive Officer)</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Gordon Dunn</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Chief Financial Officer</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Gordon Dunn</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">(Principal Financial Officer and Principal Accounting Officer)</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr style=\"height:9.55pt;\"><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Denise Carter</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Denise Carter</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director and Chief Operating Officer</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Joseph Cooper</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Joseph Cooper</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ James Culverwell</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">James Culverwell</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Dennis Langer</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Dennis Langer</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Natalie Leong</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Natalie Leong</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">/s/ Michael Sember</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:25.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Michael Sember</p></td><td style=\"vertical-align:top;width:2.51%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:50.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:18.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">March 14, 2024</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;\"><tr style=\"height:5.85pt;\"><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;\"><span style=\"font-size:8pt;margin-bottom:12pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">Page</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;\"><a href=\"#ReportofIndependentRegisteredPublicAccou\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Reports of Independent Registered Public Accounting Firm</span></a><span style=\"font-size:10pt;\"> (PCAOB Firm ID: </span> <span style=\"font-size:10pt;\">Marcum LLP</span> <span style=\"font-size:10pt;\"> #</span> <span style=\"font-size:10pt;\">688</span> <span style=\"font-size:10pt;\">)</span></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-2</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;\">Consolidated Financial Statements</p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;\"><span style=\"font-size:10pt;margin-bottom:12pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;\"><a href=\"#BalanceSheets_433143\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022</span></a></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-4</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;\"><a href=\"#StatementsofOperations_631444\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Operations for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-5</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;\"><a href=\"#StatementsofStockholdersEquityDeficit_51\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Shareholders\u2019 Equity for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-6</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;\"><a href=\"#StatementsofCashFlows_736426\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-7</p></td></tr><tr><td style=\"vertical-align:top;width:90.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;\"><a href=\"#NOTE1ORGANIZATIONANDBUSINESS_628032\" style=\"font-size:10pt;\"><span style=\"font-style:normal;font-weight:normal;\">Notes to consolidated financial statements</span></a></p></td><td style=\"vertical-align:top;width:9.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\">F-8 \u2013 F-22</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;\"><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><i style=\"font-style:italic;\">Critical Audit Matter Description</i></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">As discussed in Note 3 to the financial statements, the Company records costs for clinical trial activities based upon estimates of costs incurred through the balance sheet date for services performed by contract research organizations, clinical study sites and other vendors.</p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Auditing the recognition of pre-clinical and clinical trial costs associated with contracted organizations is challenging due to the significant judgment required to determine the nature and level of services that have been received, including determining the progress to completion of specific tasks and activities conducted in relation to what has been invoiced and recorded.</p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\"><i style=\"font-style:italic;\">How We Addressed the Matter in Our Audit</i></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">The primary procedures we performed to address this critical audit matter included:</p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"width:18pt;display:table-cell;\"></div><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Obtained an understanding of the design and operating effectiveness of internal controls for pre-clinical and clinical cost recognition.</span></div></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"width:18pt;display:table-cell;\"></div><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Tested the completeness and accuracy of the underlying data used in the estimates including, but not limited to, the estimated costs per project milestone and duration.</span></div></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"width:18pt;display:table-cell;\"></div><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Assessed the reasonableness of the significant assumptions, corroborated the progress of the pre-clinical and clinical trials with the Company\u2019s operations personnel and to information obtained by the Company directly from third parties, and to information in contracts or statements of work including costs for those activities and project duration.</span></div></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:20.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:normal;width:76.64%;margin:0pt;padding:0pt;\"><div style=\"border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><div style=\"display:table-row;\"><div style=\"width:18pt;display:table-cell;\"></div><div style=\"display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</div><div style=\"display:table-cell;padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Examined subsequent invoicing received from such third parties.</span></div></div></div></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">ASSETS</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Current assets:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Cash and cash equivalents</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,401,198 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,860,628 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Investments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,293,663 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,992,900 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Prepaid expenses and other current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  591,034 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  516,584 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  11,285,895 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  13,370,112 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Prepaid expenses - long term</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  300,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  383,390 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Intangible assets, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  583,334 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  704,561 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  12,169,229 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,458,063 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">LIABILITIES AND SHAREHOLDERS\u2019 EQUITY</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Current liabilities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Accounts payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  526,523 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  605,600 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Accrued expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,308,706 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,175,705 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Accrued interest and financing expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,146,251 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,146,251 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\"><span style=\"-sec-ix-hidden:Hidden_yNFDiClj7UeovN8BuOMfvA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Due to officers - short term</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  600,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  600,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total current liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,581,480 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,527,556 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\"><span style=\"margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\"><span style=\"-sec-ix-hidden:Hidden__65oBco9okanm2b2PRkn4w;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Due to officers - long term</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,923,733 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,523,733 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  6,505,213 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  7,051,289 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Commitments and contingencies</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Shareholders\u2019 equity:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Ordinary shares,   no   par value per share,  100,000,000  and  8,333,334  ordinary shares authorized at December 31, 2023 and 2022, respectively -  987,220  ( 987,220  ADS\u2019s) ordinary shares <span style=\"-sec-ix-hidden:Hidden_GZ1QF_d88UOSfAkD6yUoLA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">issued</span></span> and <span style=\"-sec-ix-hidden:Hidden_Nxfx3d7ZzEiVMl5pSnDL0w;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">outstanding</span></span> at December 31, 2023 and  403,887  ( 403,887  <span style=\"-sec-ix-hidden:Hidden_Vw1HvzBcxk2q5N6Ojtl85Q;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">ADS\u2019s</span></span>) at <span style=\"-sec-ix-hidden:Hidden_hwOAzlVycUySnuKnoRZ2dw;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">December 31, 2022</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  \u2014 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Treasury stock, - 0 - ordinary shares issued at December 31, 2023 and  45  ordinary shares issued at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 2,932,000 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Additional paid in capital</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  51,867,336 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  47,855,521 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;\">Accumulated deficit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 46,203,320 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 37,516,747 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total shareholders\u2019 equity</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,664,016 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  7,406,774 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;\"><span style=\"margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;\">Total liabilities and shareholders\u2019 equity</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  12,169,229 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,458,063 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Years Ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">General and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  6,070,517 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  6,584,868 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,307,987 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,672,836 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Total operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,378,504 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,257,704 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Other (income) and expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Forgiveness of accounts payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 416,000 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Warrant liability (income) expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 77,237 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Unrealized loss (gain)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,683 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1,307 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Realized and accrued interest income</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 694,614 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 95,745 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Interest and financing expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  714,081 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Total other (income) expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 691,931 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  123,792 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 8,686,573 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9,381,496 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Deemed dividend on warrant modification</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 65,266 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Net loss attributable to shareholders</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 8,686,573 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9,446,762 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\"><span style=\"margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Loss per ADS</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Loss per ADS</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Basic</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9.64 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 46.81 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Fully-diluted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9.64 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 46.81 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Weighted average number of ADS\u2019s outstanding</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Basic</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  900,919 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  201,826 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Fully-diluted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  900,919 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  201,826 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Additional</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Ordinary</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">No Par</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Treasury</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Paid in</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Accumulated</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Shares</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">ADS\u2019s</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Value</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Stock</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Capital</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> Deficit</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2021</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  55,913 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  55,913 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 2,932,000 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  31,659,017 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 28,069,985 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  657,032 </p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 9,381,496 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 9,381,496 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Stock based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  764,007 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  764,007 </p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Issuance of ADS and Pre-Funded Warrants, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  280,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  280,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,877,332 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,877,332 </p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Cashless exercise of warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  64,292 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  64,292 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Settlement of accrued expenses </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,682 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,682 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  193,537 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  193,537 </p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Reclassification of warrant liability upon issuance of Exchange warrant</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  296,362 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  296,362 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Deemed dividend on warrant modifcation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  65,266 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 65,266 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  403,887 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  403,887 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 2,932,000 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  47,855,521 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 37,516,747 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  7,406,774 </p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 8,686,573 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 8,686,573 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Stock based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,094,549 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,094,549 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Retirement of Treasury Stock</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,932,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 2,932,000 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:40.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">Issuance of ADS and Pre-Funded Warrants, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  583,333 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  583,333 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,849,266 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,849,266 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:40.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">Balance at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  987,220 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  987,220 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  51,867,336 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;\"> ( 46,203,320 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,664,016 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Years Ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Cash flows used in operating activities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 8,686,573 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9,381,496 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Change in fair value of warrant liability</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 77,237 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Stock based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,094,549 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  764,007 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Forgiveness of trade payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 416,000 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Amortization of intangibles</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  103,706 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  104,043 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Asset impairment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  17,521 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Increase in accrued interest and financing expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  714,081 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Unrealized gain and accrued interest on investments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 489,079 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 93,779 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Changes in assets and liabilities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Increase in accounts payable and accrued expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  53,924 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 217,806 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Decrease in prepaid expenses &amp; other assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  41,523 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  123,455 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;\">Net cash used in operating activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 7,864,429 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 8,480,732 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Cash flows provided by (used in) investing activities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Purchase of investments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 18,090,684 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 9,899,121 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Proceeds from maturity of investments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  20,279,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Payment for license acquisition</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 250,000 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;\">Net cash provided by (used in) investing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,188,316 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 10,149,121 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Cash flows provided by financing activities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Payments of deferred financing costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 32,583 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  42,045 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Payment of amounts due to officers</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 600,000 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 599,999 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Payment of interest on \u201cBridge Notes\u201d </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 311,670 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Proceeds from sale of equity securities, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,849,266 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,877,332 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;\">Net cash provided by financing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,216,683 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  14,007,708 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Net change in cash and cash equivalents:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 459,430 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 4,622,145 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"white-space:pre-wrap;\">Cash and cash equivalents - beginning of year</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,860,628 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  7,482,773 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Cash and cash equivalents - end of year</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,401,198 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,860,628 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Supplemental information - Non cash items:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Reclassification of warrant liability to equity upon issuance of \u201cExchange warrants\u201d</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  296,362 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Deemed dividend on warrant modification</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  65,266 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Offering expenses associated with warrant modification </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  238,231 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  491,601 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Settlement of accrued expenses </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  193,537 </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant changes in the manner of our use of the acquired assets or the strategy for our overall business,</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant underperformance relative to expected historical or projected development milestones,</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant negative regulatory or economic trends, and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Significant technological changes which could render the platform technology obsolete.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:55.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:55.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 1</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 2</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 3</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;\">US Treasury Bills</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,293,663 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,293,663 </p></td></tr><tr><td style=\"vertical-align:bottom;width:55.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;\">Total US Treasury Bills Asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,293,663 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,293,663 </p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:55.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:55.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 1</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 2</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 3</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:55.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">US Treasury Bills</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,992,900 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,992,900 </p></td></tr><tr><td style=\"vertical-align:bottom;width:55.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;\">Total US Treasury Bills Asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,992,900 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,992,900 </p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:82.54%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:82.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2020 Note</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Warrants</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:82.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Beginning Balance January 1, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  373,599 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:82.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Change in Fair value of warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 77,237 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:82.54%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Reclassification of warrant liability to an equity instrument</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 296,362 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:82.54%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Ending Balance December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">ADS Underlying</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Contractual</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Options</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Terms</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Outstanding at December 31, 2021</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  479 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,640.88 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  0.33 </p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  25,595 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  210.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Forfeited/Cancelled</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 479 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,640.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Outstanding at December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  25,595 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  210.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  9.28 </p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  252,416 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.62 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Forfeited/Cancelled</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Outstanding at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  278,011 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  25.34 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> <b style=\"font-weight:bold;\"> 9.68</b> </p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exercisable options at December 31, 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,382 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  210.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  8.38 </p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected volatility</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  110.6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  106.0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Risk-free interest rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.8 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2.7 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected dividend yield</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  0.0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  0.0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected life of options in years</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.4 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exercise Price</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.62 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  210.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Fair value of common stock</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.31 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  184.56 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Estimate fair value of option</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3.60 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  155.04 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Prepaid R&amp;D costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  447,979 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  383,390 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Prepaid insurance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  401,972 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  508,084 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Prepaid expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  8,500 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  8,500 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Deferred offering costs (note 18)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  32,583 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  891,034 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  899,974 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Less: Short-term portion</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 591,034 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 516,584 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Long-term portion</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  300,000 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  383,390 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Research contract expenses (note 13)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  358,287 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  105,071 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Payroll (note 12)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  804,156 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  788,169 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Payroll taxes (note 12)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  93,989 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  159,593 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Professional fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  50,534 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  44,278 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Other expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,740 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  78,594 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,308,706 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,175,705 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Acquired technology \u2013 Polytherapeutics</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  40,433 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Technology license \u2013 Skinvisible</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,000,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,000,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total cost</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,000,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,040,433 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Accumulated amortization</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 416,666 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 335,872 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net book value</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  583,334 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  704,561 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_KohwzCB9gEaaLhH6o3kDFQ;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Salaries and other compensation</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,523,733 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,108,500 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_KIRlhwwCLEu157w3J-fLDA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Invoices paid on behalf of the Company</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,232 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_GrFSI4Qym0Os0QDCL_sznQ;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Total</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,523,733 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,123,732 </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_78vMRv5JV06G_QcZuekAVA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Less: Short-term portion</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 600,000 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 600,000 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"-sec-ix-hidden:Hidden_OKsak8NvZ0uUJ-jePvcSUQ;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Long-term portion</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  2,923,733 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3,523,733 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">ADSs</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Underlying</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Exercise Price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Warrants</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Per ADS</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2021</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  11,440 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  664.68 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Granted Common Warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  448,779 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  134.52 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">**</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Terminated</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 19,362 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  597.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">*</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Exercised - Cashless and Pre Funded Warrants </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 160,122 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  280,735 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  64.20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">**</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Granted Common Warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  583,346 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  12.00 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Granted Pre-Funded Warrants</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  170,833 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Exercised Pre-Funded Warrants </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 170,833 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding and exercisable at December 31, 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  864,081 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  16.13 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;\">*</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;\">Note that the exercise price of certain warrants was reduced from $ 597  to $ 0  on July 14, 2022 and to refer to Note 5 </p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\">**</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\">Note that the exercise price of certain warrants were reduced from $ 60.00  to $ 13.20  per ADS for Common Warrants issued in the 2022 Offering to investors who participated in both the Company\u2019s 2022 Offering and 2023 Offering, see above.</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(table in thousands)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Net operating losses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,276 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,334 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Accrued Expenses and Other</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  175 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  189 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">R&amp;D Credit Carryforward</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  321 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  76 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Stock Compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  289 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  178 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">R&amp;D Capitalization</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,104 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  581 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Intangibles</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  51 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  34 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-style:italic;font-weight:bold;\">Total gross deferred tax assets/(liabilities)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  6,216 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  4,392 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;\">Less valuation allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 6,216 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 4,392 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-style:italic;font-weight:bold;\">Net deferred tax assets/(liabilities)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:middle;white-space:nowrap;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(table in thousands)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:middle;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:middle;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Federal Statutory Rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,824 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,970 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Permanent Differences</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  167 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  153 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Research and Development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 195 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 76 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">State Income Tax</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  79 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  388 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Change in Valuation Allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,824 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  347 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Deferred True Up</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 51 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,158 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Effective Tax</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr></table>"
    ]
}